SEARCH:      Monitor Keywords |  Custom RSS

Drug, bio-affecting and body treating compositions June archive of inventions by patent app class 06/07

20070148099 - Use of aroma compounds as defoaming agents for ophthalmic solutions with high concentrations of surfactants: A method of reducing foam formation and improving odor in ophthalmic solutions, such as multipurpose cleaning and conditioning solutions and contact lens packing solutions. The ophthalmic solutions contain surfactant and aroma compound in an amount effective to decrease foam formation. The aroma compound has a low molecular weight and pleasing... Agent: Bausch & Lomb Incorporated

20070148127 - Antimicrobial ophthalmic treatment system and method: An ophthalmic treatment system comprises an ophthalmic treatment solution and a biguanide antimicrobial agent in solid form and in contact with said treatment solution such as to inhibit bacterial and/or fungal growth in said solution. The biguanide is partially or wholly terminated with an amine compound.... Agent: Bausch & Lomb Incorporated

20070148155 - Use of alkaline phosphatase to maintain healty tissue mass in mammals: Embodiments of the present invention relate to the use of placental alkaline phosphatase, and other members of the alkaline phosphatase family, to enhance protein synthesis in the muscle as well as the survival of non-cancerous differentiated cells in the muscle, adipose and other tissues. The ability of alkaline phosphatase to... Agent: Faegre & Benson LLP Patent Docketing

20070148088 - Cytotoxic therapy: Anticancer, antimicrobial and autoimmune disease, and anti-organ rejection therapy using cytotoxic agents is improved using cytokines to prevent, mitigate or reverse adverse radiation-induced or drug-induced toxicity, especially to hematopoietic cells. Cytotoxic agents can include radioisotopes, drugs, toxins and even unconjugated cytotoxic antibodies. A preferred cytokine is IL-1. Higher doses of... Agent: Faegre & Benson LLP Patent Docketing

20070148087 - Tame based chelators and uses thereof: New bifunctional chelation complexes are described. These are based on the structure of the so-called “TAME-HexA” molecule. The compounds are especially useful for forming chelation complexes with metal ions, including radioisotopes.... Agent: Fulbright & Jaworski, LLP

20070148089 - Novel serpentine transmembrane antigens expressed in human cancers and uses thereof: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigen of the Prostate). Four... Agent: Heller Ehrman LLP

20070148092 - Compositions and methods for imaging pain and stress in vivo: Briefly described, embodiments of the present disclosure relate to methods and compositions for imaging pain and/or stress in a subject and methods and compositions for treating associated conditions. In particular, the present disclosure relates to the use of labeled compounds to provide objective diagnosis of pain and/or stress, for imaging... Agent: Thomas, Kayden, Horstemeyer & Risley, LLP

20070148091 - Peptides and compounds that bind to a receptor: Described are peptides and peptide mimetics that bind to and activate the thrombopoietin receptor. Such peptides and peptide mimetics are useful in methods for treating hematological disorders and particularly, thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions as well as in diagnostic methods employing labeled peptides and peptide... Agent: Philip S. Johnson Johnson & Johnson

20070148090 - Per (3,6-anhydro) cyclodextrin derivatives, preparation thereof and use thereof for transporting metal elements to biological targets or for decontaminating biological targets of fluids: in which: at least one of the values R1 represents a radical chosen from peptides, proteins, lipids, oligonucleotides or polynucleotides, oligosaccharides or polysaccharides, and biopolymers, and the other possible values R1, which may be identical or different, represent a group chosen from OH, OR3, OM, SH, SR3, OCOR3, NH2, NHR2,NR3R4,... Agent: Hutchison Law Group PLLC

20070148093 - Non-terminal method of identifying anti-migraine compounds: The present invention relates to in vivo non-terminal method of identifying anti-migraine compounds.... Agent: Louis J. Wille Bristol-myers Squibb Company

20070148095 - Fluorescent magnetic nanoparticles with specific targeting functions: Magnetic nanoparticles with fluorescent properties and specific targeting functions. The fluorescent magnetic nanoparticle includes a magnetic nanoparticle, a biocompatible polymer chemically modifying the magnetic nanoparticle, a fluorescent dye coupled to the biocompatible polymer, and a specific targeting agent coupled to the biocompatible polymer. The fluorescent and magnetic properties of the... Agent: Birch Stewart Kolasch & Birch

20070148094 - Polymeric imaging agents and medical imaging methods: Provided herein are image-enhancing agents that are useful for managing disease by imaging disease tissue using magnetic resonance imaging techniques, optical imaging techniques, and a combination of magnetic resonance imaging techniques and optical imaging techniques. Also provided are methods of imaging disease tissue and managing disease using the image-enhancing agents.... Agent: General Electric Company Global Research

20070148096 - Contrast agents: The present invention relates to a class of compounds and to diagnostic compositions containing such compounds where the compounds are iodine containing compounds. More specifically the iodine containing compounds are chemical compounds containing a benzene scaffolding moiety allowing for the arrangement of three iodinated phenyl groups bound thereto. The invention... Agent: Ge Healthcare, IncIPDepartment

20070148097 - Abuse resistant transmucosal drug delivery device: The present invention relates to a solid pharmaceutical dosage form for abusable drug delivery with reduced illicit abuse potential. The dosage form is presented as a bioerodable transmucosal delivery device that includes an abusable drug and an antagonist to the abusable drug associated with an abuse-resistant matrix. The devices of... Agent: Lahive & Cockfield, LLP

20070148098 - Sublimable sustained release deiverly system and method of making same: The invention relates to compositions suitable for the delivery and/or stabilization of biologically active substances. The compositions comprise a sublimable matrix material and the biologically active agent to be delivered. The compositions can be used as drug delivery systems to treat a wide variety of diseases or as systems for... Agent: Pearne & Gordon LLP

20070148100 - Nanoparticulate aripiprazole formulations: The present invention is directed to compositions and methods comprising nanoparticulate aripiprazole, or salts or derivatives thereof, having improved bioavailability, faster rates of absorption and a faster onset of therapeutic effect. The nanoparticulate aripiprazole compositions are proposed to have an average effective particle size of less than about 2000 nm,... Agent: Elan Drug Delivery, Inc. C/o Foley & Lardner LLP

20070148101 - Foamable alcoholic composition: A stable foam composition includes greater than about 40 weight percent of an alcohol, based upon the total weight of the alcoholic composition, and a foaming surfactant selected from fluorosurfactants, siloxane polymer surfactants, and combinations thereof. When the foaming surfactant includes a fluorosurfactant, the alcoholic composition further includes a polymeric... Agent: Renner, Kenner, Greive, Bobak, Taylor & Weber

20070148102 - Hair treament method using dry foam as mechanical support for hair: The present invention relates to a cosmetic treatment method comprising the steps of providing a foamable composition, forming a foam from said foamable composition on release from a pressurized container, drying said foam wherein the foam does not disappear upon drying, wherein said foam is applied or generated between the... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070148103 - Compositions providing a heating sensation for oral or dermal delivery: The present invention relates to a heating or warming composition that may be delivered orally or to the skin or mucous membranes. The composition contains a warming agent in combination with a cooling agent. The warming agent and cooling agent may be provided in one composition or they may be... Agent: Hoffmann & Baron, LLP

20070148104 - Animal chew articles: Edible chew articles for animals that comprise: (a) edible chew base, (b) an effective amount of antimicrobial lipid, and (c) at least one of (1) an effective amount of tartar control agent or (2) an effective amount of a long chain fatty acid. Also a method comprising chewing or eating... Agent: 3m Innovative Properties Company

20070148105 - Compositions and methods comprising magnetic particles for health use: The present invention provides a topical composition comprising a topical composition base and a plurality of magnetic particles. The topical composition can further comprise one or more active agents. The magnetic particles and/or active agent(s) can optionally be encapsulated and/or coated. Methods for making and using the topical composition are... Agent: Glen M. Diehl Norton & Diehl LLC

20070148107 - Skin protection and improvement: This invention relates to compositions, and methods of use thereof, for (i) reducing ultraviolet (UV)-induced skin erythema and/or photoaging, and for (ii) improving skin quality, each method comprising orally administering to a subject in need thereof, certain polyphenols described herein such as flavanols, procyanidins, or pharmaceutically acceptable salts or derivatives... Agent: Nada Jain, P.C.

20070148106 - Treatment, prevention, and modulation of aging of the skin: Methods to treat, prevent, and modulate aging of the skin are provided. More particularly, methods are provided for treating or preventing non-light induced skin aging in an organism and for reducing the basal MMP-10 expression in unirradiated cells of an organism and/or reducing the basal MMP-1 RNA transcription and protein... Agent: Stephen M. Haracz, Esq. Bryan Cave LLP

20070148110 - Aqueous-alcoholic depigmenting gels comprising mequinol and adapalene: Stable, topically applicable cosmetic/pharmaceutical skin depigmentation compositions contain a combination depigmentation effective amount of mequinol and adapalene, and optionally, at least one sunscreen, formulated as aqueous-alcoholic gels or gel-creams in topically applicable, physiologically acceptable media therefor.... Agent: Buchanan, Ingersoll & Rooney PC

20070148109 - Cosmetic and/or dermatological compositions containing polyphenols stabilized by perfluoropolyether phosphates and use of perfluopolyether phosphates as stabilizing agents for polyphenols: The present invention concerns the use of perfluoropolyether phosphates, in particular perfluoropolyether diphosphates, as stabilizing agents for polyphenols in cosmetic and/or dermatological compositions for topical application, and it also concerns cosmetic and/or dermatological compositions containing polyphenols and optionally vitamin E and free ascorbic acid, stabilized by perfluoropolyether diphosphates.... Agent: Lucas & Mercanti, LLP

20070148108 - Stable vitamin b6 derivative: wherein R1 represents a glycosyl group, a phosphate group, or a cyclic phosphate group bound to R2; R2 represents —CH2OH, —CHO, —CH2NH2, —CH2-amino acid residue, or —CH2—OPO2H; and R3 represents hydrogen atom, or —PO3H2, and a composition for cosmetics, medicaments, foodstuffs, and/or feeds containing the aforementioned compound or a salt... Agent: Greenblum & Bernstein, P.L.C

20070148112 - Foaming, color-changing topical composition and method of imparting a cosmetic effect: There is an anhydrous topical composition. The composition has a) an active ingredient; b) a base compound of a carbonate or bicarbonate salt of an alkali metal or an alkaline earth metal; c) an acid compound; and d) a cosmetically acceptable anhydrous vehicle. The base compound and the acid compound... Agent: Charles N. J. Ruggiero Ohlandt, Greeley, Ruggiero & Perle, L.L.P.

20070148111 - Peel off synthetic body paint: A peel off synthetic body paint, and a method of making the peel off synthetic body paint, is disclosed. The peel off synthetic body paint is made from a combination of a non-toxic paint and a peel masque product. The non-toxic paint comprises a binder, a pigment, a diluent, and... Agent: Michael Coblenz

20070148113 - Antiperspirant compositions comprising at least one dispersion of cationic colloidal silica particles, antiperspirant product, and cosmetic process for treating perspiration: The present disclosure relates to the use of a dispersion of cationic colloidal particles of silica modified with a multivalent cation in a cosmetic composition, as an antiperspirant active agent. The present disclosure also relates to antiperspirant compositions comprising at least one dispersion of cationic colloidal particles of silica modified... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070148116 - Concentrated ingredient for treating and/or modifying surfaces, and use thereof in cosmetic compositions: The present invention relates to a concentrated ingredient for treating and/or modifying surfaces, especially for treating and/or modifying the skin and/or the hair. The invention also relates to the use of this ingredient in cosmetic compositions, for example in shampoos, shower gels or leave-in or rinse-out hair conditioners. The ingredient... Agent: Jean-louis Seugnet Rhodia Inc.-legal Department

20070148115 - Mq-t propyl siloxane resins: MQ-T propyl siloxane resins comprising (R13SiO1/2)a, (R22SiO2/2)b, (R3SiO3/2)c, and (SiO4/2)d units, where at least 40 mole % of the R3 groups are propyl are disclosed. A method of preparing such siloxane resins by reacting a MQ siloxane resin with a T propyl siloxane resin is also disclosed. These siloxane resins... Agent: Dow Corning Corporation Co1232

20070148117 - Skin dressings: A skin dressing comprises a hydrated hydrogel material including a source of lactate ions and a supply of glucose, optionally also including a source of zinc ions and a source of iodide ions. The dressing has beneficial effects on skin.... Agent: Morgan Lewis & Bockius LLP

20070148118 - Cosmetic composition for skin application suitable for relaxing expression wrinkles: The present invention relates to a cosmetic composition for skin application suitable for relaxing expression wrinkles which combines a selected active peptide component with a decontracting or relaxing action on the muscular fiber with a micro-element which reduces the muscular contraction level by acting directly or indirectly on a muscular... Agent: James V Costigan Hedman & Costigan

20070148119 - Enzyme delivery systems, application in water based products: Aqueous enzyme delivery systems as well as aqueous cosmetics and personal care products were provided which comprise at least one stabile enzyme and a polyglycerol containing at least 15 carbons. In addition, stabile non-aqueous enzyme delivery systems which are dispersions of at least one enzyme in an non-aqueous viscous liquid... Agent: Darby & Darby P.C.

20070148121 - Cosmetic product, nanoparticles for cosmetics, and powder for cosmetics: u

20070148120 - Skin preparations for external use for wrinkle reduction: To provide a skin treatment composition for wrinkle reduction that is superior in terms of the wrinkle reduction effect, usability, and the sensation during use. A skin treatment composition having a water dispersion of a polymer in which a non-water soluble film-forming polymer is dispersed in water wherein the main... Agent: Townsend & Banta C/o Portfolio Ip

20070148122 - Hair treating composition: Hair treatment compositions comprising at least one ester of a C8-C22 fatty acid and pentaerythritol and at least one cationic surfactant and having a pH of 1.5 to 7.0 are provided.... Agent: Cognis Corporation Patent Department

20070148114 - Composition in the form of a foam for coating the eyelashes: i

20070148123 - Substances and agents for positively influencing collagen: The invention relates to the use of a substance and/or substances or a composition containing said substance and/or substances, whereby said substance and/or substances inhibit(s) the formation and/or the effect of estrogen to stabilize, increase and/or restore collagen. The appropriate substances are aromatase inhibitors and/or anti-estrogens. Optionally, 5-alpha-reductase inhibitors are... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20070148124 - Cellulose and acrylic based polymers and the use thereof for the treatment of infectious diseases: The present invention provides methods for the treatment or prevention of a viral, bacterial, or fungal infection using an anionic cellulose- or acrylic-based polymer, a prodrug thereof, or a pharmaceutically acceptable salt of said anionic cellulose based polymer or acrylic based polymer or prodrug of either. The present invention also... Agent: Scully Scott Murphy & Presser, PC

20070148125 - Coordination complex of diaminocyclohexaneplatinum(ii) with block copolymer containing poly(carboxylic acid) segment and antitumor agent comprising the same: A coordinate complex of diaminocyclohexane platinum (II) with a block copolymer comprising a poly(ethylene glycol) segment and a poly(carboxylic acid) segment is provided. The complex can be effectively used in treatments for tumors, in particular malignant tumors.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070148126 - Inhibitors of type 2 vascular endothelial growth factor receptors: The present disclosure relates to novel vascular endothelial growth factor receptor (VEGFR)-binding polypeptides and methods for using these polypeptides to inhibit biological activities mediated by vascular endothelial growth factors (VEGFs). The present disclosure also provides various improvements relating to single domain binding polypeptides.... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070148128 - Carbodiimide crosslinking of functionalized polyethylene glycols: A synthetic composition is provided which includes an acid-functional polymer having at least one pendant acid group, an amine-functional polymer having at least one pendant amine group, and a coupling agent. The synthetic composition can be used in human and animal medical applications as an adhesive or sealant.... Agent: United States Surgical, A Division Of Tyco Healthcare Group Lp

20070148131 - Methods and compositions for needleless delivery of binding partners: The present invention relates, in part, to methods and compositions for needleless delivery of macromolecules to a subject. In one aspect, the methods and compositions involve administering to the subject a delivery construct comprising a carrier construct non-covalently bound to a binding partner, wherein the carrier construct comprises a receptor-binding... Agent: Jones Day

20070148130 - Native trre: protein implicated in tnf receptor shedding for treating arthritis and inflammation: This disclosure provides a new family of proteins implicated in causing the release of TNF receptors and other cytokine receptors from the surface of cells involved in inflammation. Receptor releasing activity was isolated and purified from a monocyte cell line, and sequenced to deduce the gene and protein structure of... Agent: Meyer Pharmaceuticals LLC

20070148129 - Therapeutic agents and uses therefor: The present invention relates generally to therapeutic agents and methods which enhance or otherwise maintain a state of immune tolerance in a subject. The present invention further provides agents and methods for preventing or at least delaying onset of an autoimmune disease such as but not limited to autoimmune diabetes.... Agent: Scully, Scott, Murphy & Presser, P.C.

20070148133 - Potent inhibition of influenza virus by specifically designed short interfering rna: said sequences being inhibitory against influenza virus in animals including humans. The invention further includes one or more of said siRNA sequences in the form of an aqueous suspension suitable for nasal inhalation. Still further, the invention includes one or more of said siRNA sequences in the form of a... Agent: Joseph E. Mueth, Esq. Joseph E. Mueth Law Corporation

20070148134 - Potent inhibition of influenza virus by specifically designed short interfering rna: said sequences being inhibitory against influenza virus in animals including humans. The invention further includes one or more of said siRNA sequences in the form of an aqueous suspension suitable for nasal inhalation. Still further, the invention includes one or more of said siRNA sequences in the form of a... Agent: Joseph E. Mueth, Esq. Joseph E. Mueth Law Corporation

20070148132 - Tetracycline-regulated adeno-associated viral (aav) vectors for gene delivery to the nervous system: A vector and a method are provided for delivering a nucleic acid to a nervous system cell. The vector includes a first nucleic acid, a second nucleic acid, inverted terminal repeats of adeno-associated virus, and a tetracycline-off regulatable promoter system that includes a first promoter operably linked to the first... Agent: Brinks Hofer Gilson & Lione

20070148144 - Gene-enhanced tissue engineering: Provided are mammalian cells comprising a recombinant sonic hedgehog (SHH) gene such that a recombinant SHH protein can be expressed by the cell. Also provided are matrices suitable for applying to a tissue defect. Additionally provided are tissue regeneration compositions. Methods of regenerating tissue at the site of a tissue... Agent: Amster, Rothstein & Ebenstein LLP

20070148145 - Protein modulators of resistance to alkylating agents: There is disclosed a method for identifying a therapeutically responsive phenotype, as distinguished, e.g. from an alkylating agent resistant phenotype in a cell, which method may be used to evaluate the likelihood of successful outcome of treating a tumor cell with an alkylating agent. The method is directed to the... Agent: Peters Verny , L.L.P.

20070148135 - Combination bacteriolytic therapy for the treatment of tumors: Current approaches for treating cancer are limited, in part, by the inability of drugs to affect the poorly vascularized regions of tumors. We have found that spores of anaerobic bacteria in combination with agents which interact with microtubules can cause the destruction of both the vascular and avascular compartments of... Agent: Banner & Witcoff, Ltd.

20070148136 - Methods of using ammonia oxidizing bacteria: A use of ammonia oxidizing bacteria in the manufacture of a medicament and a method for treating a subject who has developed or is at risk of developing at least one of hypertension, hypertrophic organ degeneration, Raynaud's phenomena, fibrotic organ degeneration, allergies, autoimmune sensitization, end stage renal disease, obesity, diabetes... Agent: Lowrie, Lando & Anastasi

20070148147 - Bacterial composition and its use: The subject of the present invention is a bacterial composition having immunomodulation properties comprising at least one strain selected from the group consisting of Lactobacillus acidophilus PTA-4797, Lactobacillus plantarum PTA-4799, Lactobacillus salivarius PTA-4800, Lactobacillus paracasei PTA-4798, Bifidobacterium bifidum PTA-4801 and Bifidobacterium lactis PTA-4802. An other subject of the invention is... Agent: Fay Sharpe LLP

20070148148 - Bacterial composition and its use: The subject of the present invention is a bacterial composition having immunomodulation properties comprising at least one strain selected from the group consisting of Lactobacillus acidophilus PTA-4797, Lactobacillus plantarum PTA-4799, Lactobacillus salivarius PTA-4800, Lactobacillus paracasei PTA-4798, Bifidobacterium bifidum PTA-4801 and Bifidobacterium lactis PTA-4802. An other subject of the invention is... Agent: Fay Sharpe LLP

20070148146 - Composition and method for inhibiting salmonella and campylobacter colonization in poultry: One embodiment of the present invention is directed to the use of a novel competitive exclusion bacterial composition to prevent or reduce Salmonella or Campylobacter colonization in poultry.... Agent: Barnes & Thornburg LLP

20070148149 - Novel lactobacillus strains and uses thereof: The invention concerns new isolated Lactobacillus cells, which are capable to aggregate Helicobacter pylori under culture conditions of the human digestive tract, in particular of the stomach, and to the uses of such cells.... Agent: Mayer & Williams PC

20070148140 - Compositions and methods to enhance viability and function of islet cells: This invention uses placental alkaline phosphatase (“PALP”), and other members of the alkaline phosphatase family, to reduce the death and thereby maintain or enhance the viability and function of insulin-producing islet β-cells including insulin secretion. PALP may be administered to a patient that has received transplanted islet cells to protect... Agent: Faegre & Benson LLP Patent Docketing

20070148139 - Fabrication of vascularized tissue using microfabricated two-dimensional molds: A method and materials to create complex vascularized living tissue in three dimensions from a two-dimension microfabricated mold has been developed. The method involved creating a two dimensional surface having a branching structure etched into the surface. The pattern begins with one or more large channels which serially branch into... Agent: Edwards Angell Palmer & Dodge LLP

20070148138 - Hair follicle graft from tissue engineered skin: The present invention provides a hair graft comprising (a) tissue engineered skin comprising a tissue engineered epidermal layer, a tissue engineered dermal layer, and hair follicle progenitor cells and (b) a scaffold. The invention also provides methods of making and using the hair grafts of the present invention.... Agent: Michael Best & Friedrich, LLP

20070148143 - Human cytokine receptor: Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor16.”... Agent: Zymogenetics, Inc. Intellectual Property Department

20070148141 - Method of using hepatic progenitors in treating liver dysfunction: Methods of using hepatic progenitors in treating liver dysfunction are provided. More particularly, methods of using hepatic progenitor cells, including hepatic stem cells, in treating liver dysfunction in the absence of immune-suppressing amounts of an immunosuppressant.... Agent: Foley And Lardner LLP Suite 500

20070148142 - Pharmaceutical composition for treatment of wounds containing blood plasma or serum: The present invention relates to a pharmaceutical composition for the treatment of wounds containing blood plasma or serum and a method for treating wounds effectively by applying said composition to the wound site to normalize the tissue-environment around the site.... Agent: King & Spalding LLP

20070148137 - Regenerated corneal endothelial cell sheets, processes for producing the same, and methods of using the same: e

20070148150 - Mkk7 activation inhibitor: PAK4 and JIK, both of which bind to MKK7 and directly phosphorylate MKK7, were found in the present invention. The present invention provides an inhibitor of c-Jun phosphorylation caused by JNK3 and a method for inhibiting the same, and an agent for preventing and/or treating a disorder attributable to c-Jun... Agent: Kilyk & Bowersox, P.l.l.c.

20070148153 - Controlled release pharmaceutical compositions for acid-labile drugs: An enteric-coated oral dosage form comprising an acid labile active pharmaceutical ingredient where the composition is substantially free of monomeric phthalic acid esters and synthetic oils is described herein. Also provided are methods for making and using the enteric-coated oral dosage form. The disclosed pharmaceutical compositions comprise an enteric coating... Agent: Mayer, Brown, Rowe & Maw LLP

20070148152 - Process for the manufacture and use of pancreatin micropellet cores: A process for manufacturing and using pancreatin micropellet cores and pancreatin micropellets which are substantially free of synthetic oils. In one embodiment, a pharmaceutical composition is provided comprising a pancreatin micropellet with the enteric coating being designed to deliver pancreatin to the upper portion of the intestine of a mammal... Agent: Mayer, Brown, Rowe & Maw LLP

20070148151 - Processes for the manufacture and use of pancreatin: A process for the manufacture and use of pancreatin in which the concentration of one or more biological contaminants is reduced, such as viruses and/or bacteria, through heating the pancreatin at a temperature of at least 85° C. for a period of less than about 48 hours.... Agent: Mayer, Brown, Rowe & Maw LLP

20070148154 - Use of superoxide dismutase mimetics and reductase gultatione in the form of anticancer drugs: The invention relates to the use of superoxide dismutase mimetics and reductase glutathione (preferably Mangafodipir) in order to produce an anticancer drug. Said mimetic, in particular makes it possible to potentiate the actions of antitumoral agents generating active oxygen forms on tumoral cells and to protect non-tumoral cells against said... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070148157 - Chondroitinase abc i polynucleotides: The invention relates to chondroitinase ABC I and uses thereof. In particular, the invention relates to recombinant and modified chondroitinase ABC I, their production and their uses. The chondroitinase ABC I enzymes of the invention are useful for a variety of purposes, including degrading and analyzing polysaccharides such as glycosaminoglycans... Agent: Wolf Greenfield & Sacks, P.C.

20070148156 - Human chondroitinase glycoprotein (chasegp), process for preparing the same, and pharmaceutical compositions comprising thereof: The invention relates to the discovery of a novel Chondroitinase Glycoproteins (CHASEGP's), methods of manufacture, and potential uses in conditions where removal of chondroitin sulfates may be of therapeutic benefit. Chondroitinase Glycoproteins require both a substantial portion of the catalytic domain of the CHASEGP polypeptide and asparagine-linked glycosylation for optimal... Agent: Dla Piper US LLP

20070148158 - Rationally designed heparinases derived from heparinase ii: Modified heparinases having altered binding specificity and activity are provided. Isolated nucleic acids encoding the same as well as vectors and host cells are provided. Methods for using the modified heparinases are also provided.... Agent: Wolf Greenfield & Sacks, P.C.

20070148161 - Biopolymer membrane and methods for its preparation: A biopolymermembrane in its substantially dry form having a thickness less than about 75 microns, a solvent content less than about 5% by weight of the membrane, a radius of curvature of less than about 5 centimeters, a density greater than about 1 g/cm3, and a maximum pore size of... Agent: Baxter Healthcare Corporation

20070148160 - Methods, devices, and compositions for lysis of occlusive blood clots while sparing wound sealing clots: It has now been discovered that certain mutant forms of pro-urokinase (“pro-UK”), such as so-called pro-UK mutant “M5” (Lys.sup.300.fwdarw.His)-, perform in the manner of pro-UK in lysing “bad” blood clots (those clots that occlude blood vessels), while sparing hemostatic fibrin in the so-called “good” blood clots (those clots that seal... Agent: Kevin Farrell Pierce Atwood

20070148159 - Use of crotoxin as an analgesic - cip: A method of producing analgesia and enhancing analgesia is disclosed. The method includes administering a beta-neurotoxin that is characterized by its ability to bind to pre- and postsynaptic receptors resulting in the inhibition of neurotransmission.... Agent: Robert J. Van Der Wall Gables One Tower

20070148162 - Molecule which binds cd80 and cd86: The present invention relates to the identification of molecules, which are specific to CD80 and CD86 antigens. Also preferably, such antibodies are capable of inhibiting the binding of CD28 and CTLA4 to those receptors. Those molecules are able to inhibit T cell mediated immune reactions.... Agent: Jacobson Holman PLLC

20070148163 - Mutants of anti-cd40 antibody: A mutant of a potentially therapeutic anti-CD40 antibody is provided which mutant has reduced ADCC and CDC activities designed to be optimized as a pharmaceutical agent. A mutant of an agonistic anti-CD40 antibody, comprising mutation and/or substitution of at least one amino acid in the constant region to reduce the... Agent: Foley And Lardner LLP Suite 500

20070148168 - Compositions and methods for the treatment and prevention of fibrotic, inflammatory and neovascularization conditions: The present invention relates to compositions and methods for prevention and treatment of diseases and conditions, including ocular diseases and conditions, characterized by aberrant fibrogenesis or scarring, inflammation and/or aberrant neovascularization or angiogenesis. The compositions and methods of the invention utilize immune-derived moieties that are specifically reactive against bioactive lipids... Agent: Biotechnology Law Group C/o Portfolioip

20070148164 - Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto: The compositions and methods of the present invention are based, in part, on our discovery that an effector function mediated by an Fc-containing polypeptide can be altered by modifying one or more amino acid residues within the polypeptide (by, for example, electrostatic optimization). The polypeptides that can be generated according... Agent: Lahive & Cockfield

20070148167 - Non-immunostimulatory antibody and compositions containing the same: The present invention relates to a non-immunostimulatory antibody which lacks antibody-dependent cell-mediated cytotoxicity, Fc gamma receptor binding and complement-mediated cytotoxicity. In some embodiments, the antibody contains a modified immunoglobulin G2 (IgG2) Fc region with at least one substitution in the B/C loop, FcRn binding domain, and the F/G loop. The... Agent: Jane Massey Licata Licata & Tyrrell P.C.

20070148165 - Recombinant antibody composition: The present invention relates to a recombinant antibody composition having higher complement-dependent cytotoxic activity than a human IgG1 antibody and a human IgG3 antibody, wherein a polypeptide comprising a CH2 domain in the Fc region of a human IgG1 antibody is replaced by a polypeptide comprising an amino acid sequence... Agent: Nixon & Vanderhye, PC

20070148166 - Scfvs in photosynthetic microbes: Expression of functionally active recombinant single chain antibodies in prokaryotic and eukaryotic heterotrophic algae for pathogen treatment or control in aquaculture and agriculture applications is disclosed; and subsequent modification of the strains to generate transgenic algae propagated under defined conditions.... Agent: Baker & Mckenzie LLP

20070148169 - Therapeutic agent for chronic arthritides diseases of childhood-related diseases: A therapeutic agent for chronic arthritides diseases of childhood-related diseases, for example chronic arthritides diseases of childhood, Still's disease and the like, comprising an interleukin-6 (IL-6) antagonist as an active ingredient.... Agent: Foley And Lardner LLP Suite 500

20070148170 - Fc variants with optimized fc receptor binding properties: The present invention relates to Fc variants with optimized Fc receptor binding properties, methods for their generation, Fc polypeptides comprising Fc variants with optimized Fc receptor binding properties, and methods for using Fc variants with optimized Fc receptor binding properties.... Agent: Morgan, Lewis & Bockius, LLP

20070148171 - Optimized anti-cd30 antibodies: An antibody that targets CD30, wherein the antibody comprises at least one modification relative to a parent antibody and the antibody binds with altered affinity to an FcγR or alters effector function as compared to the parent antibody. Also disclosed are methods of using the anti-CD30 antibody.... Agent: Morgan, Lewis & Bockius, LLP

20070148172 - Method for the treatment of inflammatory bowel disease: The present invention provides a method for the treatment and/or prophylaxis of inflammatory bowel disease (IBD) comprising administering a therapeutically effective amount of an inhibitor of CSF-1 activity.... Agent: Woodcock Washburn LLP

20070148174 - Nuclease inhibitor cocktail: Methods and compositions for inhibiting and/or inactivating nucleases by employing nuclease inhibitors are provided. The nuclease inhibitors comprise anti-nuclease antibodies and non-antibody nuclease inhibitors. The anti-nuclease antibodies of the present invention may be a polyclonal or monoclonal antibodies, and may be anti-ribonuclease antibodies, anti-deoxyribonuclease antibodies, or antibodies to non-specific nucleases.... Agent: Michael R. Krawzsenek Fullbright & Jaworski L.L.P.

20070148173 - Treatment of acute lung injury, fibrosis and metastasis with antagonists of alpha v beta 6: Methods and compositions comprising antagonists of αvβ6 are provided for the treatment of acute lung injury fibrosis.... Agent: Townsend And Townsend And Crew, LLP

20070148175 - Diagnostics and therapeutics for diseases associated with kallikrein 12 (klk12): The invention provides a human KLK12 which is associated with the gastrointestinal and liver diseases, cancer disorders, hematological diseases, inflammatory diseases, respiratory diseases, neurological disorders, cardiovascular disorders, reproduction disorders and urological disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of gastrointestinal... Agent: Banner & Witcoff, Ltd.

20070148179 - Gankyrin: Gankyrin having the amino acid sequence as set forth in SEQ ID NO: 2, or modified gankyrin comprising an amino acid sequence modified by the deletion and/or addition of one or a plurality of amino acids and/or the substitution with other amino acids in the amino acid sequence of SEQ... Agent: Foley And Lardner LLP Suite 500

20070148176 - Isolation of five novel genes coding for new fc receptors-type melanoma involved in the pathogenesis of lymphoma/melanoma: This invention provides an isolated nucleic acid molecule which encodes immunoglobulin receptor, Immunoglobulin superfamily Receptor Translocation Associated, IRTA, protein. Provided too, are the IRTA proteins encoded by the isolated nucleic acid molecules, IRTA1, IRTA2, IRTA3, IRTA4 or IRTA5 proteins, having the amino acid sequences set forth in any of FIGS.... Agent: Cooper & Dunham, LLP

20070148177 - Treatment with anti-vegf antibodies: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.... Agent: Genentech, Inc.

20070148178 - Treatment with anti-vegf antibodies: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.... Agent: Genentech, Inc.

20070148180 - Peptide-immunoglobulin-conjugate: The current invention is related to peptide-immunoglobulin-conjugates in which at least two of the termini of the immunoglobulin polypeptide chains are conjugated to a peptide, whereby the peptides can be different, similar or identical. The conjugation is effected on the nucleic acid level.... Agent: Roche Palo Alto LLC Patent Law Dept. M/s A2-250

20070148183 - Chemically programmable immunity: The present invention is related to methods and compositions that are capable of immediately immunizing a human or animal against any molecule or compound. The present invention comprises an immunity linker molecule with at least two sites; (1) a first binding site that binds to an immune system molecule in... Agent: King & Spalding LLP

20070148182 - Formulation of antigen: The present invention regards methods and formulations for diagnosis, prevention and treatment of disease. More particularly, the present invention teaches methods and formulations for diagnosis, prevention and treatment with antigen in autoimmune disease, allergy, rejection of transplants and cancer. Examples illustrate how the methods and formulations of the invention may... Agent: Roger A. Gilcrest

20070148181 - Ganglioside based vaccine compositions for subcutaneous administration: Vaccine compositions in which gangliosides and the OMP of N. meningitidis were combined to form very small size proteoliposomes (VSSP) to be administered subcutaneously are described, these compositions do not require the use of any additional adjuvant. The described compositions allow the immunological treatments with gangliosides, particularly N-AcGM3/VSSP and N-GcGM3/VSSP,... Agent: Lackenbach Siegel, LLP

20070148184 - Survivin-derived peptides and use thereof: MHC Class I-restricted peptides derived from the tumor associated antigen, survivin, which peptides are capable of binding to Class I HLA molecules at a high affinity, capable of eliciting INF-γ-producing cells in a PBL population of a cancer patient and capable of in situ detection of cytotoxic T cells in... Agent: Hunton & Williams LLP Intellectual Property Department

20070148185 - Novel therapeutic target for protozoal diseases: A novel Hemozoin Detoxification Protein (HDP) from Plasmodium and related parasites is provided as a target for therapeutic intervention in diseases caused by the parasites. HDP has been shown to play a critical role in adhesion to, or invasion into, host cells by the parasite. Furthermore, HDP catalyzes the neutralization... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20070148186 - Simarouba amara and/or momordica charantia extracts for the treatment of coccidiosis in poultry: Described is the use of a coccidiostatically effective amount of Simarouba amara either alone or in combination with Momordica charantia for the manufacture of a medicament for the therapy of coccidiosis in poultry. Further described is a method for controlling coccidiosis in poultry based on the administering of said medicament.... Agent: Novartis Corporate Intellectual Property

20070148187 - Mastic gum composition for use as a dietary supplement in humans and animals: A dietary supplement and herbal formula and treatment methodology for humans and animals, having as its primary ingredient mastic gum extract, for the support, increase and production, function, and/or treatment of the kidneys.... Agent: Dennis G. Lapointe Lapointe Law Group, Pl

20070148188 - Anthrax vaccine: This invention provides a conjugate between poly-D-gamma glutamic acid and a carrier protein. The conjugate can be used for therapeutic or prophylactic immunization against anthrax infections. The invention also includes methods of purifying poly-D-gamma glutamic acid, methods of conjugation, vaccines and methods of vaccination against B. anthracis.... Agent: Merck And Co., Inc

20070148189 - Stable liquid formulations of botulinum toxin: The invention includes liquid formulations of botulinum toxin that are stable to storage in liquid form at standard refrigerator temperatures for at least 1-2 years and to storage at higher temperatures for at least 6 months. The invention also includes methods of treatment using such formulations for various therapeutic and... Agent: Wilson Sonsini Goodrich & Rosati

20070148190 - Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine: The present invention describes derivatized polysaccharide-protein conjugates, a composition comprising one or more of such derivatized polysaccharide-protein conjugates and methods of immunizing human patients with the same. The derivatized polysaccharide-protein conjugates are purified capsular polysaccharides from Nesseria meningitidis serogroups A, C, W-135, and/or Y, derivatized chemically activated and selectively attached... Agent: Sanofi Pasteur, Inc.

20070148191 - Use of ligands of specific antigen for the diagnosis and treatment of solid tumours and bone-related cancerous diseases: The present invention relates to the use of ligands of specific antigens for the diagnosis and treatment of solid tumours and bone-related cancerous diseases, and in particular to the use of ligands for CDw52 for the preparation of a medicament for the treatment of CDw52-expressing solid tumours, such as bone... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070148195 - Compositions and methods for transdermal oxybutynin therapy: The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at... Agent: Thorpe North & Western

20070148193 - Lutein concentrate: The invention relates to a lutein solubilized product comprised of one part, which consists of a lutein-containing composition, and of approximately 7 to approximately 9 parts polysorbate, and to a method for the production thereof, during which a lutein-containing composition is mixed with approximately seven to nine times the amount... Agent: Jacobson Holman PLLC

20070148194 - Novel nanoemulsion formulations: An oil-in-water nanoemulsion delivery system that includes at least one oil having a concentration of greater than or equal to 2% (w/w) of at least one polyunsaturated fatty acid, preferably of the omega-3 or omega-6 family, is disclosed. The delivery system further includes at least one emulsifier and also an... Agent: Weingarten, Schurgin, Gagnebin & Lebovici LLP

20070148192 - Stable ophthalmic composition: The present invention provides a clear stable ophthalmic composition comprising (a) an anti-infective agent; (b) a steroidal anti-inflammatory agent; (c) a complexing agent capable of forming an inclusion complex and (d) other pharmaceutically acceptable excipients in a liquid vehicle such that the composition is free of any other complexation enhancing... Agent: Merchant & Gould PC

20070148198 - Method of manufacturing self-warming products: Microencapsulated delivery vehicles comprising an active agent are disclosed. In one embodiment, the microencapsulated delivery vehicles are heat delivery vehicles capable of generating heat upon activation. The microencapsulated heat delivery vehicles may be introduced into wet wipes such that, upon activation, the wet wipe solution is warmed resulting in a... Agent: Senniger Powers (kcc)

20070148196 - Method for producing colloidal nanoparticles with a compounder: The invention relates to an improved method for producing homogenous colloidal nanoparticles, preferably liposomes, using a compounder.... Agent: Morgan Lewis & Bockius LLP

20070148199 - Preparations for topical skin use and treatment: Topical preparations for release of an active agent to the skin are provided. The preparations have an internal phase dispersed within an external phase. The internal phase includes a hydrophilic carrier and an enzyme active agent. The external phase comprises a silicone matrix.... Agent: Dinsmore & Shohl LLP One Dayton Centre

20070148197 - Treating inflammation with ondansetron and pharmaceutical compositions comprised thereof: Inflammatory skin disorders such as rosacea, including a variety of skin diseases, whether or not accompanied by dermatosis, are treated by topically applying onto the affected skin area, a thus effective amount of Ondansetron, or salt or base thereof.... Agent: Buchanan, Ingersoll & Rooney PC

20070148200 - Agricultural compositions for through bark application to woody plants: An agricultural composition for topical application to woody plant periderm, the composition comprising (a) an insecticide or a plant growth regulator, (b) an organosiloxane surfactant, and (c) water.... Agent: Arthur M Reginelli Renner Kenner Greive Bobak Taylor & Weber

20070148201 - Muteins of a bilin-binding protein with affinity for a given target: The present invention relates to novel muteins derived from a bilin-binding protein (BBP) that binds a given target, for example a macromolecular target, with detectable affinity. In particular, the invention relates to a mutein of the bilin-binding protein of Pieris brassicae. The invention also refers to a corresponding nucleic acid... Agent: Foley And Lardner LLP Suite 500

20070148202 - Food bait comprising a specific attractant for combating tephritidae insects: The present invention refers to a food bait characterized in that it comprises at least: one or more food components, a preservative or a mixture of preservatives, at least one toxic ingredient and a fourth component selected between: at least one specific attractant of tephritidae insects, and at least a... Agent: Klauber & Jackson

20070148203 - Insecticide and molluscicide composition and methods: Bait compositions of spinosyns in combination with metal complexones and other mollusicides are provided in an environmentally safe composition that is effective to a treat and/or control a wide spectrum of insect and mollusc pests.... Agent: Nutter Mcclennen & Fish LLP

20070148204 - Wide spectrum insecticide and miticide composition: An environmentally safe, pesticidally effective composition is provided to control insect/mite pests. In an exemplary embodiment, a composition is provided that includes a pesticidally effective, yet environmentally safe, concentration of at least one spinosyn with at least one additional contact-acting insecticide and/or miticide and at least one solvent or carrier.... Agent: Nutter Mcclennen & Fish LLP

20070148206 - Method and systems for forming and using nanoengineered sculptured thin films: A method of forming a sculptured thin film on a surface includes rotating the surface and depositing a sculptured thin film comprised of a polymer on the surface to form submicron wires during the step of rotating. The submicron wires may be columnar, helically columnar, chevron shaped, chiral shaped, distinct... Agent: Mckee, Voorhees & Sease, P.L.C Attn: Pennsylvania State University

20070148205 - Prevention of arterial restenosis with active vitamin d compounds: The present invention relates to a method for preventing, treating, or ameliorating arterial restenosis after angioplasty in an animal by administering to the animal active vitamin D compounds. The invention further relates to a method for preventing, treating, or ameliorating restenosis after angioplasty in an animal by administering to the... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070148207 - Therapeutic inhibitor of vascular smooth muscle cells: Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle... Agent: Jones Day

20070148208 - Anti-excititoxic sustained release intracular implants and related methods: Biocompatible intraocular implants include an anti-excitotoxic agent and a biodegradable polymer that is effective to facilitate release of the anti-excitotoxic agent into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is... Agent: Allergan, Inc.

20070148209 - Allergic constitution ameliorator: An agent for improving allergic predisposition is provided. This agent is effective in improving the allergic predisposition, safe, and readily ingestible. More specifically, an agent for improving allergic predisposition and an agent for suppressing production of IgE antibody containing a hydrolysate of water-soluble dietary fibers as its effective component are... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070148210 - Composition for enhancing physical performance: This invention relates to a composition that contains quercetin, vitamin B1, vitamin B2, vitamin B3, vitamin B6, vitamin B12, vitamin C, caffeine, epigallocatechin gallate, epicatechin, epicatechin gallate, and epigallocatechin.... Agent: Fish & Richardson PC

20070148211 - Processes for making particle-based pharmaceutical formulations for oral administration: A method is provided for making an oral dosage form of a pharmaceutical agent which includes the steps of (a) providing particles which include a pharmaceutical agent; (b) blending the particles with particles of a pre-processed excipient to form a primary blend, wherein the pre-processed excipient is prepared by (i)... Agent: Sutherland Asbill & Brennan LLP

20070148212 - Feed additive composition for ruminants, and feed containing the same, and method of fabricating such feed additive composition for ruminants: The coating composition which coats the biologically active substance includes at least one protective material selected from the group consisting of a hardened animal fat, a hardened vegetable oil, a linear or branched, saturated or unsaturated aliphatic monocarboxylic acid having 12 to 22 carbon atoms, a fatty acid ester, and... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070148213 - Film containing compositions: An oral care, personal care or cleansing composition with a carrier comprising a functional material and at least two polymers. One polymer has a greater solubility in water than the other polymer; one of the polymers may be water-soluble and the other polymer water-insoluble. The polymers are selected and apportioned... Agent: Colgate-palmolive Company

20070148215 - Therapeutically active dressings, their manufacture and use: The invention relates to therapeutically active wound dressings based on polysaccharides, in particular chitosan, and protein, in particular collagen/gelatine, with improved properties, their manufacture, in particular the use of polycarbonic acids and polyfunctional amino acids, and their use, especially in the medical field.... Agent: William Collard Collard & Roe, P.C.

20070148214 - Wound dressing for the controlled release of therapeutic agents: A wound dressing material for controlled activation of a wound healing therapeutic compound in the presence of a protease enzyme in a wound fluid, the material comprising: a medically acceptable polymer; a wound healing therapeutic agent; an inhibitor of the protease enzyme; and a linker group which is cleavable by... Agent: Philip S. Johnson Johnson & Johnson

20070148216 - External preparation for percutaneous administration containing nonsteroidal anti-inflammatory analgesic: An external preparation for percutaneous administration which contains a light-sensitive nonsteroidal anti-inflammatory analgesic and a UVA-shielding agent which inhibits the analgesic to cause light toxicity and a light allergy. This external preparation for percutaneous administration, which contains a nonsteroidal anti-inflammatory analgesic, can be prevented, with higher certainty, from causing the... Agent: Edwards Angell Palmer & Dodge LLP

20070148219 - Liposomal nanowater-containing patch-type nanodermal gel for transdermal delivery and method for preparing the same: Disclosed herein is a patch-type nanodermal gel including liposomal nanowater, which can deliver cosmetically active substances, such as those functioning to moisturize the skin, into and through the skin stably and effectively. The patch-type cosmetic composition for transdermal deliver, based on nanodermal gel, comprises nanowater in an amount from 0.01... Agent: Steptoe & Johnson LLP

20070148218 - Olanzapine containing transdermal drug delivery compositions: The invention features compositions for the transdermal administration of olanzapine. The compositions include olanzapine or a pharmaceutically acceptable salt thereof, a pressure sensitive adhesive, and an excipient, such as a permeation enhancer and/or a solubilizer of olanzapine. The compositions are useful for the treatment of certain psychiatric disorders, for example... Agent: 3m Innovative Properties Company

20070148217 - Percutaneous absorption type cerebral protective agent: e

20070148224 - Skin treatment compositions containing copper-pigment complexes: This invention discloses compositions and method for treating various types of skin disorders, based on topical cutaneous delivery of copper chemically bound with botanical pigments. Sodium-copper-chlorophyllin is used as an example, showing benefits in the treatment of rosacea, acne, oily skin, enlarged pores, and in relieving skin inflammation. Benefits are... Agent: Theodore Jay Suite 600

20070148220 - Liposomes and liposomal compositions for vaccination and drug delivery: The present invention relates to liposomes and compositions comprising liposomes, their production and use for the prevention and therapy of proliferative diseases, infectious diseases, vascular diseases, rheumatoid diseases, inflammatory diseases, immune diseases, and allergies.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070148226 - Mahonia aquifolim extract, extraction process and pharmaceutical composition containing the same: The present invention provides a skin treatment composition comprising a Mahonia aquifolium extract in a liposome delivery system. The Mahonia aquifolium extract is present in the skin treatment composition in a range of from 5% to 20% by weight of the total composition. The skin treatment composition is particularly effective... Agent: Patrea L. Pabst Pabst Patent Group LLP

20070148221 - Method of producing lipid complexed camptothecin-carboxylate: An improved method for producing a cationic liposomal preparation comprising a camptothecin drug with enhanced physical and chemical stability, a cationic liposomal preparation obtainable by this method and pharmaceutical compositions thereof are disclosed.... Agent: Morgan Lewis & Bockius LLP

20070148225 - Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye: The present invention relates to development of efficacious pharmaceutical compositions comprising an active compound in a therapeutically effective amount encapsulated or solubilized in phospholipid vesicles.... Agent: Alcon

20070148222 - Skin treatment compositions containing copper-pigment complexes: A therapeutic method is described in which copper is delivered into the skin as a complex with sodium chlorophyllin. Sodium copper chlorophyllin is encapsulated in suitable lecithin-type liposomes, containing a high concentration of linoleic acid and having diameters in the range 150-350 nanometers. The method provides therapeutic benefits in the... Agent: Theodore Jay Suite 600

20070148223 - Skin treatment compositions containing copper-pigment complexes: A therapeutic method is described in which copper is delivered into the skin as a complex with sodium chlorophyllin. Sodium copper chlorophyllin is encapsulated in suitable lecithin-type liposomes, containing a high concentration of linoleic acid and having diameters in the range 150-350 nanometers. The method provides therapeutic benefits in the... Agent: Theodore Jay

20070148227 - Physically/molecularly distributed and/or chemically bound medicaments in capsule shells: The present invention proposes a design to incorporate medicaments in the capsule shells (body and cap). Medicaments in the cap and body of the capsules may be different. Other medicaments in the form of granules, beads etc. can be filled in the capsules, which may contain medicaments capsule shell. Thus,... Agent: Tara Enterprises

20070148228 - Solid oral dosage form containing an enhancer: The invention relates to a pharmaceutical composition and oral dosage forms comprising an HDAC inhibitor in combination with an enhancer to promote absorption of the HDAC inhibitor at the GIT cell lining. The enhancer is a medium chain fatty acid or a medium chain fatty acid derivative having a carbon... Agent: Synnestvedt & Lechner, LLP

20070148231 - Fast-disintegrating tablets: The invention relates to a method of manufacture of fast-disintegrating tablets, and tablets obtained comprising chemicals, foodstuff, oral drug components and the like. The method is characterized in that the components in pulverized form are contacted with a pressurized liquefied gas or gas mixture, homogenized, introduced into moulds under pressure,... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070148230 - Medicament-containing particle and a solid preparation containing the particle: The invention provides a medicament-containing particle wherein an unpleasant taste of the medicament is alleviated, which is obtainable by mixing and granulating the following ingredients: (1) the medicament with an unpleasant taste, (2) methylcellulose and (3) mannitol; and a solid preparation including the particle. The invention can make an unpleasant... Agent: Birch Stewart Kolasch & Birch

20070148235 - Pharmaceutical composition: The present invention relates to a granular pharmaceutical composition comprising a drug having a disagreeable taste, a wax and a sugar alcohol; a method for preparing the same; and a pharmaceutical product for oral administration, comprising the granular composition. The product excellently masks a disagreeable taste possessed by a drug... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070148236 - Pharmaceutical compositions of adsorbates of amorphous drug: Pharmaceutical compositions comprise a low-solubility drug adsorbed onto a high surface area substrate to form an adsorbate. The compositions in some embodiments include a concentration-enhancing polymer.... Agent: Pfizer Inc.

20070148234 - Pharmaceutical formulations: The present invention relates to oral formulations comprising an active agent comprising at least one of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, salts of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid or buffered 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid.... Agent: Robert Deberardine D-377/ap6a-1

20070148233 - Pharmaceutical formulations of fenofibrate having improved bioavailability: Provided are pharmaceutical compositions of fenofibrate, and dosage forms containing them, that include fenofibrate, a polyethylene glycol, and a polyethylene-polypropylene glycol; wherein the compositions are made by subliming a sublimable carrier from a combination of fenofibrate, the polyethylene glycol, and the polyethylene-polypropylene glycol with the sublimable carrier, for example menthol.... Agent: Kenyon & Kenyon LLP

20070148232 - Stabilized pharmaceutical solid compositions of low-solubility drugs and poloxamers, and stabilizing polymers: Solid compositions with improved physical stability comprise an amorphous, low-solubility drug, a poloxamer, and a stabilizing polymer. The compositions provide good physical stability during storage and concentration enhancement of dissolved drug when administered to an aqueous environment of use.... Agent: Pfizer Inc.

20070148229 - Tablet with coloured core: Press-coated tablets comprising a care and a coating. The core contains an active substance and a colouring agent such that when the tablet is exposed to penetrating radiation the core is contrasted with the coating and is visible through the coating. The invention also relates to the use' of a... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070148237 - Sustained-release formulation of zonisamide: Pharmaceutical formulations comprise sustained-release zonisamide. Methods of preparing such pharmaceutical formulations involve intermixing zonisamide with a suitable excipient configured to control the dissolution profile of the zonisamide. Methods of treatment involve administering the pharmaceutical formulations to patients in need of such treatment.... Agent: Knobbe Martens Olson & Bear LLP

20070148238 - Dosage forms for movement disorder treatment: The invention relates to the improvement in the treatment of certain neural disorders/diseases, such as Parkinson's disease and other motor disorders. One aspect of the invention relates to drug compositions and dosage forms comprising said drug composition. Another aspect of the invention relates to methods of manufacturing the drug compositions... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070148239 - Ion exchange resin treated to control swelling: The present invention provides a method and composition are provided for loading one or more drugs in a solution onto one or more ion exchange resin particles to form a drug-loaded resin particle. The drug-loaded resin particle is a sustained-release coated layered pharmaceutical drug-ion exchange resin having a one or... Agent: Chalker Flores, LLP

20070148240 - Oral formulation containing itraconazole and methods for manufacturing and using the same: The present invention provides oral pharmaceutical formulation for azole antimicrobial drugs such as itraconazole, saperconazole, ketoconazole, and fluconazole. The oral pharmaceutical formulation contains a core and a drug coating layer. The drug coating layer contains the azole antimicrobial drug and a binder, but not containing an emulsion (such as polyoxypropylene-polyoxyethylene... Agent: Andrews Kurth LLP

20070148241 - Use of an intermediate for controlling the release profile of an oral formulation of a medicament: A swellable intermediate layer that includes a swellable material selected from the group of starch, starch derivatives such as pregelatinised starch, sodium carboxyethyl starch, sodium starch gycolate, cellulose, cellulose ethers such as HPMC, HPC, HEC MC, sodium carboxymethyl cellulose, carrageenans, aginates, pectins, xanthanes and their derivatives, guar gum, tragacanth, polyvinyl... Agent: Ratnerprestia

20070148243 - Containment of a treatment agent in a body vessel: Medical devices useful for the containment of a treatment agent in a body vessel are described. The medical devices comprise a compressible plug having compressed and uncompressed diameters. Upon delivery to a treatment site in a body vessel, the compressible plug expands to engage the interior wall of the body... Agent: Dunlap, Codding & Rogers, P.C.

20070148242 - Preparation for repairing cartilage tissue, especially articular cartilage defects: The invention relates to preparations which are suitable for repairing enchondral or osteochondral defects (4) by means of implantation, said preparations comprising a cartilage element (A) and optionally a bone element (B) which is connected to the cartilage element (A). The cartilage element (A) can already contain cells during the... Agent: Williams, Morgan & Amerson

20070148245 - Compressed solid dosage forms with drugs of low solubility and process for making the same: One of the objects of the present invention is directed to a process of preparing a pharmaceutical formulation of a drug of low aqueous solubility, comprising (A) fixing the drug in a strong matrix comprising at least one at least partially amorphous sugar to obtain a sugar-drug matrix; and (B)... Agent: Kenyon & Kenyon LLP

20070148244 - Drug delivery systems: e

20070148246 - Nucleic acid-based matrixes: Various nucleic acid-based matrixes are provided, comprising nucleic acid monomers as building blocks, as well as nucleic acids encoding proteins, so as to produce novel biomaterials. Methods of utilizing such biomaterials include delivery of biologically active agents, cell and tissue culture, and cell-free protein synthesis.... Agent: Wilson Sonsini Goodrich & Rosati

20070148247 - Pharmaceutical composition which reduces or eliminates drug abuse potential: A pharmaceutical composition which reduces or eliminates the drug abuse potential of central nervous system stimulant comprising: (a) a drug selected from the group consisting of methylphenidate, amphetamine, methamphetamine, and combinations thereof; and (b) a gel forming polymer wherein the gel forming polymer is a polymer that forms a gel... Agent: Novartis Corporate Intellectual Property

20070148248 - Gastric reflux resistant dosage forms: Gastric resistant film-forming compositions are described herein. The composition comprises a gastric resistant natural polymer, a film-forming natural polymer, and optionally a gelling agent. Suitable gastric resistant natural polymers include polysaccharides such as pectin and pectin-like polymers. The film-forming composition can be used to prepare soft or hard shell gelatin... Agent: Patrea L. Pabst Pabst Patent Group LLP

20070148250 - Loading of a camptothecin drug into colloidal nanoparticles: The present invention relates to an improved method of producing a colloidal nanoparticulate preparation comprising a camptothecin drug in its carboxylate form, a kit and a pharmaceutical composition.... Agent: Morgan Lewis & Bockius LLP

20070148249 - Method of preparation of oral solid dosage form with instant release of acting: A method of preparation of an oral solid dosage form with instant release of an active agent containing as the active agent finasteride characterized in that an aqueous suspension containing 5% to 50% by weight of finasteride, based on the total weight of the suspension, and 0.1 to 50% by... Agent: Notaro & Michalos

20070148253 - Modified release formulation of lithium carbonate and method for preparation thereof: Modified release formulation of lithium carbonate in microgranules or similar comprising, for around 300 Kg of Lithium Carbonate, at least: Overall Povidone in quantity between 8.0 Kg and 40.0 Kg; Ethylcellulose in quantity between Kg 0.9 and Kg 3.6.... Agent: Laubscher & Laubscher, P.C.

20070148251 - Nanoparticle releasing medical devices: Nanoparticles comprising a matrix or shell material and a bioactive agent and medical devices containing the nanoparticles are provided.... Agent: Squire, Sanders & Dempsey LLP

20070148252 - Solid ganaxolone formulations and methods for the making and use thereof: In certain embodiments, the invention is directed to composition comprising stable particles comprising ganaxolone, wherein the volume weighted median diameter (D50) of the particles is from about 50 nm to about 500 nm.... Agent: Davidson, Davidson & Kappel, LLC

20070148254 - Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres: Hydrophobic ion pairing (HIP) is applied to solubilize proteins and/or adjuvants in an organic medium. A polymer is cosolubilized in the medium and microspheres encapsulating the protein and/or adjuvant can be produced by a single emulsion method. Microspheres prepared by this method exhibit low initial burst of the protein and... Agent: Karen S. Canady Canady & Lortz LLP

20070148255 - Compositions for delivery of drug combinations: Methods to prepare compositions which comprise delivery vehicles having stably associated therewith non-antagonistic combinations of two or more agents. The compositions exhibit non-antagonistic effects when combinations of drugs are administered.... Agent: Morrison & Foerster LLP

20070148256 - Pharmacologic-functioning water and usage of the same: The present invention provides a new pharmacologic-functioning water demonstrating pharmacologic function without any side effects, and usage of the same. The pharmacologic-functioning water, which demonstrates pharmacologic function without any side effects and includes antioxidant-functioning water as an active principle containing hydrogen-dissolved water, which is made up of molecular hydrogen used... Agent: Greenblum & Bernstein, P.L.C

20070148257 - Transparent thermoplastic antimicrobial molding composition: wherein M1 is at least one ion selected from the group consisting of alkali metal ion, alkaline earth metal ion, ammonium ion and hydrogen ion, M2 a tetravalent metal selected from the group consisting of Ti, Zr and Sn, and where a and b are positive numbers where a+mb=1 where... Agent: Bayer Material Science LLC

20070148258 - Dialysates and methods and systems related thereto: Compositions, systems, and methods of treating conditions such as vascular calcification conditions are disclosed. A representative method includes administering to an individual in need of treatment an effective amount of at least one effector agent. Another method includes prophylactically treating vascular calcification or vascular calcification-related conditions by administering to an... Agent: Thomas, Kayden, Horstemeyer & Risley, LLP

20070148259 - Parenteral nutrition composition containing iron: Bioavailable iron-containing parenteral nutrition compositions are provided that are physico-chemically stable. Iron is present in the form of soluble ferric pyrophosphate. Methods of preparation and use of the compositions are provide, as well as kits.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20070148260 - Method for maintaining cerebral hemispheric oxygen saturation during surgery: A method for preventing or reducing hemispheric cerebral oxygen desaturation in a subject undergoing surgery, wherein the method comprising the prophylactic administration of a vasodilator to the subject.... Agent: Louis Tessier

20070148261 - Cancer treatment method: A method of treating cancer is described including administration of a 4-quinazolineamine and at least one other anti-neoplastic agent as well as a pharmaceutical combination including the 4-quinazolineamines.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070148262 - Bactericidal and virucidal composition containing natural products: A bactericidal and virucidal composition containing the natural products malic acid and grapefruit seed extract. Such compositions exhibit disinfectant effects on a broad spectrum of bacteria and viruses, and are particularly useful for disinfection of stalls, domestic animals and drinking water.... Agent: Intellectual Property / Technology Law

20070148263 - Composition to enhance the bioavailability of curcumin: A composition having a curcuminoid and an essential oil of turmeric. A composition having a curcuminoid and an essential oil of turmeric, wherein the essential oil is present in an amount sufficient to cause an enhancement of bioavailability of curcumin when the composition is administered to a human as compared... Agent: Jyoti C. Iyer, Esq.

20070148264 - Agent for the prevention and/or treatment of septicemia: What is provided is an agent for the prevention or treatment of septicemia caused by the infection of microorganism. The agent for the prevention and/or treatment of septicemia caused by the infection of microorganism has (1) a soybean extract or soybean fermented product as an effective; (2) or isoflavone as... Agent: Birch Stewart Kolasch & Birch

20070148265 - Extract of nelumbinis semen for the treatment of depression: Provided is a method for treating depression with a Nelumbinis Semen extract. The Nelumbinis Semen extract is prepared by extracting Nelumbinis Semen with an alcohol or an alcohol solution. The Nelumbinis Semen extract has been demonstrated using animal behavioral, bio-chemical and molecular biological methods to have strong antidepressive activity, as... Agent: Robert E. Bushnell

20070148266 - Pine needle extract: A composition which is obtainable as an extract from pine needles, having therapeutic activity and comprising isocupressic acid compounds in an amount of less than 0.01 wt % and further comprising one or more organic acids, can be used in foodstuffs, pharmaceutical compositions and food supplements.... Agent: Morgan Lewis & Bockius LLP

20070148267 - Method for producing plant extracts enriched with protease inhibitors for regulation of appetite and food intake in mammals: The present invention relates to a method for manufacturing a potato protein extract enriched with one or more protease inhibitors, such as potato proteinase inhibitor II, potato proteinase inhibitor I, potato cysteine protease inhibitor, and potato carboxypeptidase inhibitor, that offer a significant therapeutic benefit in controlling appetite, food intake, and... Agent: Mathews, Shepherd, Mckay, & Bruneau, P.A.

20070148268 - Chemical compounds and their use as therapeutic agent and means of quality assessment of herbal medicines: Two novel benzofuran glycosides, named psoralenoide and isopsoralenoide, isolated and purified from the seeds of Psoralea corylifolia. The compounds are useful as therapeutic agents for diseases defined under TCM and as a more accurately means of quality control and assessment for Psoralea corylifolia, an important herbs used in TCM.... Agent: Evan Law Group LLC

20070140959 - Method of preparing rhenium-tricarbonyl complex and its precursor: Disclosed herein is a method of preparing a 188Re-tricarbonyl complex for radiopharmaceutical use and of preparing a precursor thereof, and a contrast agent using the same. Particularly, this invention provides a method of preparing a 188Re-tricarbonyl precursor by reacting perrhenate with borane-ammonia (BH3.NH3), potassium boranocarbonate (K2[H3BCO2]) and phosphate in the... Agent: Lucas & Mercanti, LLP

20070140977 - Methods of transdermally administering an indole serotonin receptor agonist and transdermal compositions for use in the same: Methods of transdermally delivering a therapeutic amount of an indole serotonin receptor agonist to an individual in need thereof, e.g., to provide a therapeutic level of an indole serotonin receptor agonist to an individual in need thereof, are provided. Also provided are transdermal formulations of indole serotonin receptor agonists that... Agent: Bozicevic, Field & Francis LLP

20070140995 - Aqueous starch-oil dispersions having improved uv stability and absorbing ability: A delivery system for UV-protective sunscreen agents, antioxidants, skin care agents, cosmetics and the like comprising feruloylated acylglycerols (FAG) and other cinnamate-modified vegetable oils (CMVO) incorporates the agents into starch-based composites. These composites permit the use of a lower level of CMVO for comparable UV protection than if the CMVO... Agent: Usda-ars-office Of Technology Transfer National Ctr For Agricultural Utilization Research

20070140957 - Hierarchical chromonic structures: A method of making a chromonic structure comprises (a) preparing a first aqueous mixture comprising (i) a continuous water-soluble polymer phase and (ii) a discontinuous chromonic phase comprising a chromonic material, to form chromonic nanoparticles; (b) non-covalently crosslinking the resulting chromonic nanoparticles with a multivalent cation salt; (c) dispersing the... Agent: 3m Innovative Properties Company

20070140962 - Light sensitive compounds for instant determination of organ function: Highly hydrophilic indole and benzoindole derivatives that absorb and fluoresce in the visible region of light are disclosed. These compounds are useful for physiological and organ function monitoring. Particularly, the molecules of the invention are useful for optical diagnosis of renal and cardiac diseases and for estimation of blood volume... Agent: Wood, Herron & Evans, LLP

20070140960 - Methods for imaging soluble a-beta: Provided herein are agents that bind to soluble beta-amyloid. Also provided are in vivo and in vitro methods for detecting soluble beta-amyloid in a sample that may include brain tissue.... Agent: General Electric Company Global Research

20070140961 - Radiotherapeutic high specific activity tin-117m and methods of use: The present invention provides a radiotherapeutic composition comprising a high specific activity tin-117m source of radiotherapeutic atomic electrons and a delivery vehicle, e.g., a chelator or nanosphere or microsphere effective to contain tin-117m therein. The present invention also provides a targeting moiety linked to the delivery vehicle. Further provided are... Agent: Stuart Lee Adelman, Ph.d.

20070140958 - Rubidium generator for cardiac perfusion imaging and method of making and maintaining same: An 82Sr/82Rb generator column is made using a fluid impervious cylindrical container having a cover for closing the container in a fluid tight seal, and further having an inlet for connection of a conduit for delivering a fluid into the container and an outlet for connection of a conduit for... Agent: Ogilvy Renault LLP

20070140963 - Cytokine receptor zcytor17 multimers: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and... Agent: Zymogenetics, Inc. Intellectual Property Department

20070140964 - Cytokine receptor zcytor17 multimers: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and... Agent: Zymogenetics, Inc. Intellectual Property Department

20070140965 - Methods to ameliorate and image angioplasty-induced vascular injury: Methods for inhibiting restenosis in blood vessels expanded by angioplasty are described. The method comprises administering blood vessel wall-targeted emulsion containing an anti-restenotic agent.... Agent: Morrison & Foerster LLP

20070140966 - Multivalent immunoglobulin-based bioactive assemblies: The present invention concerns methods and compositions for stably tethered structures of defined compositions, which may have multiple functionalities and/or binding specificities. Preferred embodiments concern hexameric stably tethered structures comprising one or more IgG antibody fragments and which may be monospecific or bispecific. The disclosed methods and compositions provide a... Agent: Faegre & Benson LLP Patent Docketing

20070140967 - Agents and methods for analyzing protein interactions: Agents and methods for qualitative and quantitative analysis a protein complex or protein complexes using isotope-labeled symmetrical bifunctional crosslinkers and mass spectrometry are provided. Targeting moieties, cell permeability moieties, or affinity moieties, may be appended to the bifunctional crosslinkers. The isotope-labeled symmetrical bifunctional crosslinkers may be used in a kit... Agent: General Electric Company Global Research

20070140969 - Method for comparing botulinum neurotoxins: Skin topographical methods for quantifying pharmacodynamic parameters of a paralytic effect of a Clostridial toxin, such as a botulinum toxin upon a muscle, such as a frontalis muscle. The methods are effective in determining the potency of a Clostridial toxin, and in comparing toxins. For example, wrinkle reduction effects caused... Agent: Allergan, Inc.

20070140968 - Method for determining botulinum potency: Skin topographical methods for quantifying pharmacodynamic parameters of a paralytic effect of a Clostridial toxin, such as a botulinum toxin upon a muscle, such as a frontalis muscle. The methods are effective in determining the potency of a Clostridial toxin, and in comparing toxins. For example, wrinkle reduction effects caused... Agent: Allergan, Inc.

20070140973 - Contrast agents for myocardium perfusion imaging: The present invention is directed, in part, to compounds and methods for diagnostic imaging, comprising administering to a patient a contrast agent which has an overall negative charge.... Agent: Louis J. Wille Bristol-myers Squibb Company

20070140974 - Targeted nanoparticles for magnetic resonance imaging: In some embodiments, the present invention is directed to novel targeted contrast agents for magnetic resonance imaging (MRI). The present invention is also directed to methods of making such targeted MRI contrast agents, and to methods of using such MRI contrast agents. Typically, such targeted MRI contrast agents provide enhanced... Agent: General Electric Company Global Research

20070140972 - Targeting compositions and preparation therof: The present invention relates to targeted cancer therapy and tumour imaging, and concerns specifically new derivatives of small matrix metalloproteinase inhibitor peptides. These new derivates are the hydrophilic peptides GRENYHGCTTHWGFTLC and derivates thereof. These peptides have an increased solubility and may be used in the preparation of targeting compositions together... Agent: Birch Stewart Kolasch & Birch

20070140970 - Cell targeting conjugates: The present invention relates to cell targeting conjugates and in particular, but not exclusively, to methods of their use in selectively eliminating and in selectively imaging target cells. The invention also relates to processes for production of the conjugates and to intermediate compounds that may be used in production of... Agent: Sughrue Mion, PLLC

20070140971 - Method for screening for bacterial conjunctivitis: A method for rapidly detecting infectious conjunctivitis in a host is provided. The method includes contacting an ocular test sample with a chromogen (e.g., Reichardt's dye) that exhibits a color change in the presence of a microbe. The present inventors have discovered that the extent of the color change may... Agent: Dority & Manning, P.A.

20070140975 - Opioid formulations having reduced potential for abuse: The invention provides opioid formulations having reduced potential for abuse, and having reduced potential for illegal sale and distribution. The opioid formulations of the invention comprise at least one opioid and a sustained release delivery system.... Agent: Wilmer Cutler Pickering Hale And Dorr LLP

20070140978 - Adrenergic complement inhaler: Pharmaceutical compositions consisting essentially of: (a) an adrenergic complement; and (b) a pharmaceutically-acceptable carrier suitable for respiratory administration. Adrenergic complements include ascorbates, tocopherols, and polycarboxylic acid chelators. Methods are also provided for the treatment of respiratory disorders, particularly asthma.... Agent: Harness, Dickey & Pierce, P.L.C

20070140976 - Aqueous inhalation pharmaceutical composition: An aqueous inhalation pharmaceutical composition comprising a polypeptide or protein is provided. The composition of the present invention can improve the bioavailability of the polypeptide and protein, and avoid inducing toxicity in the lung.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070140979 - Method for accelerating the rate of mucociliary clearance: The instant invention provides for a composition and method for using Kunitz-type serine protease inhibitors, e.g., aprotinin or bikunin, for stimulating the rate of mucociliary clearance of mucus and sputum in lung airways of subjects afflicted with mucociliary dysfunctions such as cystic fibrosis.... Agent: Lisa A. Haile, J.d., Ph.d. Dla Piper US LLP

20070140982 - Diuretic aerosols and methods of making and using them: Described herein are diuretic condensation aerosols and methods of making and using them. Kits for delivering a condensation aerosol are also described. The diuretic aerosols typically comprise diuretic condensation aerosol particles that comprise a diuretic compound. In some variations the diuretic compound is selected from the group consisting of bumetanide,... Agent: Swanson & Bratschun, L.l.c

20070140981 - Intranasal compositions: The present invention provides compositions for the intranasal administration of zolpidem or a pharmaceutically acceptable salt thereof. Preferred compositions of the invention are in the form of aqueous solutions. Optionally the compositions of the invention comprise a cyclodextrin and/or chitosan, a salt or derivative thereof or a salt of a... Agent: Akin Gump Strauss Hauer & Feld L.L.P.

20070140980 - Preparation of sterile aqueous suspensions comprising micronised crystalline active ingredients for inhalation: Disclosed is a process for the preparation of sterile aqueous suspensions based on active ingredients in the form of micronised crystalline particles designed for administration by inhalation. In particular, a process for the preparation of sterile aqueous suspensions based on pharmaceutical active ingredients in the form of crystalline hydrates is... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070140983 - Ion exchange resin treated to control swelling: The present invention provides a method and composition for loading one or more drugs in a solution onto one or more ion exchange resin particles to form a drug-loaded resin particle. The drug-loaded resin particle is separated from the solution and dried before recombining the drug-loaded resin particle with the... Agent: Chalker Flores, LLP

20070140986 - Abrasive system for oral care compositions: Oral compositions comprising a first and a second abrasive are provided. The first abrasive preferably has an Einlehner hardness of greater than about 5 mg loss per 100,000 revolutions, and the second abrasive preferably has an Einlehner hardness of less than about 5 mg loss per 100,000 revolutions. A ratio... Agent: Colgate-palmolive Company

20070140985 - Cleaning and/or polishing compositions and methods of use thereof: Compositions for cleaning and/or polishing are provided. The compositions comprise a first abrasive, a film comprising a second abrasive, and a carrier. The carrier can be in the form of an oral care composition, a personal care composition, a household care composition, and the like. The present invention also provides... Agent: Colgate-palmolive Company

20070140984 - Functional powdery product: The present invention has objects to provide a functional powdery product prepared by allowing carriers to support one or more members selected from vitamin glycosides, and to provide external dermatological agents having satisfactory usability, which contain the above functional powdery products and effectively exert the functions of vitamins. These objects... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070140987 - Promoting whole body health: The present invention relates to promoting whole body health in humans and animals by using topical oral compositions comprising a safe and effective amount of an antimicrobial agent in admixture with a pharmaceutically acceptable carrier, said compositions being effective in controlling bacterial-mediated diseases and conditions present in the oral cavity... Agent: Emelyn L. Hiland Health Care Research Center (box 1050)

20070140990 - Oral compositions comprising propolis: Oral compositions are provided that comprise a propolis extract; an oral care active compound chosen from: a cationic antibacterial agent, an anti-attachment agent, a biofilm disruption agent, and an anti-inflammatory agent; and a source of fluoride ions. Further, in certain embodiments, the oral composition comprises an anionic polymeric linear polycarboxylate.... Agent: Colgate-palmolive Company

20070140989 - Protein with activity of hydrolyzing dextran, starch, mutan, inulin and levan, gene encoding the same, cell expressing the same, and production method thereof: Disclosed is an enzyme, having the amino acid sequence of SEQ. ID. No. 1 with the activity of hydrolyzing dextran, starch, mutan, inulin and levan, a gene encoding the enzyme, and a transformed cell expressing the gene. Also disclosed is a method of producing an enzyme capable of degrading dextran,... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20070140988 - Therapeutic agent for periodontal disease: A therapeutic agent for periodontal diseases is provided which is prepared by utilizing a scallop shell material and which has antimicrobial activity against periodontal disease-inducing bacteria, promotes the regeneration of the alveolar bone and enables adequate prevention and treatment of periodontal diseases. The therapeutic agent for periodontal diseases is obtained... Agent: Weingarten, Schurgin, Gagnebin & Lebovici LLP

20070140991 - Pressure sensitive adhesives for cosmetic applications: Compositions and methods are provided for forming a film on a biological surface which are long-lasting, flexible, transfer-resistant, water-proof, and comfortable to the wearer. The compositions generally comprise pressure sensitive adhesive polymers, optionally with the addition of plasticizers, tackifiers, or other film formers, and are useful for formulating cosmetics and... Agent: Avon Products, Inc.

20070140992 - Taste masking of essential oils using a hydrocolloid: The present invention relates to oral care compositions containing select hydrocolloids and essential oils, wherein the undesirable taste of the essential oils is masked by the hydrocolloid.... Agent: Johnson & Johnson

20070140997 - Photoprotective compositions containing a triazine derivative, an amide-based oil and a eutectic mixture of n-butylphthalimide/isopropylphthalimide: Stable, topically applicable cosmetic/dermatological photoprotective compositions contain: a) at least one 1,3,5-triazine compound, b) at least one oil containing in its structure at least one amide structural unit, and c) at least one eutectic mixture of n-butylphthalimide and of isopropylphthalimide, and have enhanced sun protection factors and cosmetic properties.... Agent: Buchanan, Ingersoll & Rooney PC

20070140993 - Skincare compositions: There is disclosed a skincare composition suitable for topical application to the skin. The composition comprises a cosmetically acceptable skincare composition in the form of a hydroalcoholic gel dispersion, the composition comprising salicylic acid or a salt thereof and a gelling agent in the form of a copolymer of acryloyl... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070140994 - Substituted hydrocarbyl functional siloxanes-silicone resin: Sunscreen compositions containing a hydrocarbyl functional organopolysiloxane are disclosed. The hydrocarbyl functional organopolysiloxane contains at least one siloxy unit of the formula —R2OCH2CH2OH, where R2 is a divalent hydrocarbon group containing 2 to 6 carbon atoms. The inclusion of the hydrocarbyl functional organopolysiloxane in the sunscreen composition improves the sun-protection... Agent: Dow Corning Corporation Co1232

20070140996 - Synthesis of a nitroxide antioxidant and methods of use in cosmetic and dermatological compositions: The present invention provides a dermatological and/or cosmetic composition which includes a methoxycinnamate, and a cyclic nitroxide. The present invention further provides a method of synthesizing photo absorbing-antioxidant compounds and their use in dermatological and/or cosmetic compositions. In addition, the present invention relates to the use of methoxycinnamate, and nitroxide... Agent: Mccarter & English LLP Cityplace I

20070140998 - Agent for skin external use containing salt of ascorbic acid derivative, method for stabilizing the agent for skin external use, and stabilizer: An agent for skin external use of the invention contains a salt of higher fatty acid ester of ascorbic acid-2-phosphoric acid ester and a polyhydric alcohol. According to the present invention, occurrence of turbidity or precipitation with time can be prevented to enhance stability even when the agent for skin... Agent: Sughrue Mion, PLLC

20070141000 - Stabilized ascorbic acid derivative: (wherein X and Y each represents H or a protective group for OH, R1 and R2 each represents an alkyl group having from 1 to 19 carbon atoms, which may be linear or branched, and the total number of carbon atoms in R1 and R2 is an integer of 5... Agent: Sughrue Mion, PLLC

20070140999 - Topical skin care composition containing refined peanut oil: A vehicle containing refined peanut oil for topical use in skin care and for use in skin care therapeutics, and a process for making the vehicle and a composition and therapeutic composition made from that process.... Agent: Bell, Boyd, & Lloyd LLP

20070141002 - Compositions and methods for imparting vibrancy: Leave-on hair care composition, comprising from about 0.1% to about 20% of a shine enhancing system comprising a first non-soluble particle reflecting a first color, a second non-soluble particle reflecting a second color, and a third non-soluble particle reflecting a third color; from about 0.001% to about 5% of a... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070141001 - Non-migrating colorants in multi-phase personal cleansing compositions: A multi-phase personal cleansing composition comprising: (a) a structured aqueous cleansing phase comprising a surfactant and water; and (b) at least one additional, non-lamellar aqueous phase; wherein at least one of said structured aqueous cleansing phase and said additional aqueous phase comprises at least one non-migrating colorant, said non-migrating colorant... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070141003 - Cosmetic composition with a volumizing effect: The present invention relates to the cosmetic use of at least one C4-C16 glycol with a hydrocarbon-chain and/or of a hydroxylated ester resulting from the esterification of polyol and/or of C4-C16 carboxylic acid(s), in a composition for caring for and/or making up the skin and/or the lips, as an agent... Agent: Oliff & Berridge, PLC

20070141004 - Topical administration carrier composition and therapeutic formulations comprising same: A topical administration carrier composition including water, glycerin and polysorbate, suitable for use with compositions containing active ingredients such as minoxidil that are susceptible to volatilization and transdermal penetration in application to the body. The carrier formulation retards the evaporative and systemic migration losses of the active ingredient composition, to... Agent: Intellectual Property / Technology Law

20070141007 - Novel hair treatment compositions: An aqueous and/or aqueous alcoholic leave-in composition to reduce the time to dry wet hair containing (a) at least one wetting agent having a Draves wetting value of 100 seconds of less selected in an amount sufficient to enhance the hydrophobicity of hair thereby causing water to dewet the hair,... Agent: Avon Products, Inc.

20070141008 - Cosmetic remover composition: A cosmetic removal composition suitable for removing “permanent” or long lasting color cosmetics is described. The composition comprises at least one silicone crosspolymer with solvent properties.... Agent: Kevin W. Grierson Willcox & Savage, P.C.

20070141009 - Sirna mediated post-transriptional gene silencing of genes involved in alopecia: Compositions and methods for the use of inhibitory nucleic acids, for example small inhibitory ribonucleic acids (siRNA), to adjust, manipulate, prevent, inhibit, interfere, or block the androgen signal transduction pathway in a host cell, for example in a host's hair cell are provided. Aspects of the disclosure provide compositions and... Agent: Patrea L. Pabst Pabst Patent Group LLP

20070141012 - Skin care compositions: The invention provides materials and methods for making skin care compositions that contain dried or fresh fruit particles, and also can contain suspending agents, surfactants, emollients, emulsifiers, and/or cationic polymers. The basic fruit components typically are from the pulp and peel of the fruit, which can be specially processed to... Agent: Fish & Richardson P.C.

20070141011 - Use of dynamic mixtures for a controlled release of fragrances: The present invention relates to a delivery system in the form of a dynamic mixture obtained by reacting together, in the presence of water, at least one hydrazine derivative with at least one perfuming, flavoring, insect repellent or attractant, bactericide or fungicide aldehyde or ketone. The inventive mixture is capable... Agent: Winston & Strawn LLP Patent Department

20070141010 - Wrinkle-diminishing agent: e

20070141013 - Ampholytic anionic copolymers: Ampholytic copolymers which contain a molar excess of anionogenic and/or anionic groups, polyelectrolyte complexes which contain such an ampholytic copolymer, cosmetic and pharmaceutical compositions which contain at least one such copolymer or polyelectrolyte complex and the use of these copolymers and polyelectrolyte complexes are described.... Agent: Connolly Bove Lodge & Hutz, LLP

20070141005 - Composition for the permanent shaping of human hair: p

20070141014 - Formulation assistants: The invention relates to the use of compounds of the formula (I), where R1, R2 and R3 may be identical or different and are selected from: straight-chain or branched C1- to C24-alkyl groups, straight-chain or branched C3- to C24-alkenyl groups, straight-chain or branched C1- to C24-hydroxyalkyl groups, where the hydroxyl... Agent: Millen, White, Zelano & Branigan, P.C.

20070141015 - Topical administration carrier composition and therapeutic formulations comprising same: A topical administration carrier composition including water, glycerin and polysorbate, suitable for use in formulations with active ingredient compositions containing active ingredients such as minoxidil that are susceptible to systemic penetration, and solvents that are susceptible to evaporative loss, when the active ingredient composition is topically applied to the body.... Agent: Intellectual Property / Technology Law

20070141006 - Cosmetic compositions containing modified polyamines and the uses thereof: and is devoid of any vinyl amine or vinyl amide unit, wherein said polymer compound is modified with one or more hydrophilic and/or hydrophobic hydrocarbon segments, said segment(s) being different from sugar and being devoid of any sulfur, silicone or amidino group, wherein the modification with hydrophobic hydrocarbon segments is... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070141016 - The shaving stick: The shaving stick is a means of dispensing shaving lubricant directly onto the skin without the need of other tools. The saving stick is the combination of a shaving lubricant and an applicator assembly; whereby, the shaving lubricant may be any formulation of shaving soap, cream, gel, lotion, or liquid.... Agent: Kevin Monte De Ramos

20070141018 - Food composition comprising glucosamine: The present invention relates to an orally ingestible food or pet food composition or cosmetic composition containing glucosamine generated from plant materials through a drying process for the maintenance of joint health or prevention, alleviation and/or treatment of osteoarthritis, or the improvement of the skin quality and prevention or restoration... Agent: Bell, Boyd & Lloyd LLP

20070141019 - Haircare compositions and methods: Compositions and methods are disclosed for use in the treatment or prevention of hair loss and/or the promotion of hair growth. The compositions comprise in combination Centella asiatica extract, or one or more active principles thereof, green coffee extract, or one or more active principles thereof, and one or more... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070141017 - Penetration enhancing agent and method of its production from the hemp seeds: The conveying and absorption agent, preferably for the active substances of the pharmaceutical, dietetic, and cosmetic preparations, consists of the extract from the hemp seeds, obtained by action of carbon dioxide. Advantageously, the extract is a component of the fat or wax base of the pharmaceutical or cosmetic preparation, preferably... Agent: Hershkovitz & Associates

20070141021 - Methylmaleimidyl polymer derivatives: Novel N-2-methylmaleirnide pegylating reagents for the site specific pegylation of therapeutically active proteins and methods for such pegylation using said reagents.... Agent: Gibbons P.C.

20070141022 - Polymeric delivery agents and delivery agent compounds: Polymeric delivery agents, delivery agent compounds and compositions comprising them which are useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well.... Agent: Darby & Darby P.C.

20070141020 - Use of biocompatible polymers for the preparation of a composition or a medical device: The invention relates to a biocompatible polymer having general formula (I) AaXxYy, wherein: A denotes a monomer; X denotes an RCOOR′ group; Y denotes an O or N-sulphonate group which is fixed to A and which has either formula —ROS03R′ or —RNS03R′ in which R denotes an optionally branched and/or... Agent: Leydig Voit & Mayer, Ltd

20070141023 - Assays and methods using biomarkers: Methods and assays examining expression of one or more biomarkers in a mammalian tissue or cell sample are provided. According to the disclosed methods and assays, detection of the expression of one or more such biomarkers is predictive or indicative that the tissue or cell sample will be sensitive to... Agent: Genentech, Inc.

20070141025 - Compositions and methods for cancer immunotherapy: Provided is a cancer therapeutic agent comprising a cancer targeting molecule linked to a liver-expressed chemokine (LEC). In one embodiment, the cancer targeting molecule is an antibody that targets cancer cells or tumors in vivo. The cancer targeting molecule is associated non-covalently or covalently with LEC. The cancer therapeutic agents... Agent: Foley & Lardner LLP

20070141024 - Mammalian cytokine; reagents and methods: Provided are cytokines and methods of modulating activity of the immune system using cytokine agonists or antagonists. Also provided are methods of treatment and diagnosis of immune and proliferative disorders.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070141026 - Immunotherapy in cancer treatment: The present invention relates to a novel method of cancer immuno-therapy and to a kit for use in this method. Specifically, the present invention relates to a novel method of collecting lymphocytes from sentinel lumph nodes and in vitro culture for the multiplication thereof lymphocytes.... Agent: Fish & Richardson P.C.

20070141028 - Cancer gene therapeutic drug: A cancer gene therapeutic drug of the present invention includes a carrier cell to be infected with an oncolytic virus, so as to make the oncolytic virus act on a tumor cell within a living body, wherein the carrier cell is selected from A549 cell, 293 cell, SW626 cell and... Agent: Kirk Hahn

20070141029 - Methods of gene therapy for treating disorders of the ear by adminstering a vector encoding an antonal-associated factor: The invention is directed to a method of changing the sensory perception of an animal. The method comprises administering an expression vector comprising a nucleic acid sequence encoding an atonal-associated factor, which is expressed to produce the atonal-associated factor resulting in generation of hair cells that allow perception of stimuli... Agent: Leydig Voit & Mayer, Ltd

20070141027 - Non-lethal conditioning methods for conditioning a recipient for bone marrow transplantation: Mixed chimerism induces donor-specific transplantation tolerance to organ allografts. Strategies to establish mixed chimerism using partial conditioning having significantly reduced the morbidity associated with conditioning. The donor hematopoietic cell lineage(s) responsible for the induction and subsequent maintenance of tolerance in partially conditioned recipients are not defined at present. As one... Agent: Fish & Richardson P.C.

20070141030 - Targeted pre-mrna/mrna modification and gene regulation: Methods for affecting mRNA expression or translation through the modification of pre-mRNA or mRNA transcripts are described. In one embodiment of the methods of the present invention, the branch point adenosine of a pre-mRNA transcript is 2′-O-methylated to block splicing and subsequent expression of the protein encoded by the transcript.... Agent: Blank Rome LLP

20070141038 - Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site: Methods of modifying, repairing, attenuating and inactivating a gene or other chromosomal DNA in a cell are disclosed. Also disclosed are methods of treating or prophylaxis of a genetic disease in an individual in need thereof. Further disclosed are chimeric restriction endonucleases.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070141039 - Bifidobacterium in the treatment of inflammatory disease: A strain of Bifidobacterium isolated from resected and washed human gastrointestinal tract is significantly immunomodulatory following oral consumption in humans. The strain is useful in the prophylaxis and/or treatment of undesirable inflammatory activity, especially gastrointestinal inflammatory activity such as inflammatory bowel disease or irritable bowel syndrome. The inflammatory activity may... Agent: Wolf Greenfield & Sacks, P.C.

20070141032 - Insecticidal oil-based formulations comprising an insecticidal filamentous fungus: The present invention provides an insecticidal oil-based formulation, which comprises a petroleum hydrocarbon oil, a nonionic surfactant suitable for emulsifying the petroleum hydrocarbon oil, a desiccating agent and an insecticidal filamentous fungus; and a method for controlling insect pests, which comprises applying said formulation to an insect pests, a habitat... Agent: Sughrue Mion, PLLC

20070141031 - Method for producing plant protection or plant-strengthening agent for controlling bacterial and/or fungal plant diseases, in particular against fire blight: A method for producing plant protection or plant-strengthening agent for fighting against bacterial and/or fungal plant diseases, in particular against a fire blight consisting in adding capable to proliferate fungal structures into an acid medium for treating plants.... Agent: Bachman & Lapointe, P.C.

20070141033 - Purging of cells using viruses: The subject invention relates to viruses that are able to purge (reduce or eliminate) undesirable cells in a mixture of cells. Undesirable cells can include neoplastic cells, cells mediating graft-versus host diseases, and autoimmune cells. The subject invention also relates to the purging of undesirable cells from bone marrow or... Agent: Lewis J. Kreisler

20070141036 - Composition and procedure for tissue creation, regeneration and repair by a cell-bearing biological implant enriched with platelet concentrate and supplements: A composition and method for enhancing tissue growth, regeneration, and repair includes a Biological Glue formed by extraction of an Extremely Platelet Rich Plasma (EPRP) derived from whole blood, and subsequent activation and clotting. The Biological Glue may be utilized alone to fill defects or may be used as an... Agent: Gallagher & Dawsey Co., L.p.a.

20070141037 - Enhanced submucosal tissue graft constructs: An improved tissue graft construct comprising submucosa of a warm-blooded vertebrate and a preselected group of eukaryotic cells are described. The improved tissue graft constructs can be used in accordance with the present invention to enhance the repair of damaged or diseased tissues in vivo.... Agent: Barnes & Thornburg LLP

20070141034 - Methods for isolating t cells and uses thereof: Provided herein are methods for obtaining viable populations of T cells and enriched populations of T cells.... Agent: Foley Hoag, LLP Patent Group (w/huv Hmv)

20070141035 - Pluripotent olfactory stem cells: Disclosed is a cultured pluripotent animal cell that is prepared from nasal polyps. Also disclosed are methods for making the cell and methods of treating a brain tissue damage or of promoting cerebral angiogenesis, cerebral neurogenesis, stem cell homing to the brain, neurotrophic factor expression in the brain.... Agent: Fish & Richardson PC

20070141040 - Protein kinase c peptide modulators of angiogenesis: The present invention provides peptides for inhibiting various protein kinase C isozymes. The peptide can be directed to any region of the protein kinase C isozyme, and in one embodiment, is directed to the V5 domain. The peptide can be conjugated to a carrier, in a releasable or non-releasable manner.... Agent: Morrison & Foerster LLP

20070141041 - Enzymes for reduced immunological stress: Compositions suitable for oral administration to an animal comprising at least one immune stress-reducing enzyme in an amount effective to decrease the level of positive acute phase protein in an animal, increase the level of negative acute phase protein in an animal, and/or improve animal growth performance is provided, as... Agent: Foley And Lardner LLP Suite 500

20070141042 - Methods for the treatment and prevention of diseases of biological conduits: Methods are described for dilating biological conduits by removing elastin and remodeling collagens in the wall of the conduit. Methods include the use of agents that increase the release of endogenous elastase and collagenase in the wall of the conduit, either by cells that are normally present in the wall... Agent: Jones Day

20070141043 - Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions: A non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy to the proliferative form of diabetic retinopathy comprising intravitreally administering to a patient suffering from non-proliferative diabetic retinopathy an effective amount of serine proteinase enzyme sufficient to create, without surgery, a posterior vitreal detachment... Agent: Denis A. Polyn Bausch & Lomb Incorporated

20070141044 - Method for treating cancer patients undergoing chemotherapy: A method for treating cancer patients undergoing chemotherapeutic treatments by administering Product R, a peptide-nucleic acid preparation, is disclosed.... Agent: Jones Day

20070141046 - Activated carbon for medical use: The invention relates to the use of a particulate active carbon, in particular in the form of active carbon particles, preferably active carbon beads, for the field of medicine and/or for the production of a medicament, wherein the active carbon employed has a large micropore volume content, based on the... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20070141045 - Use of adsorbent carbon microspheres for the treatment of irritable bowel syndrome: Adsorbent carbon microspheres are administered to treat irritable bowel syndrome or symptoms associated with irritable bowel syndrome.... Agent: Knobbe Martens Olson & Bear LLP

20070141047 - Feline immunoglobulin e proteins and compositions thereof: The invention relates to: nucleic acid molecules encoding the light chain and heavy chain of feline immunoglobulin E (IgE), including species-specific regions of feline IgE; proteins encoded by the nucleic acid molecules; inhibitors to the nucleic acids and proteins; antibodies to the proteins; cells transformed with the nucleic acid molecules;... Agent: Kristine H. Johnson

20070141049 - Bivalent igy antibody constructs for diagnostic and therapeutic applications: This invention relates to the field of recombinant antibody technology. It provides novel recombinant IgY antibody constructs for diagnostic and therapeutical applications. The bivalent antibody constructs display a heterotetrameric or homodimeric format stabilized by disulfide bonds. The constant heavy chain domains CH2-CH4 are partly or completely of avian origin, whereas... Agent: Needle & Rosenberg, P.C.

20070141048 - Method for linking sequences of interest: Multiplex overlap-extension RT-PCR provides an efficient method of linking two or more nucleotide sequences encoding for domains or subunits of a heteromeric protein, in a single reaction. Especially, the linkage of variable region encoding sequences from e.g. immunoglobulins, T cell receptors or B cell receptors is eased with the method... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070141050 - Methods of depleting antibodies directed towards major histocompatibility complex: The invention provides a method of depleting anti-MHC antibodies in a sample comprising contacting said sample with one or more recombinant MHC molecules or functionally equivalent variants, derivatives or fragments thereof and removing at least the recombinant MHC molecules to which antibodies to said recombinant MHC molecules contained within the... Agent: Invitrogen C/o Intellevates Sughrue Mion PLLC

20070141051 - Nucleic acid encoding cytokine receptor zcytor17: Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can... Agent: Zymogenetics, Inc. Intellectual Property Department

20070141054 - Anti-a33 antibody: The present invention provides: an antibody or a antibody fragment thereof, which can bind to A33, which specifically attacks A33-expressing tumor cells with the use of ADCC and CDC based on the immune system, and for which no HAHA is produced; and a preventive or therapeutic agent for various malignant... Agent: Foley And Lardner LLP Suite 500

20070141052 - Fc region variants: The present invention provides polypeptide Fc region variants and oligonucleotides encoding Fc region variants. Specifically, the present invention provides compositions comprising novel Fc region variants, methods for identifying useful Fc region variants, and methods for employing Fc region variants for treating disease.... Agent: Eli Lilly & Company

20070141053 - Treatment of inflammatory respiratory diseases: The present invention relates to the use of immune modulatory factors which act at CD114, CD116, and or CDw131 to successfully treat various forms of inflammatory respiratory disease, including, but not limited to ARDS, IRDS, SARS, PRRS, PEARS and SIRS.... Agent: Millen, White, Zelano And Branigan, P.C. C/o Berlex Biosciences

20070141057 - Anti-tnf antibodies and peptides of human tumor necrosis factor: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070141056 - Growth factor homolog zvegf3: Polypeptide growth factors, methods of making them, polynucleotides encoding them, antibodies to them, and methods of using them are disclosed. The polypeptides comprise an amino acid segment that is at least 90% identical to residues 46-163 of SEQ ID NO: 2 or residues 235-345 of SEQ ID NO: 2. Multimers... Agent: Zymogenetics, Inc. Intellectual Property Department

20070141058 - Method of correcting immunopathological reactions and a medicament: The principle of the present invention is the use of an activated form of ultra-low doses of monoclonal, polyclonal, or natural antibodies to cytokines implicated in the course of inflammation, including autoimmune inflammation, the activated form being prepared by multiple consecutive dilutions and exposure to external factors, preferably according to... Agent: Ilya Zborovsky

20070141055 - Methods and compositions for protein-hydroxy apatite complexes and their application in testing and modulating immunological system including a novel in vitro test for the detection of antibodies against calcium binding protein-hydroxy apatite complexes: The invention relates to methods and compositions for the manufacture and use of novel hydroxy apatite (HA)-calcium binding protein (CaBP) complexes (CaBP-HA complex) that are useful as antigen preparations for immunological assays for the diagnosis, prognosis, and monitoring of mammalian diseases. The CaBP-HA complexes may be manufactured using synthetic HA... Agent: Hogan & Hartson LLPIPGroup, Columbia Square

20070141060 - Hmgb1 protein inhibitors for the regulation of smooth muscle cells and endothelial cells profileration: The use of molecules that modulate the action of HMGB1 protein (or molecules having sequence homology) for the preparation of therapeutic agents for the treatment of diseases to related to endothelial and smooth muscle cells proliferation; said proliferation can be due to endothelium damage, caused by surgical operation and manipulation... Agent: Young & Thompson

20070141059 - Use of cathepsin s inhibitors for treating an immune response caused by administration of a small molecule therapeutic or biologic: The present invention is directed to the use of Cathepsin S inhibitors in combination with a therapy that causes a deleterious immune response in patients receiving the therapy.... Agent: Millen, White, Zelano And Branigan, P.C. C/o Berlex Biosciences

20070141065 - Anti-vegf antibodies: Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naive libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in... Agent: Merchant & Gould PC

20070141062 - Control of proliferation and apoptosis in cancer cells: The invention includes a method of inhibiting or reducing cellular proliferation through the use of one or more agents that prevent the association or interaction of pp32 polypeptides with the hyperphosphorylated form of Retinoblastoma protein. The invention also discloses agents that are useful in preventing the association or interaction of... Agent: Hunton & Williams LLP Intellectual Property Department

20070141064 - Fully human hybridoma fusion partner cell lines: Certain aspects of the present invention are directed to new fully human fusion partner cell lines called human Karyochi cells, and to methods for making them. Human Karyochi cells are then fused with human antibody-secreting lymphoid cells to make fully human hybridomas called Karyochi-based hybridomas, which likewise secrete fully human... Agent: Evans & Molinelli, PLLC

20070141066 - Method for diagnosing, prognosing and treating glioma: The invention provides generally a method of monitoring, diagnosing, prognosing and treating glioma. Specifically, the invention provides for three (3) prognostic subclasses of glioma, which are differentially associated with activation of the akt and notch signaling pathways. Tumor displaying neural or proneural PN lineage markers (including notch pathway elements) show... Agent: Genentech, Inc.

20070141069 - Method for use of igf-binding protein for selective sensitization of target cells in vivo: New methods for the treatment of human disease are provided. IGFBP-3 is administered together with a co-administered agent to subjects having disease, thereby alleviating the symptoms of the disease, under conditions where administration of IGFBP-3 alone at the maximum practicable dose has no measurable beneficial effect on the disease condition.... Agent: Foley And Lardner LLP Suite 500

20070141068 - Methods for the treatment of carcinoma: The invention concerns compositions and methods for the diagnosis and treatment of neoplastic cell growth and proliferation in mammals, including humans. The invention is based upon the identification of genes that are amplified in the genome of tumor cells, such as renal cell carcinoma. Such gene amplification is expected to... Agent: Genentech, Inc.

20070141063 - Peptide having ability to activate cancer-related gene: To provide a cancer diagnostic reagent for determining malignancy of a cancer patient or a cancer cell and a tendency of canceration of a healthy subject, the reagent including a peptide having an ability to activate a cancer-related gene and extracted from cell membrane surfaces of human squamous-cell carcinoma cells... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20070141061 - Protein involved in carcinoma: The present invention provides a polypeptide, MAL2, of use in the treatment and/or prophylaxis of carcinoma, in particular liver cancer, stomach cancer and/or colon cancer. Also provided are agents which interact with or modulate the expression or activity of the polypeptide, methods for the identification of such agents and the... Agent: Klauber & Jackson

20070141067 - Targeted cancer therapy: Methods and compositions are described for determining the expression profile of a tumor and subsequently determining an appropriate cancer therapy. Accordingly, a database can correlate expression profile data of a particular tumor before a chemotherapeutic is administered, and after the chemotherapeutic is administered and after tumor progression, such as when... Agent: Fish & Richardson P.C.

20070141070 - Methods and compositions for needleless delivery of antibodies: The present invention relates, in part, to methods and compositions for needleless delivery of antibodies to a subject. The present invention also relates, in part, to methods for needleless delivery of fusion proteins comprising a bioactive molecule and an antibody fragment to subject. In one aspect, the methods and compositions... Agent: Jones Day

20070141071 - Hot melt coating by direct blending and coated substrates: A method of coating a pharmaceutical substrate which is not a hot-melt coating by fluid bed method comprises applying a molten coating material to the pharmaceutical substrate wherein the substrate is coated with the coating material; optionally applying to the coated substrate the same or different molten coating material, and... Agent: Klarquist Sparkman, LLP

20070141073 - Antigen-drug vehicle enabling transmucosal and transdermal administration, and method of inducing mucosal immunity and mucosal vaccine and dds using the same: Disclosed are an antigen-drug vehicle (AD vehicle) exerting a function of inducing the preferential and selective production of an antigen-specific secretory IgA antibody, local immunity or mucosal immunity; a method of inducing mucosal immunity, a mucosal vaccine and a preventive or a remedy for allergy using the above AD vehicle;... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070141072 - Use of multifunctional transcription factor yin-yang-1 and variants thereof for treating illnesses, especially type 1 diabetes: The present invention relates to the influence of the activity and/or the expression of the multifunctional transcription factor Yin Yang 1 (YY1), and of variants thereof, for the treatment of many different illnesses. The invention especially relates to a mutated nucleic acid sequence which encodes a variant of the human... Agent: Marshall, Gerstein & Borun LLP

20070141074 - Agents for the inhibition of virus replication through regulation of protein folding: The invention concerns agents for the treatment of acute and chronic infections with human and animal pathogenic viruses which assemble along the cell membrane and are released through budding on the surface of the cell. Hereunto count especially causative agents of infectious diseases such as AIDS, hepatitis, hemorrhagic fever, SARS,... Agent: Jordan And Hamburg LLP

20070141076 - Antigen fragments for the diagnosis of toxoplasma gondii: The invention described herein relates to a method for identifying antigen fragments of Toxoplasma gondii proteins, and their use as diagnostic and immunogenic agents. Said method is implemented by means of selection of DNA fragments libraries of the parasite with sera of subjects who have been infected, using the phage... Agent: Nixon & Vanderhye, PC

20070141075 - Plasmodium vivax blood stage antigens, pvesp-1, antibodies and diagnostic assays: This invention is directed to novel species-specific P. vivax malarial peptide antigens which are proteins or fragments of proteins secreted into the plasma of a susceptible mammalian host after infection, and to monoclonal or polyclonal antibodies directed against those antigens. The peptide antigens, monoclonal antibodies, and/or polyclonal antibodies are utilized... Agent: Darby & Darby P.C.

20070141077 - Polysaccharide-staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections: Immunogenic polysaccharide-protein conjugates having a polysaccharide antigen (or its oligosaccharide fragment representing one or more antigenic epitopes) derived from a nosocomial pathogen conjugated to a staphylococcal surface adhesin carrier protein are used in immunogenic compositions to elicit antibody responses to both the polysaccharide antigen and the staphylococcal surface adhesin carrier... Agent: Hunton & Williams LLP Intellectual Property Department

20070141079 - Antibody production in farm animals: The present invention provides means and methods for obtaining an antibody in a mammary secretion product of a farm-animal comprising administering to said animal at least two compositions, which may be the same or different, comprising an antigen to which said antibody is to be raised, the method comprising administering... Agent: Townsend And Townsend And Crew, LLP

20070141081 - Chimeric proteins that induce effects directed against viruses: The present invention is related to the obtaining of chimeric chains coding for proteins capable of inducing, in the recipient, a serotype-specific and protective humoral immune response against the infection by the Dengue virus, thus eliminating the effects of the serotype-nonespecific viral immunoenhancement that causes hemorrhagies and clinical complications described... Agent: Hoffmann & Baron, LLP

20070141078 - Influenza vaccine: The present invention relates to monovalent influenza vaccine formulations and vaccination regimes for immunising against influenza disease, their use in medicine, in particular their use in augmenting immune responses to various antigens, and to methods of preparation. In particular, the invention relates to monovalent influenza immunogenic compositions comprising an influenza... Agent: Glaxosmihkline Corporate Intellectual Property - Uw2220

20070141080 - Treating severe acute respiratory syndrome: Severe acute respiratory syndrome is treated with a natural human alpha interferon, a dsRNA or both natural human alpha interferon and a dsRNA.... Agent: Nixon & Vanderhye, PC

20070141082 - Cell surface expression vector of parvovirus antigen and microorganisms transformed thereof: The present invention relates to a surface expression vector expressing a parvovirus antigen on the surface of microorganisms, the vector containing not only a gene encoding the capsid antigen protein of parvovirus causing canine parvovirus (CPV) infection and feline panleukopenia (FLP) but also at least one of pgsB, pgsC and... Agent: Intellectual Property / Technology Law

20070141083 - Use of a single-cell protein material: The present invention relates to the use of a single-cell protein material (SCP). The SCP material lowers the concentration of cholesterol in plasma, and triglycerides in the liver. SCP also induces a favourable change in the fatty acid pattern, and lowers the concentration of homocysteine in plasma. A preferable embodiment... Agent: Reed Smith LLP

20070141084 - Polysaccharide-protein conjugate vaccines: Abstract of the Disclosure Methods for synthesis and manufacture of polysaccharide-protein conjugate vaccines at high yield are provided. The methods involve reaction of a hydrazide group on one reactant with an aldehyde or cyanate ester group on the other reactant. The reaction proceeds rapidly with a high conjugation efficiency, such... Agent: Knobbe, Martens, Olson & Bear, LLP

20070141085 - Recombinant protective protein from streptococcus pneumoniae: The present invention discloses amino acid sequences and nucleic acid sequences relating to a Streptococcus pneumoniae surface associated Pneumo Protective Protein (PPP) having a molecular weight of about 20 kilo Daltons (kDa). The PPP exhibits the ability to reduce colonization of pneumococcal bacteria. Thus the present invention also pertains to... Agent: Hunton & Williams LLP Intellectual Property Department

20070141087 - Compounds and methods for diagnosis of tuberculosis: Compounds and methods for diagnosing tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of one or more M. tuberculosis proteins, and DNA sequences encoding such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable detection reagent may be used for... Agent: Townsend And Townsend And Crew, LLP

20070141086 - Use of antibiotics as vaccine adjuvants: The invention describes an adjuvant composition comprising an antimicrobial agent, in particular an azalide, wherein the antimicrobial agent acts as an adjuvant. More particularly, the adjuvant composition is a vaccine adjuvant. The invention further describes a vaccine comprising several components comprising (a) at least one antigen and (b) at least... Agent: Pharmacia & Upjohn

20070141088 - Glucan-based vaccines: Anti-glucan antibodies have been found to be protective against systemic fungal infection with C. albicans, but the protective efficacy can be inhibited by blocking antibodies. The invention provides an immunogenic composition comprising a glucan and a pharmaceutically acceptable carrier, characterised in that, when administered to a mammalian recipient, the composition... Agent: Robins & Pasternak

20070141092 - Biguanide composition and method of treatment and prevention of viral infections: An ophthalmically acceptable composition comprising to the ocular region of a patient, the ophthalmically acceptable composition comprising water, a biguanide containing antimicrobial in an amount effective to treat viral infection. The invention further comprises administering the ophthalmically acceptable composition to the eye of a patient in need of treatment.... Agent: Bausch & Lomb Incorporated

20070141091 - Biguanide ointment and method of treatment and prevention of infections: An ophthalmically acceptable composition comprising a biguanide antimicrobial agent and an ointment base. The invention further comprises administering the ophthalmically acceptable composition to the eye of a patient in need of treatment.... Agent: Bausch & Lomb Incorporated

20070141093 - Lipophilic di(anticancer drug) compounds, compositions, and related methods: Lipophilic di(anticancer drug) compounds, compositions that include the compounds, and methods for treating a cell proliferative disease using the compounds.... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20070141090 - Microemulsion preparation of high concentration propofol for anesthetic uses: The invention provides a method and a composition for enhancing the dissolution and bioavailable properties of propofol (2,6 diisopropyl phenol) for use as an intravenously administered anesthetic in mammals. The method produces a self-microemulsifyable emulsion base composition that is utilized in the production of a water-based microemulsiori preparation. In a... Agent: Jay P. Hendrickson

20070141089 - Topical composition comprising terbinaf ine adn hydrocortisone: The invention relates to topical pharmaceutical compositions comprising terbinafine and hydrocortisone. Said compositions exhibit beneficial antimycotic properties, especially against dermatophytes.... Agent: Novartis Corporate Intellectual Property

20070141095 - Aqueous dispersion of colloidal particles of mineral filler and fibres: The invention relates to a composition containing an aqueous dispersion of colloidal particles of at least one mineral filler, and fibres. The invention also relates to a process for treating the skin, especially wrinkled skin, via the application of the described composition to the skin.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070141094 - Composite of foamed substance and soap substance: A composite of foamed substance and soap substance includes a foamed substance formed according to a selected shape and encased by a soap substance. When the soap substance is almost totally consumed, it can still attach to the foamed substance so that it can be fully used. After the soap... Agent: Birch Stewart Kolasch & Birch

20070141096 - Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles: A liquid encapsulant component which contains an active, sensitive encapsulant, such as a live microorganism or an enzyme dissolved or dispersed in a liquid plasticizer is admixed with a plasticizable matrix material. The matrix material is plasticizable by the liquid plasticizer and the encapsulation of the active encapsulant is accomplished... Agent: Douglas J. Taylor, Attorney General Mills, Inc.

20070141098 - Method and system for dispensing dry bird repellent: Methods and apparatus for dispensing bird repelling chemical solutions, such as a methyl anthranilate (MA) solution in a bird inhalable size, are disclosed. A small particle haze, including a bird repelling chemical, such as MA, is created in an enclosed container. The small particle haze is created by one or... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20070141097 - Packaging means for emanating pyrethroid effective in controlling flying insects: The invention provides a packaging means for retaining vapour active pyrethroids comprising a holder and a cellulosic based substrate or matrix impregnated and/or dosed with the vapour active pyrethroid, wherein the holder comprises a topl), a bases and a longitudinal member vertically extending from between the topw and base, and... Agent: Merchant & Gould PC

20070141099 - Coils: Coils, such as embolic coils, and related methods, devices, and compositions, are disclosed.... Agent: Fish & Richardson PC

20070141110 - Continuous phase compositions for acl repair: An implantable interference screw for use in a soft tissue repair, the screw having a bioresorbable body comprising a plurality of interconnected pores, the body having an instrument interface in one end and a thread around an exterior of the body starting from distal end. The plurality of interconnected pores... Agent: Harness, Dickey & Pierce, P.L.C

20070141102 - Drug delivery system based on polyethylene vinylacetate copolymers: Disclosed herein is a drug delivery system consisting of one or more compartments and comprising a progestogenic compound dissolved in a thermoplastic polyethylene vinylacetate copolymer. Also disclosed are a contraceptive kit or hormone-replacement therapy kit comprising the drug delivery system, and a combination preparation that simultaneously provides contraception and treatment... Agent: Akzo Nobel Inc.

20070141106 - Drug eluting implant: The present invention provides a medical system for the administration of a pharmaceutical agent in vivo to a patient. The medical system includes a medical implant positionable in a body of a patient. A pharmaceutical agent in disposed on the medical implant and at least partially coated with a reactive... Agent: Paul D. Bianco: Fleit, Kain, Gibbons, Gutman, Bongini, & Bianco P.l.

20070141100 - Drug-eluting biodegradable stent: The present invention relates to a drug-loaded biodegradable stent and methods for treating vulnerable plaques of a patient comprising a plurality of layers or zones, each layer or zone comprising its own specific biodegradation rate and its specific drug loading characteristics. In one embodiment, the layers and zones are configured... Agent: Hosheng Tu

20070141105 - Engineered biological matrices: Biocompatible matrices or implants on which one or more specific cell-interactive molecules (“biomolecules”) can be immobilized have been developed. The matrices allow for the independent control of ligand concentration and matrix strength. In one embodiment, the matrix or implant is modified with one or more moieties capable of complexing bioconjugates... Agent: Patrea L. Pabst Pabst Patent Group LLP

20070141108 - Fiber-reinforced water-swellable articles: This invention provides water-swellable materials including polymeric fibers dispersed in a water-swellable polymer, and fiber-reinforced articles made from such water-swellable materials. The invention also provides a method of forming a fiber-reinforced, water-swellable material. These water-swellable materials and fiber-reinforced articles may be used in biomedical and pharmaceutical applications and may be... Agent: Wood, Herron & Evans, LLP (zimmer)

20070141109 - Local deliver of 17-beta estradiol for preventing vascular intimal hyperplasia and for improving vascular endothelium function after vascular injury: A device for local intracoronary delivery comprising 17-β estradiol or a derivative thereof in a dosage of 1 to 5000 μg/Kg of patient's body weight, and a pharmaceutically acceptable parenteral vehicle... Agent: Quarles & Brady LLP

20070141101 - Method for stimulating angiogenesis and wound healing: A device comprising an extracellular matrix having an internal pH between 4.0 and 6.0 is discussed. This matrix contains heparin or a heparin-related compound such as heparan sulfate. Preferably the matrix also contains fibronectin or a fragment thereof. The matrix will bind to a protein having a pH dependent binding... Agent: Ronald I. Eisenstein

20070141103 - Pliable medical device and method of use: A firm but pliable medical device for use as a bone graft substitute or bone graft extender retains its shape without the requirement of a containment device, such as a syringe. Because the device is solid, it is easy to locate or position in-vivo and, in the moist environment of... Agent: Merchant & Gould PC

20070141107 - Progenitor endothelial cell capturing with a drug eluting implantable medical device: A medical device for implantation into vessels or luminal structures within the body is provided, which stimulates positive blood vessel remodeling. The medical device, such as a stent and a synthetic graft, is provided with a coating with a pharmaceutical composition containing a controlled-release matrix and one or more pharmaceutical... Agent: Kelley Drye & Warren LLP

20070141104 - Room temperature-curable polymers: Methods of making room temperature-curable polymers. Reactants include siloxane-terminated polymers and silanols. The reactants are mixed, and the polymerization allowed to proceed in air at room temperature. The polymers are exceptionally useful because they allow for the incorporation into the polymers themselves of one or more therapeutic compounds. Thus, medical... Agent: Cameron Kerrigan Squire, Sanders & Dempsey LLP

20070141112 - Drug-eluting articles with improved drug release profiles: The present invention relates to drug-eluting articles with multiple polymeric coatings arranged and constructed to provide improved drug release profiles. Specifically, the present invention relates to drug-eluting articles that each comprises a substrate, a first polymeric layer over said substrate, and a second polymeric layer over said first polymeric layer.... Agent: Philip S. Johnson Johnson & Johnson

20070141111 - Porous medical device and method for its manufacture: Porous bioabsorbable, bioactive and load-bearing composite medical device structure includes a plurality of regular textile planar layers (1a, 1b . . . ) formed of continuous bioabsorbable polymer matrix and bioceramic fibers acting as reinforcements, both included in continuous fibrous elements (3) forming the textile layers. The layers are placed... Agent: Kenyon & Kenyon LLP

20070141113 - Unsymmetrical aromatic ether diacids and absorbable polymers therefrom: r

20070141114 - Article coated with an ultra high hydrophobic film and process for obtaining same: The present invention relates to an article having at least one surface, wherein said surface is at least partially coated with a ultra high hydrophobic film having a surface roughness such that the film exhibits a static water contact angle at least equal to 115°, preferably 120°, even better 125°,... Agent: Fulbright & Jaworski L.L.P.

20070141117 - Anti-excititoxic sustained release intraocular implants and related methods: Biocompatible intraocular implants include an anti-excitotoxic agent and a biodegradable polymer that is effective to facilitate release of the anti-excitotoxic agent into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is... Agent: Allergan, Inc.

20070141115 - Drug delivery systems: o

20070141116 - Glaucoma implant device: An aqueous humor drainage device having an elongate duct structure that provides a fluid passageway for diverting aqueous humor from the anterior chamber of the eye and at least one fixation member that extends from the elongate duct structure. In one embodiment, the fixation member is realized by a tab... Agent: Gordon & Jacobson, P.C.

20070141118 - Layered dosage form for a medicated tampon assembly: A tampon adapted to deliver a therapeutic agent includes a tampon body having a distal end and a dosage form affixed to the distal end of the tampon body, the dosage form including a first active layer dispersible by a first mechanism, and an attachment layer dispersible by a second... Agent: Kimberly-clark Worldwide, Inc.

20070141123 - Emulsions comprising non-esterified phytosterols in the aqueous phase: A stable emulsion in which an aqueous phase has one or more phytosterols or phytostanols, or mixtures thereof in free (non-esterified) form and an oil or fat phase has phytosterols or phytostanols, or mixtures thereof, in esterified form.... Agent: Kirton And Mcconkie

20070141124 - Induced-viscosity nutritional emulsions: Disclosed are induced viscosity nutritional emulsions comprising (A) protein having a protein-bound methionine sulfoxide content of 8% or less of the total protein-bound methionine, on a molar basis, (B) fat, and (C) an induced viscosity fiber system that provides the emulsion with a packaged viscosity of less than 300 cps... Agent: Ross Products Division Of Abbott Laboratories Department 108140-ds/1

20070141121 - Method of treating kidney disease: The progression of kidney disease and especially polycystic kidney disease in humans may be retarded and the symptoms ameliorated by administration of an effective amount of soy molasses or isolated soyasaponins or mixtures thereof in conjunction with the essential amino acids. Restriction of protein to a moderate level of 0.8... Agent: Gary J. Calton

20070141122 - Nutritional composition and method of manufacture: A nutritional composition, and method of making it, that includes a carbohydrate, an insulin potentiator, an amino acid, a muscle growth stimulator, an energy increaser and at least one flavoring ingredient. The composition may be provided in dry form for addition to a fluid or in liquid forms. The composition... Agent: Mitchell P. Brook C/o Luce, Forward, Hamilton & Scripps LLP

20070141120 - Peptide having an ace inhibiting effect: Use of the tripeptide XPP, wherein X= C, M, S, T, or K, and/or salts thereof for the preparation of an angiotensin-converting enzyme inhibitor and food products comprising the tripeptide XPP.... Agent: Unilever Intellectual Property Group

20070141119 - Use of additionally fermented distillers grains for preventing and/or treating increased blood sugar values: The present invention relates to the use of distillers grains fermented with a yogurt culture and/or buttermaking culture for producing a composition for preventing and/or treating increased blood sugar values.... Agent: Fitch Even Tabin And Flannery

20070141126 - Germicidal surface-covering assembly: A germicidal surface-covering assembly that includes at least two different donnable or drapable garments. Each garment defines at least one treated surface that is susceptible to pathogen contamination in a physical contamination event when used as intended in an environment subject to contamination (e.g., a clinical environment, a laboratory or... Agent: Kimberly-clark Worldwide, Inc.

20070141125 - Thermal image with antimicrobial property: The invention relates to a packaging material comprising a substrate, an image formed by thermal dye transfer on said substrate and a transparent polymer overlayer on the opposite side of the image from said substrate, and further comprising antimicrobial composition in said overlayer.... Agent: Paul A. Leipold Patent Legal Staff

20070141127 - Wet wipes with natural antimicrobial agents: Wet wipes impregnated with a composition having a pH value of between 2.5 and 5.0. The composition is in the form of an oil-in-water emulsion and comprises a non-ionic silicone surfactant, a natural antimicrobial active and a buffer system. The wipes may be used for personal cleansing, in particular as... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070141131 - Measurement of cytoskeletal proteins and uses thereof in diagnosis, prognosis and therapy: The present invention relates to monitoring patients for an inflammatory condition or infection (preferably wound infection) by testing an extracellular fluid such as a wound fluid for an elevated level of: (i) vimentin; (ii) a vimentin breakdown product; or (iii) a marker indicative of the presence of vimentin. The present... Agent: Philip S. Johnson, Esq. Johnson & Johnson

20070141129 - Wound care product comprising a substance which inhibits the growth of bacteria in wounds: Wound care product which comprises a substance which inhibits the growth of bacteria in wounds. The invention is characterized by the fact that the substance is xylitol. The invention also relates to the use of xylitol in wound care products and to the use of xylitol for producing a composition... Agent: Young & Thompson

20070141128 - Wound cleansing apparatus with actives: An apparatus for cleansing and applying therapy or prophylaxis to wounds, in which irrigant fluid containing a physiologically active material from a reservoir connected to a conformable wound dressing and wound exudate from the dressing are recirculated by a device for moving fluid through a flow path which passes through... Agent: Stites & Harbison PLLC

20070141130 - Wound or surgical dressing: A wound or surgical dressing is disclosed. The wound or surgical dressing is configured to cover or surround a wound, a surgical incision, or any type of skin irritation. In accordance with the present disclosure, the wound or surgical dressing is treated with a bacteriostatic composition that is capable of... Agent: Dority & Manning, P.A.

20070141132 - Human growth hormone patch formulations: The invention encompasses a transdermal patch formulation comprising hGH, at least one sugar, one amino acid or polyol, and a buffer, wherein the buffer maintains the pH of the formulation in the range of about 5 to about 9 and the formulation does not contain both glycine and mannitol.... Agent: Kenyon & Kenyon LLP

20070141135 - Compositions and methods for less immunogenic protein-lipid complexes: The present invention provides compositions and methods for reducing the immunogenicity and increasing the circulating half-life of therapeutic proteins such as Factor VIII. The compositions comprise lipidic structures such as liposomes, micelles and cochleates comprising a negatively charged lipid and polyethylene glycol derivatized phospatidyl ethanolamine.... Agent: Hodgson Russ LLP

20070141133 - Glutathione based delivery system: A delivery system. The delivery system includes a carrier or an active compound and a glutathione or a glutathione derivative grafted thereon. The invention also provides a compound including a moiety comprising a vitamin E derivative or a phospholipid derivative, a polyethylene glycol (PEG) or a polyethylene glycol derivative bonded... Agent: Birch Stewart Kolasch & Birch

20070141136 - Method of treating insulin resistance, adult onset diabetes and metabolic syndrome x: A method of treating insulin resistance, adult onset diabetes, and metabolic syndrome X and its related complications, in a mammalian subject is accomplished by intravenously administering to a mammalian subject, a therapeutically effective amount of a liposomal suspension of lipoprotein small unilamellar vesicles (SUVs) comprising predominantly phospholipids. The liposomal suspension... Agent: Hoffman, Wasson & Gitler, P.C.

20070141134 - Shielded micelles for polynucleotide delivery: The present invention relates to compositions that enhance the intracellular delivery of polynucleotides. The present invention is applicable to the fields of gene therapy and oligonucleotide or DNA therapy. Synthetic methods are disclosed, wherein a polynucleotide can be incorporated into the PEG shielded micelle particle to facilitate the delivery of... Agent: Matthew K. Kosak

20070141139 - Composition for intestinal delivery: The present invention relates to a new composition, use and method for oral administration to a human or an animal of a physiologically active agent comprising neutralizing agents to increase pH in the digestive system to prevent denaturation, inhibitors of digestive enzymes to substantially prevent enzymatic digestion, and at least... Agent: Faegre & Benson LLP Patent Docketing

20070141138 - Omega 3 fatty acid formulations: The present invention provides highly purified omega-3 fatty acid formulations. Certain formulations provided herein have contain greater than 85% omega-3 fatty acids by weight. Certain other formulations provided herein contain EPA and DHA in a ratio of from about 4.01:1 to about 5:1. The invention also provides methods of using... Agent: Cantor Colburn, LLP

20070141137 - Stable capsule preparation: A capsule in which an unstable active ingredient has been stabilized is obtained by lowering the moisture content of a solid preparation (granules, subtilis, tablets, etc.) containing a chemical unstable to moisture such as an imidazole PPI compound by drying or the like, and then filling in a capsule comprising... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070141145 - Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same: The present invention relates, in part, to a biocompatible hydrophobic-core carrier comprising a carrier, and a plurality of hydrophobic groups covalently linked to the polymeric carrier. The hydrophobic groups are capable of dissociably linking load molecules such as therapeutic agents. The hydrophobic-core carrier may also comprise protective side chains, orienting... Agent: Darby & Darby P.C.

20070141144 - Oral delivery system: The present invention relates generally to formulations comprising paracetamol. More particularly, the present invention provides a swallow formulation comprising paracetamol which facilitates the rapid delivery of paracetamol into the circulatory system following oral administration. The present invention further relates to methods for inducing efficient pain relief including an analgesic effect... Agent: Kenyon & Kenyon LLP

20070141141 - Pharmaceutical composition: An immediate release pharmaceutical composition comprising 4-(3′-chloro-4′-fluoroanilino)-7-methoxy-6-(3-mor-pholinopropoxy)quinazoline or a pharmaceutically-acceptable salt thereof (the Agent); a water-soluble acid; and a water-soluble cellulose ether or an ester of a water-soluble cellulose ether. The claimed compositions inhibit the rate of precipitation of the Agent from solution and/or provide enhanced solubilisation of the agent... Agent: Morgan Lewis & Bockius LLP

20070141142 - Pseudo-thermosetting neutralized chitosan composition forming a hydrogel and a process for producing the same: The composition disclosed is a pseudo-thermosetting neutralized chitosan composition, neutralized with an hydroxylated base, forming a phosphate-free transparent hydrogel at a temperature higher than 5° C. Said composition contains a homogeneously reacetylated chitosan derived from a chitosan having a deacetylation degree of 80-90%, having a molecular weight of not smaller... Agent: Harness, Dickey & Pierce, P.L.C

20070141140 - Semi-solid formulations for immediate release intended for the oral administration of drugs: The present invention relates to a pharmaceutical composition suitable for oral administration, in the form of semisolid matrix, comprising an active ingredient poorly soluble in water and present in a quantity of from 15 to 45% by weight of the percent composition of the pharmaceutical composition; a surfactant agent constituted... Agent: Pharmacia & Upjohn

20070141143 - Solid compositions of low-solubility drugs and poloxamers: Solid compositions of low-solubility drugs and poloxamers that provide concentration enhancement when administered to an aqueous environment of use are disclosed.... Agent: Pfizer Inc.

20070141147 - Sequential release pharmaceutical formulations: A mixed-release tablet or capsule formulation including vehicles for the delivery of a plurality of drugs in various combinations of immediate release, extended release, and/or delayed release modes over a predetermined time period have been developed, which provide for controlled release not just of the drugs, but controlled release that... Agent: Patrea L. Pabst Pabst Patent Group LLP

20070141148 - Neramexane mr matrix tablet: The invention provides novel oral modified release dosage forms of neramexane which are useful for the continuous therapy of patients suffering from diseases and conditions such as Alzheimer's dementia and neuropathic pain. The compositions have drug release profiles that are suitable for achieving steady state plasma concentrations of neramexane which... Agent: The Firm Of Hueschen And Sage

20070141146 - Novel compositions: An oral dosage form that provides controlled release of an active pharmaceutical agent, 5 -[4-[2-(N-methyl-N-(2 pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (hereinafter ‘Compound A’) or a pharmaceutically acceptable salt or solvate thereof in different body environments, a process for the preparation of such an oral dosage form, and the use of such a dosage form... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070141149 - Controlled-release pharmaceutical formulation: In the present invention, a new pharmaceutical formulation with controlled release of the freely water soluble low-dose active substance used for at the most once daily administration is disclosed. The active substance is maintained at a suitable therapeutic concentration in the blood throughout at least a 24 hour period independent... Agent: Novartis Corporate Intellectual Property

20070141154 - Antidiabetic formulation and method: An antidiabetic pharmaceutical formulation is provided, especially adapted for treating Type II diabetes, which includes a combination of metformin and glipizide in a manner to control moisture in the formulation so that the glipizide does not hydrolyze, yet the metformin is compressible, if necessary. A method for treating diabetes is... Agent: Louis J. Wille Bristol-myers Squibb Company

20070141151 - Lansoprazole orally disintegrating tablets: The invention provides orally disintegrating tablets that readily disintegrates in the mouth, releasing enteric coated drug sub-tablets.... Agent: Kenyon & Kenyon LLP

20070141152 - Orally administered pharmaceutical composition: It is an object of the present invention to provide an orally administered pharmaceutical composition capable of completely masking the flavor, odor and the like of a drug contained in a drug-containing layer, and to achieve this object, the outer edge of a first water-swellable gel-forming layer 12a and the... Agent: Posz Law Group, PLC

20070141153 - Orally administered pharmaceutical composition: An object of the present invention is to provide an orally administered pharmaceutical composition comprising a drug-containing layer and a functional layer wherein cracks and gaps in the drug-containing layer are prevented even if the amount of glycerin contained in the drug-containing layer is not sufficient to cause bleeding of... Agent: Posz Law Group, PLC

20070141150 - Pharmaceutical composition: A solid pharmaceutical dosage form comprises a core particle containing at least one pharmaceutical active ingredient and/or excipient that is sensitive to acid, a subcoating containing a chemically reactive component disposed over the core, and an enteric coating over the subcoating.... Agent: Dr. Reddy's Laboratories, Inc.

20070141155 - Pharmaceutical tablets having height greater than width: An immediate release compressed pharmaceutical tablet that has two or more segments and a top and a bottom and has a height that exceeds the width of the tablet. The height is measured vertically from the top to the bottom of the tablet while it is in the tablet die... Agent: Accu-break Technologies, Inc.

20070141156 - Compositions and methods for preventing or reducing postoperative ileus and gastric stasis: Disclosed are compositions and methods for preventing or reducing postoperative ileus and gastric stasis. Such compositions comprise a combination of an oxidized regenerated cellulose component and a non-steroidal anti-inflammatory drug (NSAID) which functions as an inhibitor of cyclooxygenase enzyme (Cox) activity. Such methods comprise administering an effective amount of the... Agent: Peter W. Roberts Roberts, Mlotkowski & Hobbes, PC

20070141157 - Method for producing antibiotic/antibiotics and their use: A method for producing antibiotic/antibiotics-particles characterized in that an aqueous solution of an amino glycoside-antibiotic or an aqueous solution comprising two or more amino glycoside-antibiotics is mixed under agitation with a solvent mixture comprising isopropanol and at least one additional alcohol, with the volume ratio of the solvent mixture to... Agent: Kurt G. Briscoe Norris, Mclaughlin & Marcus P.A.

20070141158 - Amphiphilic heparin derivative formed by coupling a heparin with a bile acid: The invention relates to an amphiphilic heparin derivative formed from at least one type of partially N-desulfated heparin and at least one type of bile acid comprising one or several bile acid molecules grafted on a heparin molecule by an amide bond formed between the terminal carboxylic acid function of... Agent: Foley And Lardner LLP Suite 500

20070141162 - Injectable compositions for the controlled delivery of pharmacologically active compound: The present invention provides compositions and methods for extending the release times and lowering the toxicity of pharmacologically active compounds. The compounds comprise a salt of the pharmacologically active compound with a lipophilic counterion and a pharmaceutically acceptable water soluble solvent combined together to form an injectable composition. The lipophilic... Agent: Kenyon & Kenyon LLP

20070141161 - Liquid ganaxolone formulations and methods for the making and use thereof: In certain embodiments, the invention is directed to composition comprising stable particles comprising ganaxolone, wherein the volume weighted median diameter (D50) of the particles is from about 50 nm to about 500 nm.... Agent: Davidson, Davidson & Kappel, LLC

20070141160 - Method of treatment for osteoarthritis by local intra-articular injection of microparticles: A method of treatment of osteoarthritis is described, where a therapeutically effective amount of a composition having biodegradable microparticles in an aqueous vehicle is delivered into the intra-articular space of a joint. In one aspect, the microparticle-containing composition is injected into the synovial fluid-containing portion of an affected joint.... Agent: Philip S. Johnson Johnson & Johnson

20070141159 - Methods of making nanoparticulate drug compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers: The present invention is directed to nanoparticulate compositions comprising a poorly soluble drug and at least one copolymer of vinyl pyrrolidone and vinyl acetate as a surface stabilizer adsorbed to the surface of the drug. Also encompassed by the invention are pharmaceutical compositions comprising a nanoparticulate composition of the invention,... Agent: Elan Drug Delivery, Inc. C/o Foley & Lardner LLP

20070141165 - Method for manufacturing microcapsules containing capsinoid: Capsinoid-containing microcapsules comprising 0.01 to 10 weight parts of capsinoid-containing hydrophobic material per weight part of hydrophilic solution containing 0.001 to 50 percent of capsule wall material and having a median diameter of 0.01 to 1,000 μm are provided.... Agent: Cermak & Kenealy LLP Acs LLC

20070141164 - Methods and gel compositions for encapsulating living cells and organic molecules: A method for encapsulating biologics within a hydrogel by using an aqueous solution of an isocyanate-functional polyurethane prepolymer which is mixed with an amount of biologics and an aqueous solution containing a dithiol crosslinking agent under physiological pH conditions to create a hydrogel. An additional bidentate crosslinking agent is optionally... Agent: Fitch Even Tabin And Flannery

20070141163 - Smart bio-nanoparticle elements: The invention in suitable embodiments is directed to smart bio-nanoparticle elements and intelligent bio-nanoparticle platforms employing such smart bio-nanoparticle elements. In one aspect, the smart bio-nanoparticle elements are formed with self-assembling protein molecules.... Agent: Franco Vitaliano

20070141166 - Biological artificial nerve guide and method of making: A biological nerve guide for implantation into a human body is made by providing a natural animal tissue membrane, crosslinking and fixing the membrane, minimizing the antigens from the membrane, tanning the membrane, coupling an active layer to an inner surface of the membrane, cutting the membrane into a desired... Agent: Raymond Sun

20070141167 - Use of benzyl nicotinate for pain relief: The invention is directed to novel topical compositions for relieving pain comprising benzyl nicotinate as well as methods of using these compositions.... Agent: Cheryl H Agris Phd

20070141168 - Burn treatment method and composition: e

20070141169 - Homeopathic drug composition and methods of use thereof: The present invention comprises homeopathic preparations of compounds, methods for using such preparations and delivery systems for the treatment of disease symptoms through the administration of these homeopathic compositions.... Agent: Bryan Cave LLP

20070141170 - Composition and methods for inhibiting the progression macular degeneration and promoting healthy vision: The present invention provides improved dietary supplements and methods for inhibiting the progression of macular degeneration and promoting healthy vision, while at the same time maintaining general health. The dietary supplements of the invention contain vitamin E and carotenoids in the form of Vitamin A, lutein and/or zeaxanthine. The dietary... Agent: Alcon

20070141171 - Novel composition and method for the treatment of hypertension: The present invention provides for a composition and method of treatment and prevention of hypertension and its restulting complication comprising the step of administering to a patient a therapeutically-effective amount of Quercetin or Quercetin Glycoside and Epican Forte in therapeutic proportions.... Agent: Inhouse Co.

20070141172 - Method of treating bacterial hoof infections of sheep and cattle: Bacterial infections in cattle and sheep are treated by applying a solution of zinc chloride to the hooves of the animals. Preferably, the solution is applied to the hooves by placing the solution in a foot bath and guiding the animals through the foot bath. The spent solution can then... Agent: Wood, Herron & Evans, LLP

20070141173 - Medicament comprising noble metal fine particles: A medicament for prophylactic and/or therapeutic treatment of a disease selected from the group consisting of a neurodegenerative disease such as amyotrophic lateral sclerosis and Alzheimer's disease, rheumatic disease such as rheumatoid arthritis, ischemic heart disease such as myocardial infarction, stress ulcer, dermatitis, arteriosclerosis and hyperlipidemia, which comprises fineparticles of... Agent: Greenblum & Bernstein, P.L.C

20070141174 - Enantiomeric compositions of cicletanine, in combination with other agents, for the treatment of hypertension: The invention provides formulations and methods of use of furopyridine-based compositions alone and in combination with one or more various second therapeutic agents for the treatment of human disease. The furopyridine composition may include one or more furopyridine species, of which cicletanine is an example. The furopyridines may take various... Agent: Greenberg Traurig, LLP (sv2)

20070141175 - Chemotherapy adjuvant: The present invention provides chemotherapy adjuvants for reducing the severity of side effects caused by one or more chemotherapy agent(s), methods of reducing the severity of chemotherapy agent side effects, and methods of treating cancer.... Agent: Jonathan P. O'brien, Miller Canfield Paddock And Stone

20070141176 - Elemental sulfur as an oral or parentral medical product: Title element and its acid addition salts and derivatives are physiologically acceptable, essential and are readily converted to acceptable counter parts by established procedures, they are pharmacologically active on the liver, lungs, hematopoetic system and all body systems and are thus useful when administered to warm blooded animals to induce... Agent: Jay S Cinamon Abelman Frayne And Schwab

20070141177 - Method for enhancing fertility: The present invention provides a method for enhancing fertility in a human woman. The method comprises: providing a non-toxic composition containing an alkalizing agent; and administering said composition into a vagina of the woman at least 12 hours prior to her ovulation, such that a pH value of her vagina... Agent: Pillsbury Winthrop Shaw Pittman, LLP

20070141179 - Methods for alleviating symptoms associated with menopause using sensory regimen: The invention relates to a method for alleviating on or more of the symptoms associated with menopause in a woman in the peri-menopause or menopause stage, said method comprising the step of administering a sensory regimen in an amount effective to downregulate the activity of the HPA axis of said... Agent: Philip S. Johnson Johnson & Johnson

20070141178 - Processes for obtaining lignan extracts and compositions containing the lignan extracts: Processes for obtaining lignan extracts from plant materials are disclosed. Compositions including lignan extracts as well as uses of the lignan extracts are also disclosed.... Agent: Archer Daniels Midland Company

20070141180 - Succulent plant water: Water is obtained from a succulent plant. This may be achieved by denaturing a water-based sap of the succulent plant from a water-storing portion of the succulent plant. Water may then be evaporated from the resulting liquefied sap of the succulent plant. As many succulent plants thrive in arid climates,... Agent: William F. Ryann

20070141181 - Use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals: The present invention relates to compositions for the modulation of inflammation in connective tissues in humans and animals and the modulation of markers of such inflammation, including COX-2, TNF-α, IL-1β, iNOS, p38, and chemokines, comprising any or all of anabolic, anti-catabolic, anti-oxidant and analgesic agents, including aminosugars, S-adenosylmethionine, arachadonic acid,... Agent: Covington & Burling, LLP Attn: Patent Docketing

20070141182 - Combination of multiple nonteroidal antiinflammatory drugs and muscle relaxants for local treatment of musculoskeletal pain: This invention relates to pharmaceutical compositions for use in the treatment of pain and inflammation and the treatment of muscle spasms and associated pain, soreness and tightness of muscles in mammalian organism, said composition comprising: (i) an analgesically and anti-inflammatory effective amounts of five NSAIDs and (ii) an amount effective... Agent: Sarfaraz K. Niazi

20070141183 - Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2: A novel formulation is provided that serves to inhibit the inflammatory response in animals. The formulation comprises, as a first component an effective amount of a curcuminoid species and an effective amount of a second component selected from the group consisting of an alpha-acid species or a beta-acid species or... Agent: Mcdermott Will & Emery LLP

20070141184 - Composition for oral administration containing capsaicinoids: The invention concerns a composition for oral administration containing capsaicinoids associated with a formulation base acceptable for oral administration, said formulation base comprising an oil and an additive solid or pasty at room temperature which represents 5 to 20 wt. %, preferably 8 to 15 wt. % of the composition.... Agent: Foley And Lardner LLP Suite 500

20070141185 - Oral microemulsion composition comprising biphenydimethyldicarboxylate and silybin: A microemulsion composition comprising biphenyldimethyldicarboxylate (BDD) and silybin or a derivative thereof, or a <i>Carduus marianus</i> extract containing silybin and derivatives thereof, as active ingredients; a co-surfactant; a surfactant; and an oil provides a synergistic therapeutic effect for liver diseases due to the complementary work of the two kinds of... Agent: Sughrue Mion, PLLC

20070141186 - Nopal extract: A nopal extract isolated from insoluble fibrous waste of a nopal cactus plant. The extract may be concentrated to particularly useful concentrations and provided as a drinkable health supplement. The extract may also be fermented for additional benefit.... Agent: William F. Ryann

20070141187 - Compositions for protection against superficial vasodilator flush syndrome, and methods of use: Compositions for protection against SVFS syndromes are composed of a flavonoid compound of the basic structures 2-phenyl-4H-1-benzopyran or 2-phenyl-4-keto-1-benzopyran or glycosides thereof, an inventive olive kernel extract and a non-bovine sulfated proteoglycan, and, optionally, one or more of bitter willow extract, D-glucosamine sulfate and serotonin inhibitor.... Agent: Dr. Melvin Blecher

20070134153 - Lipid-based drug delivery systems against parasitic infections: The present invention is directed to a lipid-based delivery system for administration of an active drug substance selected from lysolipid derivatives which are particularly useful in the treatment or detection of parasitic infections, especially parasitic infections which causes an elevated PLA2 level in the infected mammal. Preferred parasitic infection are... Agent: Birch Stewart Kolasch & Birch

20070134154 - Tumor-targeted nanodelivery systems to improve early mri detection of cancer: The present invention is in the fields of drug delivery, cancer treatment and diagnosis and pharmaceuticals. This invention provides a method of making antibody- or antibody fragment-targeted immunoliposomes for the systemic delivery of molecules to treat and image diseases, including cancerous tumors. The invention also provides immunoliposomes and compositions, as... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070134155 - Pharmaceutical compounds: The invention comprises pharmaceuticals of formula (I) Z-(L)n-V, wherein V denotes a peptide, L denotes an optional linker, Z denotes a group that optionally can carry an imaging moiety M, n denotes 0 or 1. The pharmaceuticals are active as therapeutic agents for the treatment of heart failure, cardiac arrhythmias... Agent: Ge Healthcare, Inc.

20070134157 - Biological assay: The invention is a method for determining an in vivo cardiac electrophysiology profile of a compound affecting one or more cardiac ion channels which comprises administering the compound to a rat, and simultaneously measuring one or more periods selected from the group consisting of an atrial refractory period, a ventricular... Agent: Merck And Co., Inc

20070134156 - Fatigue evaluation apparatus, fatigue evaluation method, and application thereof: The present invention provides a method for easily and quantitatively evaluating a degree of fatigue of a human being, a kit therefor, and an application thereof. Specifically, by measuring a concentration of amino acid in plasma taken from a subject, the degree of fatigue of the subject in daily life... Agent: Sheridan Ross PC

20070134158 - Method for comparing multiple botulinum neurotoxins: Skin topographical methods for quantifying pharmacodynamic parameters of a paralytic effect of a Clostridial toxin, such as a botulinum toxin upon a muscle, such as a frontalis muscle. The methods are effective in determining the potency of a Clostridial toxin, and in comparing toxins. For example, wrinkle reduction effects caused... Agent: Allergan, Inc.

20070134159 - Quantitation of sample properties using contrast enhancement from saturation transfer: The manipulation of RF irradiation to a subject in which a CEST agent has been administered is employed to determine a biological parameter in vivo in conjunction with an MRI imaging process. The exchange rate of the CEST agent is determined through RF manipulation which in turn enables the determination... Agent: General Electric Company Global Research

20070134162 - Labeling reactant: This invention concerns novel labeling reactants suitable for labeling of a biospecific binding reactant using solid-phase synthesis. The novel reactants are derivatives of diethylenetriaminepentaacetic acid (DTPA), wherein a suitable group is linked to the DTPA molecule, thus allowing site specific introduction of the ligand of said derivatives to bioactive molecules... Agent: Buchanan, Ingersoll & Rooney PC

20070134163 - Radiographic contrasting agents and radio-opaque polymeric materials for medical devices: The present invention discloses a radiographic contrasting agent containing multiple aromatic groups, each of which is substituted with at least three halogen atoms. The radiographic contrasting agent can initiate a polymerization process. The present invention also discloses a radio-opaque polymeric material that comprises a biodegradable polymer having at least one... Agent: Philip S. Johnson Johnson & Johnson

20070134161 - Methods of determining beta-iii tubulin expression: Provided are methods of determining the quantity and location of βIII-tubulin expression in a subject, which may be used to determine the location and/or extent of excessive or uncontrolled growth of cells such as tumors. Such methods may include administering at least one compound to a patient and determining the... Agent: Sughrue Mion, PLLC

20070134160 - Reagent system and method for modifying the luminescence of lanthanide(iii) macrocyclic complexes: Disclosed is a spectrofluorimetrically detectable luminescent composition consisting essentially of at least one energy transfer acceptor lanthanide(III) complex having an emission spectrum maximum in the range from 300 to 2000 nanometers and a luminescence-enhancing amount of at least one energy transfer donor selected from the group consisting of a fluorophore,... Agent: Nath & Associates

20070134164 - Fentanyl composition for nasal administration: The treatment of acute pain with a sufficient dosage by intranasal administration of fentanyl results in a time to onset of action comparable to intravenous administration and a significantly faster onset of action than nasal titration of fentanyl. The nasal administration of a sufficient amount of fentanyl to obtain pain... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070134166 - Airway alkalinization as therapy for airway diseases: The present invention relates to a method of treating asthma by raising the pH of the airways of an individual. The effect can be mediated directly by administering a pharmaceutically acceptable basic solution or alternatively, the effect can be mediated by enhancing the activity of glutaminase.... Agent: Woods, Rogers, P.L.C

20070134165 - Use of ciclesonide for the treatment of respiratory disease in a smoking patient: The invention relates to a new method of treatment of respiratory diseases, in particular the treatment of asthmatic smoking patients. The method comprises the administration of a pharmaceutical composition comprising ciclesonide.... Agent: Nath & Associates PLLC

20070134167 - Stable foam cream: The invention relates to a stable foam cream, containing lipophilic and hydrophilic components and a propellant gas, obtainable by subjecting the foam cream to heat treatment. The invention also relates to the production thereof.... Agent: Sterne, Kessler, Goldstein & Fox PLLC

20070134168 - Chewable compositions with fast release magnolia bark extract: A chewable oral composition for oral cleansing, breath freshening, and antimicrobial benefits includes fast release Magnolia Bark Extract in combination with a surface active agent. The effectiveness of Magnolia Bark Extract in inhibiting biofilm formation in the oral cavity is increased by a synergistic combination of the rapidly released Magnolia... Agent: Brinks Hofer Gilson & Lione

20070134169 - Methods for smoking cessation or alcohol cessation or other addiction cessation: The invention is a patch or other applicator, or other method of administration, and a process to concept is to utilize patches (or other methods of delivery), that may contain nicotine in addition to, and that contain other chemicals that have been shown, or will be shown, either by subjective... Agent: Jeffrey Furr

20070134170 - Porphyromonas gingivalis 1435/1449 lps as an immune modulator: A preparation containing lipopolysaccharide (LPS) of Porphyromonas gingivalis having a molecular negative mass ion of 1435 or 1449 is used as an immune system modulator to redirect a host's immune system against an antigen of interest. The 1435/1449 LPS preparation can be isolated from P. gingivalis or prepared as a... Agent: Townsend And Townsend And Crew, LLP

20070134171 - Vehicles for oral care with magnolia bark extract: A vehicle and a method for oral care that includes Magnolia Bark Extract in combination with a surface active agent. The effectiveness of Magnolia Bark Extract in inhibiting biofilm formation in the oral cavity is increased by a synergistic combination of the Magnolia Bark Extract with a surface active agent... Agent: Brinks Hofer Gilson & Lione

20070134176 - Color-developing composition, and cosmetic preparation, fragrance product and display article using the same: v

20070134172 - Flavonoid derivative: The invention relates to a novel flavonoid derivative, to an extract comprising the flavonoid derivative, to the cosmetic and pharmaceutical use thereof, to preparations comprising the flavonoid derivative or extract, and to a process for the preparation of the flavonoid derivative or extract.... Agent: Millen, White, Zelano & Branigan, P.C.

20070134175 - Panthenol and natural organic extracts for reducing skin irritation: Panthenol combined with natural organic extracts are well suited for reducing skin irritation that is normally elicited by exposure to irritant active agents or compounds, particularly found in hair permanent and relaxing compositions, hair colorants and depilatories.... Agent: Welsh & Flaxman LLC

20070134174 - Personal care composition: Personal care composition comprising from about 5% to about 75% of an oil phase; an aqueous phase; from about 0.1% to about 2% of a polymeric thickener; and a skin care active; wherein said composition comprises at least two separate phases, and after agitation and dispensation from a suitable container... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070134173 - Personal care compositions: Methods for stabilizing color of a personal care composition containing a skin care active that is unstable in oxidizing medium are provided. In one of the preferred embodiments, the method includes the step of incorporating into the composition a color stabilizing system including a carotenoid and an ultraviolet light absorbing... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070134177 - Effect materials: The present invention provides a cosmetic comprising pearlescent pigment. The pearlescent pigment comprises: (a) a CVD or PVD deposited layer of a first material; and (b) a CVD or PVD deposited layer of a second material.... Agent: Basf Catalysts LLC

20070134178 - Skin lightening complex: A skin lightening complex having a skin lightening agent such as hydroquinone. The complex can be formulated in a concentrate form for later dilution as a product for topical application. The concentrate can be diluted such that the product is available as a pharmaceutical product with a high coincentration of... Agent: Lawrence S. Cohen

20070134179 - Colored bright pigment: The present invention is to provide a colored bright pigment which is to be incorporated into a coating material, a resin composition, an ink, a cosmetic and the like, and exhibits not only high transparency and brightness but also high chroma and clear color. The colored bright pigment is characterized... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070134180 - Cosmetic compositions with encapsulated pigments and a method for using: There is a pigmented cosmetic composition. The composition has a cosmetically acceptable vehicle, a cosmetic active, and a plurality of encapsulated pigment particles. The particles have an encapsulant and an entrapped pigment within the encapsulant. The encapsulant has silicon dioxide and exhibits a refractive index of about 1.4 to about... Agent: Charles N.j. Ruggiero Ohlandt, Greeley, Ruggiero & Perie, L.L.P.

20070134181 - Cosmetic composition comprising an ester of dimerdilinoleic acid and of polyol(s) and a silicone surfactant: The present invention relates to an anhydrous cosmetic composition for caring for and/or making up the skin and/or the lips, comprising at least one ester of dimerdilinoleic acid and of polyol(s) or an ester thereof, the viscosity of which, measured at about 25° C., is greater than or equal to... Agent: Oliff & Berridge, PLC

20070134182 - Cosmetic composition comprising an ester of dimerdilinoleic acid and of polyol(s) and a silicone surfactant: The present invention relates to an anhydrous cosmetic composition for caring for and/or making up the skin and/or the lips, comprising at least one ester of dimerdilinoleic acid and of polyol(s) or an ester thereof, the viscosity of which, measured at about 25° C., is greater than or equal to... Agent: Oliff & Berridge, PLC

20070134183 - Aminosulfonic acid compounds for promoting desquamation of the skin: e

20070134186 - Cosmetic composition comprising at least one oxyethylenated sorbitan ester, at least one cationic polymer and at least one solid fatty substance, and a cosmetic treatment process: The present disclosure relates to a cosmetic composition comprising, in a cosmetically acceptable aqueous medium, at least one ester of oxyethylenated sorbitan and of a saturated or unsaturated, linear or branched C8-C30 fatty acid, with a number of moles of ethylene oxide of less than or equal to 20, at... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070134188 - Double-stranded rna oligonucleotides which inhibit tyrosinase expression: Novel double-stranded RNA oligonucleotides are useful for decreasing tyrosinase expression, have cosmetic and/or pharmaceutical applications, for example are useful skin depigmenting or anti-browning agents, and can be associated with cationic particles less than or equal to 1 μm in size, having a zeta potential of from 10 to 80 mV.... Agent: Buchanan, Ingersoll & Rooney PC

20070134187 - Medicament comprising a reducing alkyl-sugar monomer for the treatment of inflammatory disorders: The invention relates to a medicament comprising at least one reducing alkyl-sugar monomer having a hydroxyl function which is substituted by an alkoxy radical at C2-C40, said medicament being preferably intended to regulate inflammatory mechanisms. The reducing sugar is preferably selected from the group containing rhamnose, fucose and glucose. The... Agent: Birch Stewart Kolasch & Birch

20070134189 - Anti-wrinkle cosmetic: The invention relates to a novel anti-wrinkle cosmetic based on natural plant extracts. Said cosmetic comprises, in a W/O silicon system, between 0.05 and 2 wt. % of a Passiflora extract, and respectively between 0.05 and 3 wt. % of Papaver, Metha and Myrtus extracts, along with standard cosmetic auxiliary... Agent: Stephan A. Pendorf, P.A.

20070134190 - All weather hair conditioning composition: A cosmetic composition capable of inhibiting hair from losing water containing: at least one lecithin; at least one amphoteric surfactant; at least one nonionic surfactant; at least one film forming polymer; at least one cationic polymer; and at least one small molecule capable of inhibiting water loss from hair fibers... Agent: L'oreal Usa/ Patent Department

20070134191 - Hair styling compositions containing a nonionic amphiphilic polymer in combination with styling polymers and emulsifying agents: A process for treating a keratinous substrate involving contacting the keratinous substrate with a composition containing: (a) at least one nonionic amphiphilic polymer having at least one fatty chain and at least one hydrophilic unit; (b) at least one fixative polymer; (c) at least one emulsifying agent; and (d) a... Agent: L'oreal Usa/ Patent Department

20070134184 - Organic therapeutic and cosmetic preparation: A mixture of an aqueous solution, essential oils and mechanically extracted kelp cytoplasm results in an emulsion with cosmetic and therapeutic properties. The preparation may be used on human and animal hair or skin. The moisturizing properties of the kelp cytoplasm provide the aqueous solution to the hair (keratin) which... Agent: L. Zale Patent Law Office

20070134192 - Two-coat cosmetic product comprising an ester of dimerdilinoleic acid and of polyol(s): The present invention relates to a cosmetic product for caring for and/or making up the skin and/or the lips, comprising at least: one first composition comprising, in a physiologically acceptable medium, at least one ester of dimerdilinoleic acid and of polyol(s) or an ester thereof, whose viscosity, measured at about... Agent: Oliff & Berridge, PLC

20070134185 - Use of dithiols in a hair-perming composition: The subject of the invention is the use of particular dithiols in a composition for permanent deformation of hair. It also relates to a method for permanent deformation of hair using these dithiols, and cosmetic compositions containing at least one of these dithiols and at least one compound chosen from... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070134193 - Cosmetic and/or pharmaceutical preparations: A cosmetic or pharmaceutical composition containing an extract of a resurrection plant.... Agent: Cognis Corporation Patent Department

20070134195 - Topical analgesic for sensitive skin: A topical analgesic for sensitive skin for providing a fast-acting and deeply penetrating topical analgesic that does not irritate sensitive skin teaching a chemical composition consisting of one or more herbs containing the properties of an analgesic such as those selected from a group of herbs containing methyl salicylate, salicin,... Agent: White-welker & Welker, LLC

20070134194 - Use of licochalcone a against rosacea: The present invention relates to the use of licochalcone A for the treatment of rosacea.... Agent: Greenblum & Bernstein, P.L.C

20070134196 - Personal portable content player with aroma function and method thereof: A personal portable content player with an aroma function and a content reproducing method thereof are provided. The personal portable content player includes a storage unit storing content, an aroma chip, which is inserted into a predetermined position of the personal portable content player and diffuses an aromatic material when... Agent: Ladas & Parry LLP

20070134198 - Composition and use of rar antagonists for promoting chondrogenesis: The invention provides compositions comprising a RAR antagonist for promoting chondrogenesis and to methods employing such compositions for treating cartilage and associated bone abnormalities resulting from injury or disease and for ex vivo tissue engineering.... Agent: Kenneth D. Sibley Myers Bigel Sibley & Sajovec

20070134197 - Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination: Conjugates of hydroxyalkyl starch and a protein are provided. The conjugates are formed by a reductive amination reaction between at least one aldehyde group or keto group or hemiacetal group of the hydroxyalkyl starch or of a derivative of the hydroxyalkyl starch, and at least one amino group of the... Agent: Fish & Richardson P.C.

20070134199 - Formulation for a protein pharmaceutical without added human serum albumin (hsa): A composition for stabilization of protein agents in pharmaceuticals, the composition comprising the following two constituents: a) a surface active substance, in particular a non-ionic detergent (tenside), and b) a mixture of at least two amino acids, wherein the at least two amino acids are either Glu and Gln or... Agent: Fulbright & Jaworski L.L.P.

20070134201 - Archaeon expression system: The present invention relates to a sulfolobus expression vector comprising: (a) sulfolobus origin of replication; (b) the genes encoding the structural proteins and the site-specific integrase of SSV1, SSV2 or pSSVx, operatively linked to expression control sequences and a packaging signal; (c) one or more selectable marker gene(s), operatively linked... Agent: Pillsbury Winthrop Shaw Pittman LLP

20070134202 - Cancer gene therapeutic drug: A cancer gene therapeutic drug of the present invention comprises a combination of: a virus for immunological treatment to be administered for inducing a CTL reaction within a living body to administration of a carrier cell; and a carrier cell to be infected with an oncolytic virus before the administration... Agent: Kirk Hahn

20070134203 - Compositions and methods for increasing packaging and yields of recombinant adenoviruses using multiple packaging signals: A recombinant adenoviral vector which has multiple adenovirus packaging domains is provided. This vector has advantages over conventional adenoviral vectors in packaging plasmid vectors into adenoviral capsids. Methods of making and using this vector are described.... Agent: Howson And Howson

20070134205 - Gene delivery of detoxifying agent: Gene delivery of a detoxifying agent is described.... Agent: Bell, Boyd, & Lloyd LLP

20070134200 - Immunogenic composition and methods: A method of inducing an antigen-specific immune response in a mammalian subject includes the steps of administering to the subject an effective amount of a first composition comprising a DNA plasmid comprising a DNA sequence encoding an antigen under the control of regulatory sequences directing expression thereof in a mammalian... Agent: Howson And Howson Cathy A. Kodroff

20070134204 - Method for treating nerve injury and vector construct for the same: A method is provided for treating a nerve injury, including steps of: transforming the nerve injury site with a gene coding for an acid fibroblast growth factor (aFEF); and allowing the gene to be expressed at the nerve injury site. Also provided is a vector for use in the method.... Agent: Akin Gump Strauss Hauer & Feld L.L.P.

20070134206 - Targeting proteins to deliver therapeutic or diagnostic reagents: The present invention is directed to compositions comprising an angiogenesis inhibitor coupled to a therapeutic or diagnostic agent. In a specific embodiment, the composition is a fusion gene or fusion gene product encoding the angiogenesis inhibitor coupled to a therapeutic or diagnostic agent. In a particular embodiment, the composition is... Agent: Fulbright & Jaworski, LLP

20070134216 - Bone cell delivery device: Bone cages are disclosed including devices for biocompatible implantation. The structures of bone are useful for providing living cells and tissues as well as biologically active molecules to subjects.... Agent: Searete LLC Clarence T. Tegreene

20070134212 - Growth of foreign cells in fetal animals facilitated by conditional and selective destruction of native host cells: Foreign cells can be grown in fetal non-mammalian hosts for the production of transplant organs and tissues, the development of new therapeutic agents, and the production of biological factors and drugs. Tissue-specific injury to fetal host target cells is carried without substantial injury to the maternal host or foreign cells,... Agent: Banner & Witcoff, Ltd.

20070134214 - Inactivated host cell delivery of polynucleotides encoding immunogens: Provided herein methods for in vivo delivery of an immunogen. In particular, the methods comprise administering an inactivated host cell to a mammal, wherein the host cell comprises a polynucleotide encoding an immunogen. After administration, the immunogen is then expressed in vivo by the mammal.... Agent: Novartis Vaccines And Diagnostics Inc.

20070134219 - Method and composition for producing a cellular allogeneic vaccine: The present invention relates to a method for the production of a cellular allogeneic vaccine, which is based upon an allogeneic APC, comprising the following steps: isolation of an APC from a subject or providing an APC already established and/or isolated from a myeloid leukemia cell line, and modifying the... Agent: Young & Thompson

20070134215 - Method of inducing the differentiation of stem cells into myocardial cells: For a method of inducing differentiation of cardiomyocytes from stem cells, a method is provided to induce efficiently and selectively differentiation of cardiomyocytes by such a method in which the stem cells are cultured to induce differentiation into cardiomyocytes in the presence of a substance that inhibits BMP signaling.... Agent: Hunton & Williams LLP Intellectual Property Department

20070134218 - Methods of inducing or increasing the expression of proteoglycans such as aggrecan in cells: Methods of inducing the expression of a proteoglycan such as aggrecan in a cell are described. A method is described which includes transfecting a cell with an isolated nucleic acid comprising a nucleotide sequence encoding a LIM mineralization protein operably linked to a promoter. The LIM mineralization protein can be... Agent: Fox Rothschild, LLP

20070134217 - Plasmids, their derivatives and fragments, their methods of manufacture and application: A method is described of obtaining a plasmid contained in a difficult to separate, heterogenous plasmid DNA fraction, particularly one containing various plasmids of similar sizes. Another aspect of the present invention are new plasmids obtained via the method according to the present invention, their derivatives and/or fragments, as well... Agent: Graybeal, Jackson, Haley LLP

20070134213 - Reversibly immortalised olfactory ensheathing glia and their use to promote neuronal regeneration: The present invention is based on the capacity of the Olfactory Ensheathing Glia (OEG) to foster axonal regeneration in the adult mammalian central nervous system (CNS). This specific capacity is probably due to a combination of several factors, such as the molecular composition of cellular membrane and/or the capacity to... Agent: Fish & Richardson PC

20070134220 - Lactobacillus fermentum strain and uses thereof: The present invention concerns a new strain of Lactobacillus fermentum (LB-f) that is useful in preventing or treating gastrointestinal disorders in mammals, especially in humans. Also, this strain can be used as a dietary product that is beneficial to the wellbeing and health of mammals, including humans.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070134207 - Isolated phages and their use in food or pet food products: The present invention relates to phage isolates having a strong lytic activity against pathogenic Enterobacteriaceae such as Escherichia coli and/or Salmonella strains and their use in various human or pet food products for the treatment or prevention of bacterial diseases caused by pathogenic Enterobacteriaceae such as Escherichia coli , in... Agent: Bell, Boyd & Lloyd LLP

20070134209 - Cellular encapsulation for self-assembly of engineered tissue: Methods are disclosed of producing a cellular matrix for tissue self-assembly. Encapsulated living cells are provided, with each of the living cells separately encapsulated within a primary encapsulant. The encapsulated living cells are themselves encapsulated within a liquid or gel secondary encapsulant. The second encapsulant is polymerized.... Agent: Townsend And Townsend And Crew, LLP

20070134211 - Differentiation of adipose stromal cells into osteoblasts and uses thereof: The invention provides methods and compositions for differentiating stromal cells from adipose tissue into cells having osteoblastic properties, and methods for improving a subject's bone structure. The methods comprise culturing stromal cells from adipose tissue in β-glycerophosphate and ascorbic acid and/or ascorbate-2-phosphate for a time sufficient to allow differentiation of... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20070134208 - Methods for purifying hematopoietic stem cells: Described herein are methods for purifying hematopoietic stem cells. Also described herein are methods for purifying EPCR+ cells. The invention also provides substantially pure isolated hematopoietic stems cells, including EPCR+ hematopoietic stem cells.... Agent: Wolf Greenfield & Sacks, P.C.

20070134210 - Production of oligodendrocytes from placenta-derived stem cells: The present invention provides methods and compositions for the production of glial cells and oligodendrocytes from placenta stem cells. The invention further provides for the use of these glia and oligodendrocytes in the treatment of, and intervention in, for example, trauma, ischemia and degenerative disorders of the central nervous system... Agent: Jones Day

20070134221 - Stabilizing peptides: The invention provides peptide inhibitors of HIV infection and methods for stabilizing those peptides.... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20070134222 - Blood brain barrier device: Bone cages are disclosed including devices for biocompatible implantation. The structures of bone are useful for providing living cells and tissues as well as biologically active molecules to subjects.... Agent: Searete LLC Clarence T. Tegreene

20070134225 - Blood brain barrier device: Bone cages are disclosed including devices for biocompatible implantation. The structures of bone are useful for providing living cells and tissues as well as biologically active molecules to subjects.... Agent: Searete LLC Clarence T. Tegreene

20070134223 - Choroid plexus device: Bone cages are disclosed including devices for biocompatible implantation. The structures of bone are useful for providing living cells and tissues as well as biologically active molecules to subjects.... Agent: Searete LLC Clarence T. Tegreene

20070134224 - Choroid plexus device: Bone cages are disclosed including devices for biocompatible implantation. The structures of bone are useful for providing living cells and tissues as well as biologically active molecules to subjects.... Agent: Searete LLC Clarence T. Tegreene

20070134226 - Heparan sulfate glycosaminoglycan lyase and uses thereof: The invention provides recombinant B. thetaiotaomicron GAG lyase polypeptides. The invention also provides nucleic acid molecules encoding such polypeptides, recombinant expression vectors containing B. thetaiotaomicron GAG lyase nucleic acid molecules, and host cells into which the expression vectors have been introduced. Characterization, diagnostic and therapeutic methods utilizing compositions of the... Agent: Fish & Richardson PC

20070134227 - Catalyst for cleaving sugar chain: A catalyst which is capable of specifically cleaving one sugar chain or two or more sugar chains selected from the group consisting of hyaluronic acid, chondroitin sulfate A, chondroitin sulfate C and chondroitin sulfate D; a cleavage agent specific for the sugar chains; a medicament which is used for specifically... Agent: Sughrue Mion, PLLC

20070134228 - Human plasma hyaluronidase: The invention is based on the discovery of methods for purification of an acid active hyaluronidase found in human plasma (hpHAse), including both biochemical and immunoaffinity purification methods The method of immunoaffinity purification of the invention is based on the discovery of a method for identifying antibodies that specifically bind... Agent: Bozicevic, Field & Francis LLP

20070134230 - Method for prolonging activity of autodegradable enzymes: A method for prolonging the activity of an autodegradable enzyme comprises storing the enzyme after manufacture at a pH less than about 5, and reconstituting the acidified enzyme substantially immediately before use with a buffer having a pH in the range from about 6.5 to about 11, wherein the pH... Agent: Toan P. Vo Bausch & Lomb Incorporated

20070134229 - Non-native constitutively active osteopontin: Non-native constitutively phosphorylated forms of osteopontin are disclosed. Such osteopontin forms can be obtained, for example, using an expression vector comprising an isolated nucleic acid that encodes an osteopontin peptide, operably linked to a promoter wherein the osteopontin peptide is either constitutively phosphorylated or is capable of being constitutively phosphorylated.... Agent: Edwards Lifesciences Corporation

20070134231 - Method for prolonging activity of autodegradable enzymes and compositions thereof: A composition of a long-acting enzyme comprises the enzyme in a formulation comprising a buffer and an additive selected from the group consisting of tranexamic acid, ε-aminocaproic acid, and analogs of L-lysine other than tranexamic acid and ε-aminocaproic acid, combinations thereof, and mixtures thereof. The composition can further comprise another... Agent: Bausch & Lomb Incorporated

20070134232 - Topical bite care composition: The present invention is directed to a topical bite care composition for treating insect bites. The composition contains a steroid and a proteolytic enzyme and/or an antipruritic. The composition can be applied to the skin in any liquid form over the affected area.... Agent: Frenkel & Associates

20070134233 - Compositions and methods relating to organ-, tissue-, and cell-specific antibodies: Disclosed are methods for producing organ-, tissue-, or cell-specific antibodies, antibodies against developmentally regulated antigens, antibodies against disease-associated antigens, and antibodies against antigens that are modulated during a physiological response to an agent (e.g., in response to a drug). Also disclosed are methods for screening an agent for activity in... Agent: Townsend And Townsend And Crew, LLP

20070134235 - Endothelialization of vascular surfaces: Endothelialization of vascular surfaces. According to one aspect, the invention involves a technique for re-endothelializing an artery whose endothelial layer has been damaged by balloon angioplasty. The technique comprises, in one embodiment, introducing into the bloodstream of a patient, prior to performing the angioplasty, a quantity of a bispecific antibody,... Agent: Kriegsman & Kriegsman

20070134234 - Immunomodulatory compositions and uses therefor: The poxvirus proteins designated A41L and 130L bind to three receptor-like protein tyrosine phosphatases (RPTP), leukocyte common antigen related protein (LAR), RPTP-δ, and RPTP-σ, that are present on the cell surface of immune cells. When a host is infected with the poxvirus, binding of A41L to cell surface proteins on... Agent: Seed Intellectual Property Law Group PLLC

20070134236 - Humanized antibodies against monocyte chemotactric proteins: The invention provides humanized antibodies that bind to a plurality of b-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides therapeutic reagents and methods of treating disorders associated with detrimental MCP activity.... Agent: Biogen Idec Inc

20070134237 - Human cytokine receptor: Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor16.”... Agent: Zymogenetics, Inc. Intellectual Property Department

20070134241 - Humanized anti-cd3 specific antibodies: Novel aglycosylated antibodies having a binding affinity for the CD3 antigen complex are of value for use in therapy, particularly in immunosuppression.... Agent: Nixon & Vanderhye, PC

20070134238 - Modulation of t cell differentiation for the treatment of t helper cell mediated diseases: The present invention relates to methods for the treatment and diagnosis of immune related diseases, including those mediated by cytokines released primarily either Th1 or Th2 cells in response to antigenic stimulation. The present invention further relates to methods for biasing the differentiation of T-cells in either the Th1 subtype... Agent: Merchant & Gould PC

20070134239 - Nucleotide and protein sequences of vertebrate delta genes and methods based thereon: The present invention relates to nucleotide sequences of vertebrate Delta genes, and amino acid sequences of their encoded proteins, as well as derivatives (e.g., fragments) and analogs thereof. In a specific embodiment, the vertebrate Delta protein is a human protein. The invention further relates to fragments (and derivatives and analogs... Agent: Jones Day

20070134240 - Use of a cd28 binding substance for making a pharmaceutical composition: The invention relates to the use of a CD28-specific superagonistic monoclonal antibody (mAb) or of a mimicry compound hereto for making a pharmaceutical composition for the induction and/or multiplication of regulatory T cells.... Agent: Mayer & Williams PC

20070134246 - Antibodies to tgf-beta: The present invention relates to antibody molecules, in particular antibody molecules that bind Transforming Growth Factor beta (TGFβ), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralise TGFβ1, TGFβ2 and TGFβ3, so-called “pan-specific” antibody molecules, and uses of such antibody molecules. Preferred embodiments... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070134243 - Antibody drug conjugates and methods: where one or more 1,8 bis-naphthalimide drug moieties (D) having Formulas IIa and IIb are covalently linked by a linker (L) to an antibody (Ab). The invention also relates to pharmaceutical compositions comprising an effective amount of a Formula I ADC for treatment of hyperproliferative disorders and other disorders. The... Agent: Genentech, Inc.

20070134244 - Combination treatment for pathologic ocular angiogenesis: The present invention provides a combination therapy for the treatment of pathologic ocular disorders, such as age-related macular degeneration and choroidal neovascularization. The combination therapy of the invention includes administration of anecortave acetate and bevacizumab or ranibizumab.... Agent: Alcon

20070134242 - Mesothelioma therapeutic agent: The present invention provides a mesothelioma therapeutic agent containing an interleukin-6 (IL-6) antagonist such as antibody to IL-6 receptor (IL-6R), and a mesothelioma cell growth inhibitor containing an IL-6 antagonist such as antibody to IL-6R.... Agent: Foley And Lardner LLP Suite 500

20070134245 - Rankl antibody-pth/pthrp chimeric molecules: Chimeric molecules comprising receptor activator of NF-κB ligand (RANKL) antibodies and parathyroid hormone/parathyroid hormone-related protein (PTH/PTHrP) peptides are described. Compositions and methods for the treatment of bone diseases are also described.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070134247 - Prevention of brain inflammation as a result of induced autoimmune response: A disease characterized by amyloid aggregation in a patient may be prevented or treated by causing antibodies against a peptide component of the amyloid deposit to come into contact with the aggregated or soluble amyloid. In order to decrease the risk of inflammation in such a method, the Fc receptors... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070134251 - Assays and methods using biomarkers: Methods and assays examining expression of one or more biomarkers in a mammalian tissue or cell sample are provided. According to the disclosed methods and assays, detection of the expression of one or more such biomarkers is predictive or indicative that the tissue or cell sample will be sensitive to... Agent: Genentech, Inc.

20070134248 - Combination therapy and antibody panels: The present invention provides combination immunotherapy for Non-Hodgkin's Lymphoma. In one embodiment, the combination immunotherapy first provides for the administration of a monoclonal antibody directed to a non-idotypic portion of a lymphoma cell surface immunoglobulin (e.g. a framework region of a variable region). The combination immunotherapy next provides for the... Agent: Medlen & Carroll, LLP

20070134249 - Combination therapy and antibody panels: The present invention provides combination immunotherapy for Non-Hodgkin's Lymphoma. In one embodiment, the combination immunotherapy first provides for the administration of a monoclonal antibody directed to a non-idotypic portion of a lymphoma cell surface immunoglobulin (e.g. a framework region of a variable region). The combination immunotherapy next provides for the... Agent: Medlen & Carroll, LLP

20070134250 - Composition comprising and method of using angiopoietin-like protein 3 angptl3: The present invention is directed to methods and means for making and using Angpt13 polypeptides. The invention specifically concerns the use of Angpt13 polypeptides in inducing liver regeneration and angiogenesis. Further methods include the use of Angpt13 polypeptides in the diagnosis and treatment of liver disease. Also provided herein are... Agent: Merchant & Gould PC

20070134254 - Epha2 agonistic monoclonal antibodies and methods of use thereof: The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. The methods of the invention comprise the administration of an effective amount of one or more antibodies that bind to and agonize EphA2, thereby increasing EphA2 phosphorylation and decreasing EphA2... Agent: Jones Day

20070134252 - Method for predicting response to epidermal growth factor receptor-directed therapy: This invention provides methods for determining or predicting response to cancer therapy in an individual.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070134253 - Novel serpentine transmembrane antigens expressed in human cancers and uses thereof: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigen of the Prostate). Four... Agent: Heller Ehrman LLP

20070134255 - Hmpv treatment with ribavirin and anti-hmpv antibody: The invention relates to antimicrobial agents and antibodies and compositions comprising such agents and antibodies to treat and/or prevent respiratory and related diseases, in particular those caused by human metapneumovirus. Provided is a method for treating or preventing respiratory tract infections in a subject infected with a mammalian MPV, said... Agent: Morrison & Foerster LLP

20070134256 - Monoclonal antibodies that bind or neutralize dengue virus: The present invention relates to monoclonal antibodies that bind or neutralize dengue type 1, 2, 3, and/or 4 virus. The invention provides such antibodies, fragments of such antibodies retaining dengue virus-binding ability, fully human or humanized antibodies retaining dengue virus-binding ability, and pharmaceutical compositions including such antibodies. The invention further... Agent: Knobbe, Martens, Olson & Bear, LLP

20070134258 - Gasp1: a follistatin domain containing protein: The present invention relates to the use of a protein, GASP1, comprising at least one follistatin domain to modulate the level or activity of growth and differentiation factor-8 (GDF-8). More particularly, the invention relates to the use of GASP1 for treating disorders that are related to modulation of the level... Agent: Wyeth/finnegan Henderson, LLP

20070134257 - Metal-binding therapeutic peptides: The present invention is related methods of delivering MBD peptide-linked agents into live cells. The methods described herein comprise contacting MBD peptide-linked agents to live cells under a condition of cellular stress. The methods of the invention may be used for therapeutic or diagnostic purposes.... Agent: Morrison & Foerster LLP

20070134259 - Methods and compositions for pharmacologially controlled targeted immunotherapy: The present invention relates generally to methods and compositions for targeted immunotherapy. More specifically, the present invention relates to immuno-targeted therapies, using heteromultivalent compounds to mediate the binding of an endogenous effector molecule such as an antibody to target molecules including malignant cells and tissues, bacteria and viruses as well... Agent: Nixon & Vanderhye, PC

20070134261 - Effectors of innate immunity: The present invention provides a method of identifying agents that enhance innate immunity in a subject. The invention further provides a method of selectively supressing sepsis by suppressing expression of a proinflammatory gene while maintaining expression of an anti-inflammatory gene. Also provided are methods of identifying a polynucleotide or pattern... Agent: Dla Piper US LLP

20070134260 - Use of clusterin for the treatment and/or prevention of peripheral neurological diseases: The invention relates to the use of clusterin, or of an agonist of clusterin activity, for treatment or prevention of peripheral neurological diseases, The invention further relates to the use of a combination of clusterin and heparin, for treatment or prevention of peripheral neurological diseases.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070134262 - Antigens encoded by alternative reading frames from pathogenic viruses: The invention discloses polypeptides encoded by an alternative reading frame of a pathogenic virus, which polypeptides—start with a methionine amino acid residue,—comprise an antigenic determinant and—comprise more than 7 amino acid residues and fragments of said polypeptides comprising more than 7 amino acids.... Agent: Fulbright & Jaworski L.L.P.

20070134264 - Helicobacter system and uses thereof: Helicobacter based preparations comprising a pharmacologically active molecule of interest are disclosed, as well as methods of preparing and using said preparations. In particular, Helicobacter pylori vectors, vector plasmids and recombinant cells that include a sequence encoding a pharmacologically active molecule of interest useful in therapeutic treatments and/or vaccination against... Agent: Jagtiani + Guttag

20070134263 - Polypeptides for inducing a protective immune response against staphyloococcus aureus: The present invention features polypeptides comprising an amino acid sequence structurally related to SEQ ID NO: 1 and uses of such polypeptides. SEQ ID NO: 1 is a truncated derivative of a full length S. aureus polypeptide. The full-length polypeptide is referred to herein as full-length “sai-1”. A His-tagged derivative... Agent: Merck And Co., Inc

20070134265 - Anti-aging composition and collagen production promoting composition: There are provided an anti-aging composition, a collagen production promoting composition, a collagen gel contraction promoting composition, and an integrin production promoting composition for promoting integrin production in fibroblasts/epidermal cell, which have improved collagen production promotion effect and are effective for preventing or reducing wrinkle and/or sagging caused by aging.... Agent: Snider & Associates

20070134266 - Growth hormone-containing formulation and method of use: A growth hormone formulation includes an enzyme inactivating component and a preservative. The formulation can also include a fertilizing additive, and a surfactant. The growth hormone can be a natural one such as that found in kelp or a synthetic one or a combination of both.... Agent: Clark & Brody

20070134267 - Tuberculosis vaccine with improved efficacy: The present invention relates to novel recombinant vaccines providing protective immunity against tuberculosis. Further, the present invention refers to novel recombinant nucleic acid molecules, vectors containing said nucleic acid molecules, cells transformed with said nucleic acid molecules and polypeptides encoded by said nucleic acid molecules.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070134269 - Mycoplasma hyopneumoniae bacterin vaccine: The invention provides an improved Mycoplasma hyopneumoniae bacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivated Mycoplasma hyopneumoniae bacterin and an adjuvant mixture, which, in combination, provide immunity from Mycoplasma hyopneumoniae infection after a single administration, and elicit an immune response... Agent: Wyeth Patent Law Group

20070134268 - Vaccines: The present invention provides vaccine compositions comprising an oil-in-water emulsion optionally with 3 De-O-acylated monophosphoryl lipid A and QS21. The vaccine compositions are potent induces of a range of immune responses.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070134271 - Attenuated human-bovine chimeric parainfluenza virus (piv) vaccines: Chimeric human-bovine parainfluenza viruses (PIVs) are infectious and attenuated in humans and other mammals and useful individually or in combination in vaccine formulations for eliciting an anti-PIV immune response. Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric PIV genome or antigenome which includes a partial or complete... Agent: Birch, Stewart, Kolasch & Birch, LLP

20070134270 - Chicken rna polymerase i promoter and the use thereof: The invention relates to a novel polynucleotide exhibiting a promoting transcription activity, polynucleotide-containing vectors and to the use thereof for the transcription of interesting sequences such as the production of non-cap RNA virus. Said invention also relates to host cells preferably of avian origin, containing a polynucleotide or the inventive... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070134272 - Mannheimia haemolytica chimeric outer membrane protein pipe and leukotoxin epitopes as a vaccine or vaccine component against shipping fever: Vaccine preparations for the prevention and treatment of bovine respiratory disease (BRD) and, in particular, its most severe form, termed “shipping fever”, are provided. The preparations comprise chimeric proteins comprising immunodominant epitopes of recombinant Mannheimia haemolytica outer membrane protein PlpE, and immunodominant epitopes of recombinant M. haemolytica leukotoxin.... Agent: Fellers Snider Blankenship Bailey & Tippens

20070134273 - Composition and method for the treatment of carcinoma: The present invention relates to compositions and methods useful for treating a carcinoma or viral infection in mammals, including humans. The methods and compositions typically comprise use of an immunogenic or immunomodulatory compound, and a gamma delta T cell activator, such that the composition is effective for treating a carcinoma... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070134274 - Vaccine candidates against johne's disease: A composition and method for immunizing a mammal infected with Mycobacterium are disclosed. The genes gcpE, psta, kdpC, papA2, impA, umaA1, fabG2_2, aceAB, mbtH2, lpqP, map0834c, cspB, lipN, and map1634 of M. paratuberculosis and the products that they encode are vaccine targets for Johne's and Crohn's disease. Eighteen M. paratuberculosis-specific... Agent: Brinks Hofer Gilson & Lione

20070134275 - Medicaments for the immunotherapy of malignant tumors: The present invention relates to a composition which can be used as a medicament or for preparing a medicament for the immunotherapy of tumors of for tumor vaccination. The invention also relates to methods for preparing medicaments for the immuno-therapy of tumors of for tumor vaccination.... Agent: Jacobson Holman PLLC

20070134278 - Aqueous dispersions and solutions of difficult to dissolve materials and methods of their preparation: The present invention encompasses a method of preparing a ready-to-dissolve or ready-to-disperse composition of difficult to dissolve in water compounds and suspensions or aqueous solutions of difficult to dissolve in water compounds.... Agent: Kenyon & Kenyon LLP

20070134279 - Fast-acting oral peptide pharmaceutical products: A finished pharmaceutical product adapted for oral delivery of a physiologically active peptide agent, wherein the product comprises a therapeutically effective amount of the active peptide agent; at least one pharmaceutically acceptable pH-lowering agent; and at least one absorption enhancer effective to promote bioavailability of the active agent, wherein the... Agent: Ostrolenk Faber Gerb & Soffen

20070134276 - Microemulsions of retinoids, and pharmaceutical compositions containing them: Disclosed are water-in-oil (W/O) microemulsions containing as active ingredient a retinoid, a phospholipid emulsifier, and possibly hyaluronic acid or salts thereof.... Agent: Young & Thompson

20070134277 - Pharmaceutical formulation for sulfur-containing drugs in liquid dosage forms: The pharmaceutical formulations of the invention for masking the odor from the sulfur-containing active agent comprise at least one sulfur-containing active agent, an effective amount of at least one flavoring agent. Any flavoring agent or combinations of flavoring agents may be used in the pharmaceutical formulation of the invention. The... Agent: Nixon Peabody, LLP

20070134280 - Thixotropic ingestible formulation to treat sore throat: A thixotropic formulation includes a high molecular weight, thixotropic, gel-forming, naturally occurring polysaccharide extracted from algae and comprised of repeating sulfated and non-sulfated galactose and 3,6 anhydrogalactose (3,6-AG) units, and includes water.... Agent: Tod R Nissle

20070134281 - Investigate the potential of using beetle odours to deter slugs in vining peas: In the UK slugs can be a major problem in vining peas. Their climbing and feeding habit on pea plants can often result in large numbers being picked up by the viners, causing contamination and possible rejection of the crop, consequently leaving the growers to meet the loss and face... Agent: Ladas & Parry LLP

20070134282 - Methods for inhibiting fungal pathogen infestation and propogation: The use of camptothecin (CPT), hyperoside and/or trifolin in preventing or inhibiting the growth of fungal pathogens, including molds.... Agent: Cox Smith Matthews Incorporated

20070134283 - Surfactant-based composition and associated methods: Provided are a pesticide, a coating formulation, a cosmetic, a cleaner, and a foamable fire-fighting composition, which may include a Gemini surfactant. The Gemini surfactant may include a first hydrophobic moiety linked to a spacer, which is linked to a second hydrophobic moiety. Each hydrophobic moiety may include silicon. A... Agent: General Electric Company Global Research

20070134284 - Pesticidal compositions and methods: The present invention provides an environmentally compatible, pesticidal composition and method for the control of insect pests. The composition includes two components. The first component is a chelating agent, a metal complex of a chelating agent, and mixtures thereof, and the second component is preferably a carrier material.... Agent: Nutter Mcclennen & Fish LLP

20070134288 - Anti-adhesion agents for drug coatings: Coated medical devices and methods for coating such devices are disclosed. The invention is directed to the use of an anti-adhesion agent in a coating for a medical device. More particularly, the invention is directed to a medical device comprising an anti-adhesion agent that prevents the self-adhesion of different portions... Agent: Jones Day

20070134285 - Composite biomaterials comprising calcium phospate materials, collagen and glycosaminoglycans: A process for the production of a composite material comprising collagen, brushite and one or more glycosaminoglycans, said process comprising the steps of providing an acidic aqueous solution comprising collagen, a calcium source and a phosphorous source and one or more glycosaminoglycans, and precipitating the collagen, the brushite and the... Agent: Senniger Powers

20070134291 - Composition for cartilage: Provided herein is a composition for cartilage formation or regeneration.... Agent: Squire, Sanders & Dempsey L.L.P.

20070134290 - Drug eluting implantable medical device: A drug eluting medical device is provided for implanting into vessels or luminal structures within the body of a patient. The coated medical device, such as a stent, vascular, or synthetic graft comprises a coating consisting of a controlled-release matrix of a bioabsorbable, biocompatible, bioerodible, biodegradable, nontoxic material, such as... Agent: White & Case LLP Patent Department

20070134287 - Method for coating biocompatible substrates with antibiotics: A method for coating a biocompatible substrate with an antibiotic is provided. The method includes dissolving at least one antibiotic in an antibiotic compatible solvent to provide an antibiotic solution. The antibiotic solution is applied to the substrate and the antibiotic compatible solvent is removed from the substrate. Methods of... Agent: Harness, Dickey & Pierce, P.L.C

20070134286 - Methods for reducing intimal hyperplasia, smooth muscle cell proliferation and restenosis in mammals: The present invention relates to methods for reducing small muscle cell proliferation, restenosis or intimal hyperplasia in mammals.... Agent: Robert Deberardine Abbott Laboratories

20070134289 - Polymeric stent having modified molecular structures: A biocompatible material may be configured into any number of implantable medical devices including intraluminal stents. Polymeric materials may be utilized to fabricate any of these devices, including stents. The stents may be balloon expandable or self-expanding. By preferential mechanical deformation of the polymer, the polymer chains may be oriented... Agent: Philip S. Johnson Johnson & Johnson

20070134293 - Devices and methods for the delivery of blood clotting materials to bleeding wounds: An apparatus for promoting the clotting of blood comprises a receptacle, at least a portion of which is defined by a mesh having openings therein, and particles of clay retained in the receptacle. In similar apparatuses, bioactive glass or chitosan is retained in the receptacle. An apparatus also comprises a... Agent: Michaud-duffy Group LLP

20070134292 - Synthetic, bioabsorbable polymer materials and implants: The invention relates to synthetic, bioabsorbable polymer materials and implants, like fibres, sutures, meshes and other tissue management, wound closure or tissue engineering devices, which contain: a) a bioabsorbable polymeric matrix; b) antibiotic and/or anti-inflammatory agent particles or mixture thereof, dispersed in the matrix, and c) optionally an additive agent... Agent: Kenyon & Kenyon LLP

20070134295 - Polymeric stent having modified molecular structures: A biocompatible material may be configured into any number of implantable medical devices including intraluminal stents. Polymeric materials may be utilized to fabricate any of these devices, including stents. The stents may be balloon expandable or self-expanding. By preferential mechanical deformation of the polymer, the polymer chains may be oriented... Agent: Philip S. Johnson Johnson & Johnson

20070134294 - Polymeric stent having modified molecular structures in selected regions of the flexible connectors: A biocompatible material may be configured into any number of implantable medical devices including intraluminal stents. Polymeric materials may be utilized to fabricate any of these devices, including stents. The stents may be balloon expandable or self-expanding. By preferential mechanical deformation of the polymer, the polymer chains may be oriented... Agent: Philip S. Johnson Johnson & Johnson

20070134296 - Polymeric stent having modified molecular structures in selected regions of the flexible connectors: A biocompatible material may be configured into any number of implantable medical devices including intraluminal stents. Polymeric materials may be utilized to fabricate any of these devices, including stents. The stents may be balloon expandable or self-expanding. By preferential mechanical deformation of the polymer, the polymer chains may be oriented... Agent: Philip S. Johnson Johnson & Johnson

20070134297 - Device to aid in sexual pleasure: There is provided a dissolving strip adapted to be placed on a person's tongue to aid in giving oral sexual pleasure to both men and women. The strip comprises: a dissolvable, orally consumable, composition; and the strip is flexible and adapted to adhere to a surface in the mouth, usually... Agent: Howard M Cohn Patent Attorney LLC

20070134298 - Dietary supplement: A dietary supplement comprises a combination of colostrinin and at least one of lactoferrin and selenium.... Agent: Rankin, Hill, Porter & Clark, LLP

20070134299 - Method and formula for prevention of cold and flu and suppression of related symptoms: The present invention generally relates to methods, compositions and systems for preventing the common cold and flu, for reducing the duration of common colds and flu, for reducing the severity of common cold and flu symptoms and for reducing/eliminating the transmission of the common cold and flu. Specifically, it relates... Agent: Sheppard, Mullin, Richter & Hampton LLP

20070134300 - Novel chromium (iii) alpha amino acid complexes: Chromium (III) 1:3 complexes of alpha amino acids and their use as animal nutritional supplements.... Agent: Mckee, Voorhees & Sease, P.L.C

20070134302 - Antimicrobial substrates with peroxide treatment: An oxidizing antimicrobial treatment and products containing such treatment are described. The treatment involve, in part, preparing a substrate to accept an attachment of charged moieties, and a number of stabilized peroxide compounds on at least part of a surface of said substrate. When microbes, such as bacteria, having a... Agent: Kimberly-clark Worldwide, Inc.

20070134305 - Drug-delivering composite structures: Composite structures composed of a fibril core and a polymeric coat and designed capable of encapsulating both hydrophobic and hydrophilic bioactive agents while retaining the activity of these agents are disclosed. Further disclosed are processes of preparing such composite structures, and medical devices and disposable articles made therefrom.... Agent: Martin D. Moynihan Prtsi, Inc.

20070134303 - Protective and therapeutic article: An antimicrobial protective article is described. The article has a first, outer surface that is coated at least partially with an antimicrobial agent containing polyhexamethylene biguanide (PHMB), and at least one or a combination of the following: chitosan, a chaotropic surfactant, polyols, copper oxide, and an organic acid, and a... Agent: Kimberly-clark Worldwide, Inc.

20070134301 - Silver ion releasing articles and methods of manufacture: A biologically-active article includes a substrate having a substrate surface and a silver releasing chromonic material disposed adjacent to the substrate surface. The silver releasing chromonic material includes a chromonic compound and a silver ion source. Methods of forming the same are also disclosed.... Agent: 3m Innovative Properties Company

20070134304 - Soluble article for exfoliating the skin: An article, containing a support in the form of at least one sheet comprising fibres that are water-soluble at a temperature of 0-30° C., and a composition carried by the support, comprising at least one exfoliating agent in the form of particles. The article according to the invention can be... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070134306 - Method and device for accelerating the growth of skin appendages, in particular nails: A method and a device are provided for accelerating the growth of skin appendages. According to one embodiment, a dressing is provided having an enveloping fabric and a lining material designed to be in contact with at least one appendage, and a liquid or viscous base containing water in a... Agent: Akin Gump Strauss Hauer & Feld L.L.P.

20070134307 - Antimicrobial composite and method of manufacture and use: An antimicrobial composite is provided, comprising a catalyst capable of promoting oxidation of organic molecules incorporated in a carrier, for example a hydrophilic or water-based material, the catalyst configured such that it will not discolor surrounding material under the influence of oxidative conditions... Agent: Cantor Colburn, LLP

20070134308 - Non-steroidal anti-inflammatory drug formulations for topical applications to the skin: Topical alcoholic or aqueous alcoholic gels containing ibuprofen or other NSAIDs, such as, naproxen, in substantially neutral salt form, have enhanced penetration through skin and may provide rapid pain/inflammation relief by including in the formulation 2-n-nonyl-1,3-dioxolane or other hydrocarbyl derivative of 1,3-dioxolane or 1,3-dioxane or acetal, as skin penetration enhancing... Agent: Mayer, Brown, Rowe & Maw LLP

20070134309 - Agent containing ergoline for transdermal application: The invention relates to a transdermal therapeutic system containing ergolin compounds, preferably lisuride, in which the ergolin compound is stabilized. The oxidation-sensitive ergolin compound is stabilized by a combination of at least one liposoluble, free radical-scavenging antioxidant, preferably di-tert.-butyl methyl phenol, di-tert.-butyl metoxy phenol, tocopherol or ubiquinone and a basic... Agent: Pillsbury Winthrop Shaw Pittman, LLP

20070134311 - External preparation: An external preparation having excellent percutaneous absorption ability for ionic drugs is provided. An external preparation which comprises the following components (a) and (b); component (a): an ionic drug, component (b): an ionic liquid containing a cation and an anion. By this construction, the ionic liquid functions as a solubilizing... Agent: Sughrue Mion, PLLC

20070134310 - Transdermal risperidone delivery system: A system for transdermal delivery of risperidone to an individual. The system has a high risperidone loading with suitable permeation enhancers to effect therapeutic flux rate. Acrylate polymeric reservoir with the high risperidone and permeation enhancers dissolved therein provides desirable adhesive characteristics and effective transdermal therapeutic properties.... Agent: Philip S. Johnson Johnson & Johnson

20070134313 - Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier: This invention relates to a highly efficient artificial low-density lipoprotein (LDL) carrier system for the targeted delivery therapeutic agents across the blood-brain barrier (BBB). In particular, this invention relates to artificial LDL particles comprised of three lipid elements: phosphatidyl choline, fatty-acyl-cholesterol esters, and at least one apolipoprotein. The present invention... Agent: Milbank, Tweed, Hadley & Mccloy LLP

20070134312 - Liposomes for treatment of multiple myeloma: A method for treating multiple myeloma in newly diagnosed or previously treated patients is described. The method comprises administering a composition consisting of a combination of chemotherapeutic agents of an anthracycline antibiothic, preferably entrapped in a liposome, dexamethasone, and thalidomide, and, optionally, a reduced dose of vincristine.... Agent: Philip S. Johnson Johnson & Johnson

20070134314 - Therapeutic inhibitor of vascular smooth muscle cells: Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle... Agent: Jones Day

20070134315 - Orally administrable extended release pellet and tablet formulations of a highly water soluble compound: Pharmaceutical compositions comprising an extended release formulation of active compounds effective in the treatment of various pathological conditions are provided. More particularly, the invention provides methods of making and using extended release formulations comprising active compounds that present formulation challenges such as short biological half-life, instability, highly water soluble and/or... Agent: Foley And Lardner LLP Suite 500

20070134316 - Soft capsule of butylphthalide and a process for preparing the same: The present invention discloses a novel soft capsule of butylphthalide and a process for preparing the same. The soft capsule of butylphthalide is composed of a capsule wall material and a drug-containing oil, wherein the drug-containing oil is essentially composed of butylphthalide and a vegetable oil as the diluent in... Agent: Palmer & Dodge, LLP Kathleen M. Williams

20070134325 - Beta-lactam antibiotic-containing tablet and production thereof: This invention provides β-lactam antibiotic-containing tablets capable of being orally taken either as such owing to their being small-sized, hence still easily swallowable, or, in the case of administration to the aged encountering some difficulty in swallowing, in the form of dispersions resulting from easy self-disintegration upon being dropped into... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070134320 - Composition and regimen for the treatment of herpes simplex virus, herpes zoster, and herpes genitalia epidermal herpetic lesions: A composition and treatment regimen for the amelioration of epidermal herpetic lesions caused by Herpes Simplex Virus (HSV-1) symptoms, Herpes Zoster, and Herpes Genitalia. The treatment includes a regimen of oral administration of a composition including from about 15 to 50 mg of zinc sulfate, from about 5 to 20... Agent: Bliss Mcglynn, P.C.

20070134322 - Modified and pulsatile release pharmaceutical formulations of escitalopram: The present invention relates to modified and pulsatile release pharmaceutical formulations of escitalopram and their use for the treatment of central nervous system disorders, including mood disorders (e.g., major depressive disorder) and anxiety disorders (e.g., generalized anxiety disorder, social anxiety disorder, post traumatic stress disorder, and panic disorder, including panic... Agent: Darby & Darby P.C.

20070134317 - Non-effervescent form of sodium naproxen comprising i.a. sodium hydrogen carbonate: A non effervescent tablet of sodium naproxen, comprising a tablet core and, if desired, a sugar or film coat, wherein the tablet core, based on the weight of the tablet core, consists of 30 to 99% by weight sodium naproxen and 70 to 1% by weight auxiliary agent component comprising... Agent: Gibbons P.C.

20070134318 - Non-tabletted, chewable, individually dosed administration forms: Non-tabletted, individually dosed administration forms comprising a composition of at least one pharmaceutically active substance dissolved or dispersed within a matrix material comprising a mixture of at least 0.2% by weight of a gelatine, at least one stabilising agent and at least one water-soluble alcohol and/or water as a solvent,... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070134319 - Pharmaceutical formulations of bisphosphonates: A pharmaceutical formulation comprising an oral dosage form containing a bisphosphonic acid or a salt thereof and an inactive ingredient selected from: an ester of a medium chain fatty acid, or a lipophilic polyethylene glycol ester, said inactive ingredient having a hydrophilic lipophilic balance (HLB) of from about 1 to... Agent: Novartis Corporate Intellectual Property

20070134321 - Pharmaceutical tablets with height greater than width: Described is a compressed multiple layer pharmaceutical tablet that has a height that exceeds the width of the tablet. The height is measured vertically from the top to the bottom of the tablet while it is in the tablet die in which it is fully compressed, after compression has been... Agent: Accu-break Pharmaceuticals, Inc.

20070134324 - Therapeutic combinations: The goal of the present invention is a pharmaceutical composition including a betaine and an anti-cholesterol agent. The association and co-administration of at least a betaine allows to reducing side effects related to anti-cholesterol agents administration, in particular their deleterious effects on liver, pancreas and kidneys.... Agent: Hovey Williams LLP

20070134323 - Ziprasidone suspension: Compositions comprising ziprasidone free base or a difficult to wet pharmaceutically acceptable ziprasidone acid addition salt, a polysorbate, and colloidal silicon dioxide form good aqueous suspensions having a useful shelf life and are easily re-suspended if settling occurs.... Agent: Pfizer Inc

20070134326 - Composition for releasing a weak base for an extended period of time: An oral dosage form comprising a first composition and a second composition, each composition comprising a pharmaceutically acceptable weak base, especially Compound A or a pharmaceutically acceptable salt or solvate thereof, (‘the drug’) and a pharmaceutically acceptable carrier therefor, wherein the first and second compositions are arranged to release drug... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070134327 - Compositions and methods for improved efficacy of penicillin-type antibiotics: Disclosed are once-a-day penicillin-type antibiotic products comprising at least one modified release dosage form comprising penicillin-type antibiotics and pharmaceutically acceptable carriers, which compositions provide T>MIC90 in the serum for at least 5 hours (preferably for at least five consecutive hours), within a 24-hour dosing interval, for a given bacterial pathogen's... Agent: C/o Carella, Byrne, Bain, Gilfillan, Cecchi, Stewat & Olstein

20070134328 - Oxymorphone controlled release formulations: The invention pertains to a method of relieving pain by administering a controlled release pharmaceutical tablet containing oxymorphone which produces a mean minimum blood plasma level 12 to 24 hours after dosing, as well as the tablet producing the sustained pain relief.... Agent: Mayer, Brown, Rowe & Maw LLP

20070134329 - Venlafaxine formulations and methods of preparing the same: A method of forming a multi-particulate dosage form using rotary granulation is described in which polyethylene oxide is employed as s binder in a rotary granulation process. A multi-particulate oral dosage form comprises a plurality of pellets, the pellets comprising a core having disposed thereon a core composition layer. The... Agent: Cantor Colburn, LLP

20070134330 - Methods and compositions for improved image quality: The present invention is directed to consumable coating compositions for use on consumable products, such as pharmaceutical products (e.g., tablets, pills, capsule, gel cap, caplet).... Agent: Hewlett Packard Company

20070134331 - Orodispersible pharmaceutical composition for oromucosal or sublingual administration of agomelatine: The invention relates to a coated solid orodispersible pharmaceutical composition for the administration of agomelatine by the oral, oromucosal or sublingual route.... Agent: The Firm Of Hueschen And Sage

20070134333 - Methods of bonding or modifying hydrogels using irradiation: This invention provides methods and processes to attach or bond hydrogels to suitable surfaces using irradiation techniques and also provides methods and processes to create crosslinked regions in hydrogel articles using these irradiation techniques. Specifically, lasers at wavelengths tuned to the irradiation absorption bands of hydroxyl groups, carboxylic acid groups... Agent: Wood, Herron & Evans, LLP (zimmer)

20070134332 - Polymer particles for delivery of macromolecules and methods of use: The present invention provides biodegradable polymer particle delivery compositions for delivery of macromolecular biologics, for example in crystal form, based on polymers, such as polyester amide (PEA), polyester urethane (PEUR), and polyester urea (PEU) polymers, which contain amino acids in the polymer. The polymer particle delivery compositions can be formulated... Agent: Dla Piper US LLP

20070134334 - Crosslinked polysaccharide microparticles and method for their preparation: The present invention provides long-acting sustained-release formulations of drugs such as proteins or peptides, which are injectable, completely biodegradable and safe, as well as ensuring efficient encapsulation of the drugs such as proteins or peptides without inhibiting their biological activity. It is possible to achieve injectable sustained-release formulations that ensure... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070134335 - Polypeptides with the capacity to entrap drugs and release them in a controlled way: The present application relates to new peptide polymers comprising monomeric units derived from the residues of glutamic acid, aspartic acid and lysine, or their protected derivatives, and which are functionalized through the introduction of side chains containing thiol groups or protected thiol groups. The new peptide polymers can be crosslinked... Agent: Ostrolenk Faber Gerb & Soffen

20070134337 - Bacteria binding products: There is provided products for the removal of negatively charged particles like bacteria from surfaces. The products have a positive charge that may be developed through the use of cationic treatments. The product or substrate from which it is made may be dipped in an aqueous solution of a non-antimicrobial... Agent: Kimberly-clark Worldwide, Inc.

20070134343 - Collagen-based materials and methods for treating synovial joints: A method of treating a synovial joint by injecting particles of collagen-based material into the joint. The particles may be dehydrated before implantation, and rehydrated after implantation, or they may be implanted in a “wet” state—such as a slurry or gel. Radiocontrast materials may be included to enhance imaging of... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20070134341 - Compositions of lipoxygenase inhibitors: Pharmaceutical compositions comprising particles of lipoxygenase inhibitor compounds having an effective average size of from about 10 nm to about 50 microns are provided. More particularly, pharmaceutical compositions of particle of a 5-lipoxygenase inhibitor compound having an effective average size of from about 50 nm to about 5 microns are... Agent: Baxter Healthcare Corporation

20070134342 - Injectable carrier formulations of hyaluronic acid derivatives for delivery of osteogenic proteins: An injectable formulation is disclosed for delivery of osteogenic proteins. The formulation comprises a pharmaceutically acceptable admixture of an osteogenic protein; and formulations comprising osteogenic protein, hyaluronic acid derivatives and tricalcium phosphate are also disclosed. Methods for formulating porous injectable gels and pastes from hyaluronic acid are also disclosed.... Agent: Wyeth/finnegan Henderson, LLP

20070134340 - Method for delivering hydrophobic drugs via nanocrystal formulations: This invention provides nanocrystals or polymer doped nanocrystals of hydrophobic drug molecules as stably dispersed in an aqueous system which are prepared without stabilizers like surfactants and the like. In one embodiment, the drug is a tetra-pyrrole compound. An example is the hydrophobic photosensitizing anticancer drug 2-devinyl-2-(1-hexyloxyethyl)pyropheophorbide (HPPH). Pharmaceutical compositions... Agent: Hodgson Russ LLP

20070134336 - Method for improving the properties of amphiphile particles: The present invention provides a method for forming a dispersion comprising non-lamellar amphiphile particles having improved phase behaviour, particle size distribution and/or storage stability, said method comprising forming a dispersion of lamellar and optionally non-lamellar particles comprising at least one structuring agent in a polar solvent, heating said particles to... Agent: Nixon & Vanderhye, PC

20070134338 - Methods for producing nanoparticulate metal complexes and altering nanoparticle morphology: Nanoparticulate metal complexes, such as those involving ruthenium, iron, cobalt, and nickel salens, are formed using precipitation with compressed antisolvent technology. The nanoparticle morphology may be altered by altering the planarity of molecular structure of the metal complex starting material.... Agent: Stinson Morrison Hecker LLP Attn: Patent Group

20070134339 - Zonisamide and nsaid nanoparticulate formulations: The present invention is directed to compositions comprising zonisamide, or a salt or derivative thereof, and at least one nanoparticulate NSAID. The zonisamide and NSAID combination preferably includes nanoparticulate NSAID particles of the composition with an effective average particle size of less than about 2000 nm. The zonisamide and NSAID... Agent: Foley And Lardner LLP Suite 500

20070134344 - Antibiotic compositions: The invention provides an antibiotic composition comprising coated micropellets and a method for preparing said antibiotic composition.... Agent: Novartis Corporate Intellectual Property

20070134345 - Bone delivery device: Bone cages are disclosed including devices for biocompatible implantation. The structures of bone are useful for providing living cells and tissues as well as biologically active molecules to subjects.... Agent: Searete LLC Clarence T. Tegreene

20070134346 - Bone semi-permeable device: Bone cages are disclosed including devices for biocompatible implantation. The structures of bone are useful for providing living cells and tissues as well as biologically active molecules to subjects.... Agent: Searete LLC Clarence T. Tegreene

20070134347 - Method of making an extract of biologically active additive: This invention relates to the food industry and, in particular, to a technology of making an extract of a biologically active additive intended for wide application, and may be used as a biologically active food additive in pharmacology and the food industry. According to this invention, a method of making... Agent: Patenttm.us

20070134348 - Multi-part substitution infusion fluids and matching anticoagulants: A multi-part substitution infusion fluid for an extracorporeal blood treatment and methods for using same are provided. Generally, the multi-part substitution fluid comprises a first solution composed of electrolites but without divalent cations and a second solution comprising divalent cations. Another embodiment includes a third solution comprising a matching citrate/citric... Agent: Edwards Lifesciences Corporation

20070134349 - Methods of treating hematological malignancies: The present invention relates, in general, to methods of treating malignancies and, in particular, to methods of treating hematological malignancies and to compositions suitable for use in such methods.... Agent: Nixon & Vanderhye, PC

20070134351 - Angelicae sinensis extracts useful for treatment of cancers: The invention provides an acetone extract, chloroform extract or hexane extract of Angelicae sinensis and/or the active components purified therefrom, such as n-butylidenephthalide, which are effective in treating cancers.... Agent: Akin Gump Strauss Hauer & Feld L.L.P.

20070134350 - Oils/mixtures as deactivants: A method of deactivating an allergen comprises dispersing into an airspace containing or able to support said allergen an allergen-deactivating amount of an allergen-deactivating compound, the compound comprising one or more of the following compounds: a citrus oil; a mint oil; bois de rose oil; oil of jasmine; frankincense; oil... Agent: Norris, Mclaughlin & Marcus

20070134352 - Topical burn composition: A topical burn composition containing an extract of Mentha haplocalyx Brig. and at least one of an extract of Aloe vera and recombinant human epidermal growth factor.... Agent: Oliff & Berridge, PLC

20070134353 - Phytoestrogenic composition comprising an extract of chinese licorice root, isoliquiritin or liquiritin: A phytoestrogen composition comprising an extract of Chinese licorice root (Glycyrrhiza uralensis Fisch), liquiritin or isoliquiritin isolated therefrom, which show estrogen activity and inhibitory effect on proliferation of cancer cells, as an effective ingredient. The Chinese licorice root extract, as well as liquiritin or isoliquiritin isolated therefrom, show estrogenicity but... Agent: Intellectual Property / Technology Law

20070134354 - Process for producing a grape seed extract having a low content of monomeric polyphenols: A process of grape seed extraction from Vitis vinifera grapes previously treated in any variety of manners is characterised in that skin and seeds are separated immediately after the work up to which the grapes have been subjected, so as to avoid and/or stop any fermentation due to the presence... Agent: Young & Thompson

20070134355 - Use of plant parts of prickly pear (opuntia) and/or extracts therefrom for the treatment of depressions: The present invention relates to the use of Opuntias, plant parts thereof and/or extracts or other preparations produced therefrom for the treatment of episodes of depression and depressive diseases or other affective disorders, which can be influenced by antidepressive agents, such as anxiety or panic disorders, bipolar depressions, somatization disorders... Agent: Edwards Angell Palmer & Dodge LLP

20070128107 - Method to detect dopamine receptors in the functional d2high state: This application describes a method for identifying dopamine supersensitivity using radioactive (+)PHNO. The method involves determining the specific binding of radioactive (+)PHNO is the subject's brain. An increase in the specific binding of radioactive (+)PHNO in the subject compared to a control indicates that the subject is in a state... Agent: Bereskin And Parr

20070128109 - Stabilized and lyophilized radiopharmaceutical agents for destroying tumors: A novel method is set out of preparation of radioactive diagnostic radiopharmaceutical in a stable, shippable, lyophilized form by an apparatus designed to rapidly flash freeze and dehydrate a radiopharmaceutical composition to minimize auto radiolysis. The method proposes rapid cooling and removal of ambient vapor, and then ultra cold removal... Agent: Brooke Schumm Iii

20070128110 - Stereoisomers of fatty acid analogs for diagnostic imaging: The present invention provides novel imaging agents for clinical diagnosis of injuries and diseases, in the form of a radionuclide in spatial proximity to a substantially pure stereoisomer of a fatty acid analog. The invention also provides methods for using the novel imaging agents, and kits containing one or more... Agent: Foley And Lardner LLP Suite 500

20070128108 - Therapy of malignant neoplasias: The present invention provides a method for the treatment of malignant neoplasias comprising the step of administering an L-phenylalanine conjugated to a beta- or alpha-emitting isotope to a subject in the need thereof. Moreover, the invention provides a method for the monitoring of the progress of such treatment of malignant... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070128112 - Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof: Embodiments of the invention described herein relate to antibodies directed to the antigen monocyte chemo-attractant protein-1 (MCP-1) and uses of such antibodies. In particular, in accordance with some embodiments, there are provided fully human monoclonal antibodies directed to the antigen MCP-1. Nucelotide sequences encoding, and amino acid sequences comprising, heavy... Agent: Knobbe Martens Olson & Bear LLP

20070128111 - Methods and compositions for increasing antibody production: The invention provides methods and compositions for improved expression and production of recombinant antibodies in host cell expression systems. In particular, prokaryotic expression and production of antibodies with modified hinge cysteine residues are provided. The invention further provides compositions, kits and articles of manufacture for practicing methods of the present... Agent: Merchant & Gould PC

20070128113 - Methods for delivering mbd peptide-linked agent into cells under conditions of cellular stress: The present invention is related to methods of delivering MBD peptide-linked agents into live cells. The methods described herein comprise contacting MBD peptide-linked agents to live cells under a condition of cellular stress. The methods of the invention may be used for therapeutic or diagnostic purposes.... Agent: Morrison & Foerster LLP

20070128114 - Method for monitoring protein translation: Disclosed is a method for monitoring early treatment response of a cancer treatment comprising measuring by magnetic resonance spectroscopy (MRS), for example, proton MRS, the amount of Choline present in the tissue adjoining or surrounding the cancerous tissue before and after treatment; the treatment comprises administration of an angiogenesis inhibitor,... Agent: Leydig Voit & Mayer, Ltd

20070128118 - Polyglutamate-amino acid conjugates and methods: Various biodegradable polyglutamate-amino acids comprising recurring units of the general formulae (I) and (II) are prepared. Such polymers are useful for variety of drug, biomolecule and imaging agent delivery applications.... Agent: Knobbe Martens Olson & Bear LLP

20070128119 - Pendant fatty acid imaging agents: The disclosure provides pendant fatty acid compounds for use in diagnostic imaging, (particularly the cardiovascular system), as well as kits comprised of the same. The disclosure also provides for a method administering a imaging agent with a high specificity for the myocardium.... Agent: Foley & Lardner LLP

20070128120 - Organic radiographic contrasting agents for medical devices: The present invention discloses an organic radiographic contrasting agent containing an aliphatic or alicyclic backbone and multiple halogen-substituted aromatic groups. Each of the halogen-substituted aromatic groups in the radiographic contrasting agent is substituted with at least three halogen atoms and is covalently attached to the aliphatic or alicyclic backbone. The... Agent: Philip S. Johnson Johnson & Johnson

20070128117 - Ultrasound contrast agents and process for the preparation thereof: Method for preparing a lyophilized matrix and, upon reconstitution of the same, a respective injectable contrast agent comprising a liquid aqueous suspension of gas-filled microbubbles stabilized predominantly by a phospholipid and comprising a ligand agent. The method comprises preparing an emulsion from an aqueous medium, comprising a phospholipid and a... Agent: Bracco Research Usa Inc.

20070128116 - Multifunctional core for molecular imaging and targeted delivery of macromolecules and drugs: In the broadest sense an inventive conjugate includes a macrocyclic scaffold moiety incorporating at least one nitrogen atom. Through linkages to the ring, nitrogen atoms are bonded to at least one therapeutic species, or one cellular trafficking species, and preferably two or more types of trafficking species. The linkages between... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20070128115 - Pathological tissue detection and treatment employing targeted benzoindole optical agents: Novel tumor specific phototherapeutic and photodiagnostic agents are disclosed. The compounds consist of a carbocyanine dye for visualization, photosensitizer for photodynamic treatment, and tumor receptor-avid peptide for site-specific delivery of the probe and phototoxic agent to diseased tissues. A combination of these elements takes full advantage of the unique and... Agent: Mallinckrodt Inc.

20070128121 - Polymer hydrogels for controlled release and absorption of biocides: A material that is capable of releasing an active agent in a controlled manner. The material includes a hydrogel vehicle and an active agent dispersed throughout the hydrogel. When brought into contact with an aqueous release media, the active agent is released from the hydrogel vehicle into the release media.... Agent: Los Alamos National Security, LLC

20070128123 - Tiotropium containing hfc solution formulations: This invention relates to tiotropium containing stable pharmaceutical solution formulations suitable for aerosol administration. More particularly, this invention relates to tiotropium containing stable pharmaceutical solution formulations suitable for aerosol administration wherein either an inorganic acid or an organic acid is added to the aerosol solution formulation which contains a tiotropium... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070128122 - Volatile material-containing compositions having an end of service indicator: Volatile material-containing compositions having an end of service indicator and methods of indicating the end of service of a volatile material emitted from a volatile material-containing composition are disclosed.... Agent: The Procter & Gamble Company Intellectual Property Division

20070128124 - Aerosolized capreomycin for inhibition of pulmonary tuberculosis: The invention provides systems, methods, and compositions for the aerosolized administration of capreomycin to persons in need thereof. Administration of capreomycin by aerosol can be used to reduce the infectivity of persons with tuberculosis, or to reduce the severity or duration of a tuberculosis infection. The invention further provides for... Agent: Townsend And Townsend And Crew, LLP

20070128126 - Airway alkalinization as therapy for airway diseases: The present invention relates to a method of treating asthma by raising the pH of the airways of an individual. The effect can be mediated directly by administering a pharmaceutically acceptable basic solution or alternatively, the effect can be mediated by enhancing the activity of glutaminase.... Agent: Woods, Rogers, P.L.C

20070128125 - Pharmaceutical compositions based on tiotropium salts and salts of salmeterol: A pharmaceutical composition, comprising: (a) a tiotropium salt (1); and (b) a salmeterol salt (2), optionally in the form of the enantiomers, mixtures of enantiomers, or in the form of the racemates thereof, optionally in the form of the solvates or hydrates and optionally together with a pharmaceutically acceptable excipient,... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070128127 - Aerosol device containing a silicone, a gradient copolymer and a propellant essentially comprising dimethyl ether: The invention relates to an aerosol device containing: a hair treatment composition which comprises, in a cosmetically-acceptable aqueous medium, at least one silicone and at least one compositionally-graded copolymer comprising at least two different monomers and having a mass polydispersity index (Ip) of less than or equal to 2.5; and... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070128128 - Method for the innoformulation of a biocompatible galenic base: A high-tolerance biocompatible and bioregulatory dermic and/or cosmetic galenic base contains, in the aqueous phase thereof, at least two polyols selected from osides, oses or reduction products of oses, wherein at least two of the polyols are selected from reduction products of oses that are mannitol and xylitol. A dermic... Agent: Oliff & Berridge, PLC

20070128129 - Enzymatic bleaching system: The present invention relates to a novel enzymatic bleaching system, including at least one oxidase and at least one perhydrolase, body care agents, hair shampoos, hair care agents, mouth-, tooth- or denture care products, cosmetics, therapeutics, textile detergents, cleaning compositions, rinsing agents, textile detergents for automatic washing machines, hand detergents,... Agent: Paul And Paul

20070128130 - Remineralizing dental adhesive film: A dental adhesive film that, when applied to dental material, assists in the remineralization of dental material that exhibits damage from caries, lesions in the enamel and open dentine channels. The active compound in the dental adhesive film is a finely divided, poorly soluble calcium salt of phosphates, fluorides, fluorophosphates... Agent: Paul & Paul

20070128131 - Composition for oral cavity: There is provided a composition for oral cavity containing a monofluorophosphoric acid, which can supply calcium ions in a stable manner. The composition comprises (A) a calcium ion-supplying compound which supplies calcium ions at 100 to 16000 ppm, (B) a monofluorophosphate ion-supplying compound which supplies monofluorophosphate ions at 250 to... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070128132 - Teeth whitening composition and methods: Disclosed herein are teeth whitening compositions generally including an oxidizing agent (e.g., a peroxide), and an activating agent that has an emission wavelength between about 400 nm and about 570 nm (e.g., Eosin B). Methods of employing these compositions to whiten teeth, methods of making these compositions and kits that... Agent: Lahive & Cockfield, LLP

20070128133 - Mitigation of photodamage in analytical reactions: Compositions, devices, systems and methods for reducing and/or preventing photodamage of one or more reactants in illuminated analytical reactions by one or more of incorporating photodamage mitigating agents within the reaction mixture and/or interrogating different observation regions of the reaction mixture for a period that is less than a photodamage... Agent: Pacific Biosciences Of California, Inc.

20070128134 - Water-soluble keratin derivative and use thereof: The present invention provides a novel water-soluble keratin derivative and applications thereof. Water-soluble keratin produced by the alkali treatment of feathers, and modified keratin, gives the following useful materials: (1) a high energy wave absorber, (2) a luminescent substrate, (3) a material weatherproofness improver, (4) a water repellant, and (5)... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070128136 - Terrein compound having melanin biosynthesis inhibitors and its preparation: The present invention relates to a melanin biosynthesis inhibitor containing terrein compound as an effective ingredient. The terrein compound can be easily separated from Penicillium sp KCTC 26245, a fungal strain inhabited in domestic soil. It does not directly inhibit tyrosinase but inhibits the expression of MITF (microphthalmia-associated transcription factor)... Agent: Jhk Law

20070128135 - Use of benzoquinones in agents for oxidative treatment of hair and method and agent for permanent hair shaping: Use of benzoquinones and derivatives or salts thereof as the only oxidant in agents for oxidative treatment of hair, and agent containing at least one o-benzoquinone, and a method for permanent shaping of hair by use of such agents. The hair thus treated shows uniform and permanent transformation and no... Agent: Striker Striker & Stenby

20070128137 - Water in oil emulsion compositions containing siloxane elastomers: The present invention relates to water in oil emulsion compositions comprising: from about 0.1% to about 15% of a non-emulsifying crosslinked siloxane elastomer; from about 0.1% to about 15% of an emulsifying crosslinked siloxane elastomer; from about 1% to about 40% of a solvent for the non-emulsifying and emulsifying crosslinked... Agent: The Procter & Gamble Company Intellectual Property Division

20070128138 - Gel-based cosmetic and wound-healing formulation and method: Disclosed are gel-based cosmetic and wound-healing formulations, methods for making said formulations, and a method for simultaneously treating and concealing injuries to human skin. In one exemplary embodiment, the cosmetic and wound-healing formulation comprises live yeast cell extract, pigment, and a gel.... Agent: Technology Law Group, LLC

20070128140 - Composition incorporating emollient oils into bar soap products: A composition for incorporating emollient oils into soap, soap/synthetic combinations, or all synthetic soap products is provided. The composition comprises a dispersion, soap pellets and additional ingredients.... Agent: Snell & Wilmer, LLP (dial Corp)

20070128141 - Composition incorporating emollient oils into bodywash: A composition for incorporating emollient oils into bodywash products is provided. The composition comprises a highly stable dispersion, a bodywash base, and additional ingredients.... Agent: Snell & Wilmer, LLP (dial Corp)

20070128139 - Hair treatment compositions comprising hydroxy comopounds: The invention provides a hair treatment composition such as a shampoo or conditioner suitable for topical application to hair for the repair and prevention of damage comprising a hydroxy compound having the following parameters: i) electrotopological state indice of OH S_sOH<9.26 (ii) multigraph information content indice BIC>0.8 (iii) electrotopological state... Agent: Unilever Intellectual Property Group

20070128142 - Emulsion for conveying a hydrophobic active material to a substrate in aqueous medium: Emulsion (E) comprising a hydrophobic phase (O) containing and/or consisting of a hydrophobic active material (A), which is in the form of a multiple emulsion (Em) comprising: an inner inverse emulsion (Ei) comprising the continuous phase (O), a dispersed aqueous phase (Wi) and, at the interface of the two phases,... Agent: Jean Louis Seugnet Rhodia Inc

20070128143 - Polyether-modified polysiloxanes with block character and use thereof for producing cosmetic formulations: u

20070128144 - Opacifiers: An opacifier concentrate including (a) 5 to 50% by weight of a styrene/acrylate copolymer; (b) 3 to 90% by weight of at least one anionic, nonionic, amphoteric and/or zwitterionic surfactant; and (c) 0 to 10% by weight of an additive, and (d) the remainder up to 100% by weight water.... Agent: Cognis Corporation Patent Department

20070128145 - Amino acid adducts for percutaneous delivery of vitamin b3: The present invention relates to adducts of an amino acid or of a peptide with a vitamin B3 compound. Such adducts, thanks to the amino acid chain, easily penetrate the skin and are able to efficiently deliver the vitamin B3 compound to when applied topically. Such adducts can be used... Agent: The Procter & Gamble Company Intellectual Property Division

20070128147 - Composition comprising a particulate zinc material, a pyrithione or a polyvalent metal salt of a pyrithione and a gel network: The present invention relates to a composition comprising an effective amount of a particulate zinc material, an effective amount of a detersive surfactant including a surfactant with an anionic functional group, an effective amount of a pyrithione or a polyvalent metal salt of a pyrithione, a dispersed gel network phase... Agent: The Procter & Gamble Company Intellectual Property Division

20070128146 - Oil-in-water emulsion cosmetic composition and method for producing the same: To provide an oil-in-water emulsion cosmetic composition obtained by using a polyglycerin fatty acid ester as a surfactant, which has high stability against temperature and is excellent in tactile sensation, and a method for producing the same, the present invention provides an oil-in-water emulsion cosmetic composition, wherein the composition comprises... Agent: Knobbe Martens Olson & Bear LLP

20070128148 - Aroma-releasing polymeric gel matrix: A translucent-to-clear, plasticized PVC thermoplastic polymeric matrix gel composition comprising (i) a high loading of fragrance composition and/or odor counteractant(s)—preferably greater than about 85%; (ii) from about 4% to about 25% of a plastisol with a Shore hardness of from about 60 to about 95 that is liquid at room... Agent: Louis C. Paul & Associates, PLLC

20070128149 - Survival kit and commode: A survival kit for use in disaster areas where there is a loss of sanitation facilities. The kit is a watertight container that includes one or more survival kit items including food and water and in addition includes a packet containing a chemical toilet composition. After the survival kit items... Agent: Roger Aceto

20070128151 - Carboxylic acid esters of zosteric acid for prevention of biofouling: Carboxylic acid ester derivatives of zosteric acid are effective in preventing biofouling and are readily formulated into coatings or films. Coating or film compositions of the esters, and methods for their application, are provided which reduce the dissolution of the esters into water or loss to the environment. The Zosteric... Agent: Ciba Specialty Chemicals Corporation Patent Department

20070128154 - Bioabsorbable surgical composition: Bioabsorbable macromer compositions are provided including a diisocyanate-functional bioabsorbable polymer. In some embodiments, the diisocyanate-functional bioabsorbable polymer can be combined with a functionalized polyol. The resulting bioabsorbable macromer composition can be employed as an adhesive or sealant for medical/surgical uses.... Agent: United States Surgical, A Division Of Tyco Healthcare Group Lp

20070128153 - Biocompatible surgical compositions: Biocompatible synthetic macromer compositions are provided including a first polymer having multiple functional groups and a second functionalized polyurethane prepolymer, which can be employed as an adhesive or sealant for medical/surgical uses.... Agent: United States Surgical, A Division Of Tyco Healthcare Group Lp

20070128152 - Biocompatible tissue sealants and adhesives: The disclosure relates to compositions for medical/surgical synthetic adhesives and sealants. Adhesive compositions include a functionalized triol and functionalized diol, while sealant compositions further include a multifunctionalized polyol and at least one amine cross linker.... Agent: United States Surgical, A Division Of Tyco Healthcare Group Lp

20070128150 - Branched molecular scaffolds for linking polymer residues to biologically active moieties: Branched molecular scaffolds are provided which are capable of linking two polymer residues (derived, for example, from polyethylene glycol) to two, three or four residues derived from biologically active molecules (e.g. from whole antibodies or from functionally active fragments or derivatives thereof), the latter being attached to the scaffold by... Agent: Woodcock Washburn LLP

20070128155 - Cartilage repair methods: The present application discloses methods for repairing hyaline cartilage defects. The methods comprise a combination of introducing autologous bone mesenchymal stem cells to a joint, and applying to the joint a membrane comprising a polyester entangled with a polysaccharide. In some aspects, the bone mesenchymal stem cells are mesenchymal stem... Agent: Biotactica, LLC

20070128156 - Ophthalmic compositions containing a synergistic combination of two polymers: Ophthalmic compositions suitable for use as artificial tears or as vehicles for ophthalmic drugs are disclosed. The compositions contain a combination of two polymers that have a synergistic effect on viscosity.... Agent: Alcon

20070128159 - Chemokines as adjuvants of immune response: Dendritc cells play a critical role in antigen-specific immune responses. Materials and methods are provided for treating disease states, including cancer and autoimmune disease, by facilitating or inhibiting the migration or activation of antigen-presenting dendritic cells. In particular, chemokines are used to initiate, amplify or modulate an immune response. In... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070128158 - Cytokine protein family: The present invention relates to polynucleotide and polypeptide molecules for zcyto20, zcyto21, zcyto22, zycto24, and zcyto25 proteins which are most closely related to interferon-α at the amino acid sequence level. The receptor for this protein family is a class II cytokine receptor. The present invention includes methods of reducing viral... Agent: Zymogenetics, Inc. Intellectual Property Department

20070128157 - Tumour suppressor protein: We describe a polypeptide which binds and modulates the activity of a tumour suppressor polypeptide, for example p53; a nucleic acid molecule encoding said protein and screening methods which modulate the binding activity of said polypeptide for its target polypeptide(s).... Agent: Klarquist Sparkman, LLP

20070128160 - Methods for treating viral infection using il-28 and il-29: IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof... Agent: Zymogenetics, Inc. Intellectual Property Department

20070128161 - Methods of treating cancer using il-21: Methods for treating mammals with cancer using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a... Agent: Zymogenetics, Inc. Intellectual Property Department

20070128162 - Alpha interferon variants: The present invention provides biologically active variants of human α-2b-interferon. The variants contain carboxy terminus truncations when compared with the amino acid sequence of full-length human α-2b-interferon. It is the novel finding of the present invention that these truncated variants have the biological activity of full-length human α-2b-interferon. The invention... Agent: Alston & Bird LLP

20070128163 - Adeno-associated virus-mediated delivery of angiogenic factors: The use of recombinant adeno-associated virus (rAAV) virions for delivery of genes encoding angiogenic factors to muscle tissue is disclosed. The invention describes such methods of delivery and also describes methods for treating an ischemic condition such as myocardial ischemia. The methods include direct delivery of rAAV virions to a... Agent: Robins & Pasternak

20070128166 - Adenoviral vectors having a protein ix deletion: This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also... Agent: Townsend And Townsend And Crew, LLP

20070128167 - Complexing agents for compositions containing inclusion complexes: The invention provides a composition containing particulate composite of a polymer and a therapeutic agent. The composition also contains a complexing agent. The polymer interacts with the complexing agent in a host-guest or a guest-host interaction to form an inclusion complex. A therapeutic composition of the invention may be used... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070128169 - Inhibition of gene expression by delivery of polynucleotides to animal cells in vivo: Described is a process for intravascular delivery of a polynucleotide to an extravascular cell of a mammal to inhibit gene expression. A polynucleotide containing sequence that is similar to a sequence in the gene to be expressed is made and inserted into a vessel in the mammal. The polynucleotide is... Agent: Mirus Corporation

20070128168 - Novel genes regulated in the developing human ventral mesencephalon: A human embryonal stem cell, neural stem cell, neural precursor cell, neural cell or dopaminergic neuron is genetically modified to overexpress at least one of certain genes identified as regulated in the developing human ventral mesencephalon, and more particularly, up-regulated in the ventral tegmentum. The genes are associated with dopaminergic... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070128164 - Polypeptide: The present invention provides 5T4 tumour-associated antigen (TAA) for use in a method of immunotherapy of tumours. The invention also relates to a recombinant poxvirus vector from which at least one immune evasion gene has been deleted, which comprises a nucleic acid sequence encoding a 5T4 TAA and the use... Agent: Townsend And Townsend And Crew, LLP

20070128165 - Recombinase-based system for expression of foreign proteins using adenovirus vectors: In the present invention, viruses, plasmids or both are constructed which contain viral DNA and lox sites positioned such that site-specific recombination between lox sites in separate plasmids results in generation of infectious viral DNA at high-efficiency in cotransfected host cells that have been engineered to express the Cre recombinase.... Agent: Gerard H. Bencen Bencen & Van Dyke, P.A.

20070128177 - Methods and compositions for lowering the level of tumor necrosis factor (tnf) in tnf-associated disorders: The present invention provides recombinant adeno-associated virus (rAAV) vectors encoding a tumor necrosis factor (TNF) antagonist and methods using these vectors to reduce levels of TNF in a mammal. The invention also provides methods of using these rAAV vectors in palliating TNF-associated disorders.... Agent: Morrison & Foerster LLP

20070128176 - Stem cells of the islets of langerhans and their use in treating diabetes mellitus: Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin and ABCG2 have been identified as molecular... Agent: Palmer & Dodge, LLP Kathleen M. Williams

20070128178 - Probiotics for gut neuromuscular functions: The present invention relates to the use of proboscis in nutritional compositions or medicaments for the prevention of treatment of gut-neuromuscular abnormalities. Such abnormalities are, for example, associated with colic in babies, gut-pain or gut discomfort in general. In particular, the invention relates to the prevention or treatment of gut... Agent: Bell, Boyd & Lloyd LLP

20070128170 - Compositions of ndv and methods of use thereof for treatment of cancer: The present invention discloses methods for inducing regression of a tumor in a subject by administering a pharmaceutical composition comprising a lentogenic strain of Newcastle disease virus (NDV). A preferred viral strain of NDV for inducing regression of a tumor in a subject is a clonal strain of NDV, the... Agent: Winston & Strawn LLP Patent Department

20070128171 - Engineered blood vessels: The present invention relates to engineered blood vessels and methods of making such vessels using matrices comprising endothelial and smooth muscle cells, or cells capable of differentiating into endothelial and smooth muscle cell lineages (e.g., stem cells, or the progenitors thereof).... Agent: William F Lawrence Formmer Lawrence & Haug

20070128172 - Hair growth method: A method of enabling effective hair growth and furthermore, inducing hair growth closely similar to the natural hair state in the case of transplanting dermal papillae or cultured dermal papilla cells into the skin to regenerate the hair, characterized by comprising transplanting a composition containing the following components into an... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070128174 - Methods and compositions for organ and tissue functionality: Materials and methods for treating tissue defects in human or animal tissues using implantable cells are described. Further, culture techniques and factors for enhancing these procedures, and cell survival and adaptation are described. Many of the tissue defects may be treated with autologous cells, while applications involving non-autologous cells or... Agent: Dardi & Associates, PLLC

20070128175 - Novel hydorgels and uses thereof: The present invention provides novel hydrogels and methods of making and using such hydrogels. The present invention provides hydrogels that may be formed by the self-assembly of peptides in solution. Such self-assembly may be brought about by a change in one or more characteristics of the solution. Characteristics of the... Agent: Connolly Bove Lodge & Hutz LLP

20070128173 - Use of polysulphated alginate in cellular matrices: The present invention describes an in vitro/ex vivo method for the cultivation of connective tissue cells or progenitor cells (e.g. chondrogenic cells) in matrix comprising polysulphated alginate. These cultivated cells can be used in the preparation of a medicament for the treatment or prevention of osteochondral defects. The invention also... Agent: Clark & Elbing LLP

20070128179 - Phospholipase(s) and use(s) thereof: The present invention provides a method for the treatment and/or prevention of a bacterial related condition comprising administering to a subject a therapeutically effective amount of at least one phospholipase, isoform, derivative, mutant and/or fragment thereof. The phospholipase, isoform, derivative, mutant and/or fragment thereof, may be obtained from at least... Agent: Dickstein Shapiro LLP

20070128180 - Galactanase variants: Variants of Glycoside Hydrolase family 53 galactanases, e.g. variants of the galactanases from strains of Yersinia, Aspergillus, Humicola, Meripilus, Myceliophthora, Thermomyces, Bacillus, Bifidobacterium, Cellvibrio, Clostridium, Pseudomonas, Thermotoga, or Xanthomonas.... Agent: Novozymes North America, Inc.

20070128181 - Methods of preventing morbidity and mortality by perioperative administration of a blood clotting inhibitor: The present invention provides methods of using a blood clotting inhibitor to reduce post-surgical morbidity and mortality. In particular, perioperative use of a blood clotting inhibitor decreases surgical complications without significant adverse effects and is cost effective.... Agent: Sutherland Asbill & Brennan LLP

20070128182 - Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions: A non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy to the proliferative form of diabetic retinopathy comprising intravitreally administering to a patient suffering from non-proliferative diabetic retinopathy an effective amount of serine proteinase enzyme sufficient to create, without surgery, a posterior vitreal detachment... Agent: Denis A. Polyn Bausch & Lomb Incorporated

20070128183 - Td antigens: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from enteroaggregative E. coli, enterotexigenic E. coli, S. flexneri and C. jejuni, methods for isolating such antigens and specific uses thereof.... Agent: Fulbright & Jaworski L.L.P.

20070128185 - Identification of unique binding interactions between certain antibodies and the human b7.1 and b7.2 co-stimulatory antigens: The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies,... Agent: Pillsbury Winthrop Shaw Pittman LLP

20070128184 - Immunomodulating tumor necrosis factor receptor 25 (tnfr25) agonists, antagonists and immunotoxins: It is an object of the invention to provide novel compositions and methods utilizing immunomodulating agents that can either stimulate or indirectly augment the immune system or in other cases have an immunosuppressive effect. TNFR25 agonists disclosed herein have an anti-inflammatory and healing effect. They can be used, among other... Agent: Mcdermott Will & Emery LLP

20070128186 - Proliferative glomerulonephritis-related gene: A gene which is useful in searching for a therapeutic agent which restores tissue that suffered damage in a renal disease, a polypeptide encoded by the gene and an antibody which recognizes the polypeptide, are provided. A gene whose expression level changes depending on progression and recovery of the pathology... Agent: Fitzpatrick Cella Harper & Scinto

20070128187 - Reagents and method for modulating dkk-mediated interactions: The present invention provides reagents, compounds, compositions, and methods relating to novel interactions of the extracellular domain of LRP5, HBM (a variant of LRP5), and/or LRP6 with Dkk, including Dkk-1. The various nucleic acids, polypeptides, antibodies, assay methods, diagnostic methods, and methods of treatment of the present invention are related... Agent: Drinker Biddle & Reath (dc)

20070128190 - Anti-alpha2 integrin antibodies and their uses: The invention relates to anti-α2 integrin antibodies and their uses. Humanized antibodies are disclosed that bind to the I domain of α2 integrin and inhibit the interaction of α2β1 integrin with collagen. Also disclosed are therapeutic uses of anti-α2 integrin antibodies in treating α2β1-mediated disorders, including anti-α2 integrin antibodies that... Agent: Bozicevic, Field & Francis LLP

20070128189 - Il-21 receptor antagonists: Monoclonal antibodies to the IL-21 receptor and multimeric complexes comprising the IL-21 receptor; including monoclonal antibodies to the heterodimeric receptor, IL-21/IL-2Rγ; have been prepared. The invention also describes a method of producing said antibodies. And, the invention also describes a method of treatment comprising using said antibodies to suppress an... Agent: Zymogenetics, Inc. Intellectual Property Department

20070128188 - Novel stra6 polypeptides: The present invention is directed to novel polypeptides having sequence similarity to Stra6, a murine retinoic acid responsive protein, and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention... Agent: Merchant & Gould PC

20070128198 - Compositions comprising antibodies to human fgl2: Methods for mediating immune coagulation using novel antibodies and compounds are described. A protein Fgl2 having direct prothrombinase activity has been identified. Inhibitors of Fgl2 are useful in preventing and treating diseases which require a reduction in immune coagulation including bacterial and viral infections, allograft and xenograft rejection, glomerulonephritis, cancer,... Agent: Bereskin And Parr

20070128193 - Glp-1 agonists, compositions, methods and uses: The present invention relates to at least one novel human GLP-1 mimetibody or agonist, or specified portion or variant, including isolated nucleic acids that encode at least one GLP-1 mimetibody or agonist, or specified portion or variant, GLP-1 mimetibody or agonist, or specified portion or variants, vectors, host cells, transgenic... Agent: Philip S. Johnson Johnson & Johnson

20070128192 - Human antibody molecules for il-13: Specific binding members, in particular human anti-IL-13 antibody molecules and especially those which neutralise IL-13 activity. Methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, including asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.... Agent: Heller Ehrman LLP

20070128197 - Immunointeractive molecules: The present invention relates generally to immunointeractive molecules and more particularly antibodies which bind to vascular endothelial growth factor-B (VEGF-B) or its functional or structural equivalent and inhibit the biological activity of VEGF-B. In particular, the present invention relates to deimmunized such as humanized or human antibodies that bind to... Agent: Scully Scott Murphy & Presser, PC

20070128195 - Mammalian cytokines; related reagents and methods: Nucleic acids encoding mammalian, e.g., primate, IL-1ζ, purified IL-1ζ polypeptides and fragments thereof. Binding proteins, e.g., antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided.... Agent: Dnax Research Inc. Legal Department

20070128196 - Methods and compositions for inhibiting angiogenesis: Methods for inhibiting angiogenesis in endothelial cells and selectively inducing apoptosis in endothelial cells via compounds which binds annexin II are provided. These compounds and methods for using these compounds are useful in the treatment of diseases or disorders characterized by unwanted angiogenesis. Also provided are pharmaceutical compositions containing a... Agent: Licata & Tyrrell P.C.

20070128191 - Polyclonal antibodies, preparation method thereof and use of same: Antibodies that specifically bind to amyloid beta peptide Aβ40 or Aβ42, obtainable by immunization of a mammal with a polypeptide conjugated to a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 2, 3, and 4, and method for preparing the antibodies. Preferably,... Agent: Crowell & Moring LLP Intellectual Property Group

20070128194 - Preparation of monoclonal antibody to n-myc downstream regulated gene 2 and determination of ndrg2 using protein chip: The present invention relates to a monoclonal antibody specific for N-myc downstream regulated gene 2 (NDRG 2) protein, a cell line producing the monoclonal antibody, a method for measuring a quantity and quality of NDRG 2 protein, and a protein chip using the same. In the present invention, NDRG 2,... Agent: Staas & Halsey LLP

20070128199 - Dsp-3 dual-specificity phosphatase: Compositions and methods are provided for the treatment of conditions associated with cell proliferation, cell differentiation and cell survival. In particular, the dual-specificity phosphatase DSP-3, and polypeptide variants thereof that stimulate dephosphorylation of DSP-3 substrates, are provided. The polypeptides may be used, for example, to identify antibodies and other agents... Agent: Seed Intellectual Property Law Group PLLC

20070128200 - Growth arrest specific gene 6 peptides, antibodies, compositions, methods and uses: The present invention provides novel proteins and peptides from the receptor binding region of human Growth Arrest Specific Gene 6 (Gas6) and antibodies, including specified portions or variants, specific for at least one such Gas6 peptide or fragment thereof. The aforesaid peptides can be used to generate human, primate, rodent,... Agent: Philip S. Johnson Johnson & Johnson

20070128203 - Anti-integrin antibodies, compositions, methods and uses: The present invention relates to at least one novel anti-alpha-V subunit antibodies, including isolated nucleic acids that encode at least one anti-alpha-V subunit antibody, alpha-V subunit, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.... Agent: Philip S. Johnson Johnson & Johnson

20070128202 - Antibodies that bind to cancer-associated antigen cd46 and methods of use thereof: Provided herein is disclosure about the development and characterization of an antibody (mPA7) which binds to antigen CD46 which is present on a variety of human cancers from ovary, breast, lung, prostate, colon, kidney, and pancreas. Methods of diagnosing and treating various cancers by using antibodies such as mPA7 directed... Agent: Morrison & Foerster LLP

20070128201 - Combined use of ecteinascidin-743 and platinum antineoplastic compounds: ET-743 can be used to mitigate resistance to and potentiate the cytotoxic effects of a platinum coordination complex anti-neoplastic agent in a human cancer patient.... Agent: King & Spalding

20070128204 - Methods and compositions for inducing apoptosis in cancer cells: Anti-DR5 antibody agonists, combined with apoptosis-inducing agents, synergistically induce apoptosis in cancer cells.... Agent: Towmsend & Townsed & Crew LLP

20070128205 - Cytokine protein family: The present invention relates to polynucleotide and polypeptide molecules for zcyto20, zcyto21, zcyto22, zycto24, and zcyto25 proteins which are most closely related to interferon-α at the amino acid sequence level. The receptor for this protein family is a class TI cytokine receptor. The present invention includes methods of reducing viral... Agent: Zymogenetics, Inc. Intellectual Property Department

20070128206 - Preventives or remedies for infection, anti-endotoxin agents, vaccine adjuvants and growth promoters: A preventive or remedy for infection, an anti-endotoxin agents, a vaccine adjuvants and a growth promoter each comprising a sugar cane-derived extract as an active ingredient which agent is safe to man and animals. Also presented are foods and feeds comprising these agents.... Agent: Knoble, Yoshida & Dunleavy

20070128208 - Method for the treatment of airway diseases: A method for the treatment of allergic airway diseases in mammals related to Pythiosis insidiosum is described. The method relies upon an immunotherapeutic product of pythium proteins as antigens. The method is particularly useful in equine cicatrix.... Agent: Ian C. Mcleod Mcleod & Moyne, P.C.

20070128207 - Method of selecting wt1 vaccine adaptive patient: A method of selecting patients highly responsive to WT1 vaccine and a therapeutic method for treating cancer involving said method of selection are provided, which method of selecting patients highly responsive to WT1 vaccine comprises: (a) isolating a biological sample containing CTL precursor cells from a test subject; (b) measuring... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070128209 - Vaccine based method for protection against hiv infection: A vaccine based method for the prevention of HIV infection, suitable for HIV negative persons, is described. The method comprises the combination of (a) an immunization with material containing foreign MHC class II and (b) receiving a preparation containing the same foreign MHC class II, for example (i) taken orally... Agent: Vermette & Co.

20070128210 - Surface proteins of streptococcus pyogenes: β-hemolytic streptococci polynucleotides, polypeptides, particularly Streptococcus pyogenes polypeptides and polynucleotides, and antibodies of these polypeptides are described. The polynucleotides, polypeptides, and antibodies of the invention can be formulated for use as immunogenic compositions. Also disclosed are methods for immunizing against and reducing β-hemolytic streptococcal infection, and for detecting β-hemolytic streptococci... Agent: Hunton & Williams LLP Intellectual Property Department

20070128211 - Surface proteins of streptococcus pyogenes: β-hemolytic streptococci polynucleotides, polypeptides, particularly Streptococcus pyogenes polypeptides and polynucleotides, and antibodies of these polypeptides are described. The polynucleotides, polypeptides, and antibodies of the invention can be formulated for use as immunogenic compositions. Also disclosed are methods for immunizing against and reducing β-hemolytic streptococcal infection, and for detecting β-hemolytic streptococci... Agent: Hunton & Williams LLP Intellectual Property Department

20070128212 - Ceramidase inhibitor: The present invention provides a ceramidase activity inhibitor which inhibits ceramidase activity, specifically neutral/alkaline ceramidase activity, characterized in that the inhibitor comprises, as an active ingredient, a processed product derived from at least one plant selected from the group consisting of plants belonging to Ginkgoaceae, plants belonging to Cucurbitaceae, plants... Agent: Birch Stewart Kolasch & Birch

20070128213 - Novel plant virus particles and methods of inactivation thereof: The present invention relates generally to plant viruses, produced by plants, for use as vaccines and the like. More specifically, the present invention relates to simple inactivation methods, and plant virus particles thereby obtained. The invention described herein provides means and methods to produce a safe vaccine based on an... Agent: The Dow Chemical Company

20070128216 - Recombinant intracellular pathogen immunogenic compositions and methods for use: Immunogenic compositions comprising recombinant attenuated intracellular pathogens that have been transformed to express recombinant immunogenic antigens of the same or other intracellular pathogens are provided. Exemplary immunogenic compositions include, but are not limited to attenuated recombinant Mycobacteria expressing the major extracellular non-fusion proteins of Mycobacteria and/or other intracellular pathogens. Other... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP

20070128215 - Streptococcus phocae vaccine: The present invention relates to the use of bacteria of the species Streptococcus phocae for the manufacture of a vaccine, to methods for the production of such vaccines, to bacteria of the species Streptococcus phocae for use in a vaccine and to methods for the combating of Streptococcus phocae infection... Agent: Intervet Inc. Patent Department

20070128217 - Antigenic peptides of sars coronavirus and uses thereof: The present invention pertains to antigenic peptides of SARS-CoV and their use in diagnostic test methods and in the treatment of condition resulting from SARS-CoV. Furthermore, this invention provides antibodies capable of specifically recognizing the peptides of the invention. The antibodies can also advantageously be used in diagnostic test methods... Agent: Trask Britt

20070128218 - Diagnosis and treatment of hepatic disorders: The present invention encompasses methods and compositions useful in diagnosing and treating hepatic disorders, especially those characterized by inflammation. The method comprises administration of an agent which prevents the interaction of MAdCAM with a MAdCAM binding partner or ligand. These compositions are useful in treating diseases or disorders involving α4β7/MAdCAM... Agent: Merchant & Gould PC

20070128221 - Hepatitis-c virus testing: New styles of hepatitis C virus (HCV), referred to as HCV-3 and HCV-4, have been identified and sequenced. Antigenic regions of HCV-2, HCV-3 and HCV-4 polypeptides have been identified. Immunoassays for HCV and antibodies thereto are described, which allow more complete screening of blood samples for HCV, and allow HCV... Agent: Alston & Bird LLP

20070128220 - Materials and methods relating to fusion proteins for inducing an immune response: A nucleic acid construct is provided for delivery into living cells in vivo for inducing an immune response in a patient to an antigen; the construct directing the expression of a fusion protein, said fusion protein comprising said antigen and an adjuvant sequence derived from a plant viral coat protein.... Agent: Morgan Lewis & Bockius LLP

20070128219 - Molecular antigen arrays: The present invention provides a composition comprising an AP205 virus like particle (VLP) and an antigen. The invention also provides a process for producing an antigen or antigenic determinant bound to AP205 VLP. AP205 VLP bound to an antigen is useful in the production of compositions for inducing immune responses... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070128223 - Cd40 ligand fusion protein vaccine: Provided are methods of generating an immune response to any of various antigens including foreign antigens such as infectious agent antigens. In general, the method comprises administering an expression vector encoding a transcription unit encoding a secretable fusion protein, the fusion protein containing the foreign antigen and CD40 ligand and... Agent: Foley & Lardner LLP

20070128222 - Fusogenic, self-propagating blebs as immunogenic compositions: Self-propagating, fusogenic blebs are produced from cells infected with a population of Venezuelan Equine Encephalitis virus replicon particles (VRP). The self-propagating, fusogenic nature of the blebs is derived from expression of heterologous genes encoding viral fusion proteins that are incorporated into the replication defective replicon particles. The resulting blebs can... Agent: Wyeth Patent Law Group

20070128224 - Novel strain of sars-associated coronavirus and applications thereof: The invention relates to a novel strain of severe acute respiratory syndrome (SARS)-associated coronavirus, resulting from a sample collected in Hanoi (Vietnam), reference number 031589, nucleic acid molecules originating from the genome of same, proteins and peptides coded by said nucleic acid molecules and, more specifically, protein N and the... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070128225 - Immunogenic sequences: The application relates to nucleic acids which encode enzymes responsible for the production of the O-antigen of Francisella tularensis, and their use as or in the production of vaccines and in diagnosis.... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20070128228 - Buttock deformity treatment: Methods for treating a buttock deformity or for preventing development of a buttock deformity by local administration of a Clostridial toxin, such as a botulinum neurotoxin, to a buttock deformity or to the vicinity of a buttock deformity.... Agent: Allergan, Inc.

20070128226 - Methods of treating pain associated with abnormalities of the first metatarsophalangeal joint of the foot: Disclosed is a method for treating pain associated with abnormalities of the first metatarsophalangeal joint of the foot of a mammal comprising administering a therapeutically effective amount of neuromuscular toxin to the mammal. Preferred embodiments include administering neuromuscular toxins capable of inhibiting pain, e.g. botulinum toxin, to treat such abnormalities... Agent: Knobbe Martens Olson & Bear LLP

20070128227 - Multi-step therapy for injured muscles: Methods for treating an injured muscle by local administration of a neurotoxin, such as a botulinum toxin, to promote healing and/or to reduce the pain associated with an injured muscle.... Agent: Allergan, Inc.

20070128229 - Surface proteins of streptococcus pyogenes: β-hemolytic streptococci polynucleotides, polypeptides, particularly Streptococcus pyogenes polypeptides and polynucleotides, and antibodies of these polypeptides are described. The polynucleotides, polypeptides, and antibodies of the invention can be formulated for use as immunogenic compositions. Also disclosed are methods for immunizing against and reducing β-hemolytic streptococcal infection, and for detecting β-hemolytic streptococci... Agent: Hunton & Williams LLP Intellectual Property Department

20070128230 - Protein nmb0928 and use thereof in pharmaceutical formulations: In order to achieve this goal the NMB0928 protein was isolated and identified as a component of outer membrane preparations of Neisseria meningitidis capable of inducing bactericidal activity. Additionally the gene codifying for NMB0928 protein was cloned and expressed, and the said polypeptide was purified and its immunogenicity evaluated in... Agent: Hoffmann & Baron, LLP

20070128231 - Erythropoietin solution formulation: A stable pharmaceutical formulation of erythropoietin is disclosed which contains tris-(hydnox-ymethyl)-aminomethane as stabilizer, whereby the formulation does not contain amino acids or human serumalbumin.... Agent: Smith Patent Consulting Consulting, LLC

20070128233 - Cosmetic composition having a unique cushiony texture: A method of making-up a keratinous substrate comprising contacting the keratinous substrate with a cosmetic composition containing: (a) at least one polyorganosiloxane-containing polymer having at least one moiety containing: (i) from 1 to about 1000 organosiloxane units; and (ii) at least two groups capable of establishing hydrogen interactions; (b) an... Agent: L'oreal Usa/ Patent Department

20070128232 - Emulsified perfume oils: A fragrance and perfume oil concentrate in the form of aqueous emulsion is comprised of at least 30% by weight of perfume oil(s), where the content of the two components water and perfume oil(s) exceeds a value of together 96% by weight. The perfume emulsion is not combustible or flammable... Agent: Paul & Paul

20070128234 - Process for the incorporation of a flavor or fragrance ingredient or composition into a carbohydrate matrix: The present invention relates to a hot melt extrusion process for the preparation of an active ingredient, namely a flavor or fragrance, delivery system, wherein the quenching of the extruded product to form a glass is carried out with a cooling medium of a low temperature coolant such as liquid... Agent: Winston & Strawn LLP Patent Department

20070128239 - Benzimidazole non-aqueous compositions: The present invention provides a stable veterinary oral composition which comprises one or more surfactants, a water-miscible solvent, optionally an oil and an effective amount of each of a benzimidazole antihelmintic compound, such as triclabendazole and a macrocyclic lactone, such as moxidectin. Said composition is useful for treating and controlling... Agent: Wyeth Patent Law Group

20070128236 - Extraction process: The invention relates to extracting compounds from plant material and to formulations including compounds extracted from plant material, especially but not exclusively, spray formulations for controlling pests.... Agent: Needle & Rosenberg, P.C.

20070128235 - Juvenile hormone transmethylase genes and method of using the same: Juvenile hormone acid methyltransferase gene was cloned using a cDNA derived from the corpora allata of Bombyx mori by differential display methods. A recombinant protein expressed in Escherichia coli, which was transformed with a vector DNA incorporating the gene, was found to have juvenile hormone acid methyltransferase activity. Based on... Agent: Seed Intellectual Property Law Group PLLC

20070128238 - Method for masking feline attracting plant fragrances in human application: A method is described in which the essential oils of insect repelling plant matter are mixed with the essential oils of animal repelling matter so that the animal repelling scents mask the insect repelling scents from those animals that are attracted by the insect repelling plant matter. In this manner... Agent: I. Michael Bak-boychuk

20070128237 - Soil additive composition having visual perceptibility: A soil additive composition employing a spreadable component applicable to the surface of the soil the spreadable component is combined with a plurality of particles reflective of electromagnetic radiation such as light. The spreadable component and plurality of particles may be pumpable in order to deliver these elements to a... Agent: Theodore J. Bielen Jr.

20070128240 - Compliant biocompatible packaging scheme based on niti shape memory alloys for implantable biomedical microsystems: A compliant biocompatible packaging scheme, (i.e., coating) for implantable medical device, particularly implantable biomedical microsystems is provided. In accordance with the present invention, the compliant biocompatible coating includes an optional dielectric undercoating and an overcoat comprising a NiTi shape memory alloy.... Agent: Philip S. Johnson Johnson & Johnson

20070128244 - Bioceramic scaffolds for tissue engineering: This invention relates to a porous ceramic sphere comprising a particulate micro-porous bioinert material, in the form of spheres or scaffolds, having interconnected pores. Pores on the surface of each sphere are connected to pores inside such sphere via blow-holes and the internal pores are in turn interconnected, so that... Agent: Stuart K. J. Smyth

20070128248 - Composite bone graft substitute cement and articles produced therefrom: The invention provides a particulate composition adapted for forming a bone graft substitute cement upon mixing with an aqueous solution, including i) a calcium sulfate hemihydrate powder having a bimodal particle distribution and a median particle size of about 5 to about 20 microns, wherein the calcium sulfate hemihydrate is... Agent: Alston & Bird LLP

20070128243 - Implantable microbial cellulose materials for various medical applications: This invention relates to polysaccharide materials and more particularly to microbial cellulose having suitable implantation properties for repair or replacement of soft tissue. The invention also relates to the use of the implantable microbial cellulose as scaffolds for tendon and ligament repair, tissue closure reinforcement, buttresses for reinforcement of the... Agent: Foley And Lardner LLP Suite 500

20070128247 - Method for ionically cross-linking polysaccharide material for thin film applications and products produced therefrom: A method for producing ionically cross-linked polysaccharide material (e.g. pectin) that includes dissolving the material in a first liquid solution that includes a dissolving liquid. The first liquid solution is applied to a workpiece to form a polysaccharide-based coating on the workpiece. The coating is dried to remove a substantial... Agent: Gordon & Jacobson, P.C.

20070128241 - Methods, compositions, apparatuses containing tetrameric oxygen: Compositions and methods of treating conditions requiring oxygen or resulting from molecular damage induced by reactive metabolites, hypoxia or ischema. Tetrameric oxygen is administered alone as an aqueous solution or in conjunction with additional agents. Treatable conditions include cancer, viral disease, ocular disease, autoimmune, inflammatory disease and other conditions required... Agent: Connors Associates

20070128249 - Osteogenic paste compositions and uses thereof: Described are osteogenic paste compositions with enhanced osteoinductive properties for use in bone repair. Compositions comprising a quickly resorbable paste carrier, a more slowly resorbed mineral matrix, and Bone Morphogenetic Protein (BMP) or other osteogenic factor are described which enable increased osteoinductive activity while retaining a reliable scaffold for the... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20070128242 - Polymeric compositions for controlled release or delivery of pharmacologically active agents: The present invention relates to polymeric compositions for controlled release or delivery of pharmacologically active agents. Each polymeric composition comprises a biocompatible polymeric matrix containing at least one pharmacologically active agent that is susceptible to oxidative degradation. The biocompatible polymeric matrix comprises at least a first polymeric material with an... Agent: Philip S. Johnson Johnson & Johnson

20070128245 - Porous calcium phosphate bone material: Porous calcium phosphate implant compositions that approximate the chemical composition of natural bone mineral are provided. In addition to calcium phosphate, the compositions include an effervescent agent to promote the formation of interconnected pores and a cohesiveness agent to maintain the shape and hardness of the hardened composition. When introduced... Agent: Clark & Elbing LLP

20070128246 - Solventless method for forming a coating: Provided herein are medical device having a coating substantially free from effects of drying kinetics and methods of forming the coating.... Agent: Squire, Sanders & Dempsey LLP

20070128250 - Poly(ester urea) polymers and methods of use: The invention provides high molecular weight, crystalline or semi crystalline biodegradable and biocompatible poly(ester urea) (PEU) polymers useful for making vascular stents and hard tissue replacement implants, such as bone substitutes. The PEU polymers are based on α amino acids and are made by a polycondensation reaction. PEU polymer compositions... Agent: Dla Piper US LLP

20070128252 - Compositions and methods for treatment of body weight conditions: A nutritional supplement composition having a therapeutically effective amount of peptides is provided for the treatment of body weight conditions. The nutritional supplement may also comprise milk minerals, such as calcium and/or be combined with a protein source including κ-casein fragment 106-169. The nutritional supplement composition is administered in amounts... Agent: Banner & Witcoff, Ltd.

20070128251 - Process for manufacturing chewable dosage forms for drug delivery and products thereof: A palatable, soft chewable medication vehicle for delivery of a pharmaceutically acceptable active ingredient, such as a drug, to an animal or human subject. The soft chews contain only food grade or better inactive ingredients, and preferably do not contain ingredients of animal origin. Processes for manufacturing the soft chews... Agent: Foley & Lardner LLP

20070128253 - Encapsulated transfer factor compositions and methods of use: Methods for stress reduction comprising administering a transfer factor to an animal. The transfer factor can be combined with glucans, such as hybrid glucans and other components, to bring about stress reduction. The formulation is encapsulated when administered to adult ruminants.... Agent: Morgan, Lewis & Bockius, LLP

20070128257 - Animal wipes having catnip: An animal wipe or pet wipe is an applicator which carries a formulation containing catnip. One or more wipe is contained in a container and dispensed from the container. The wipe having catnip is rubbed on a pet, such as a cat.... Agent: Michael S. Leonard Everest Intellectual Property Law Group

20070128255 - Coated substrate with properties of keratinous tissue: Article of manufacture comprising a substrate and a coating layer. The coating layer comprises at least one coating material, and is stably affixed to said substrate to form a stable, coated surface. The coated surface has a texture that mimics the topography of mammalian keratinous tissue and demonstrates at least... Agent: The Procter & Gamble Company Intellectual Property Division

20070128254 - Methods of attaching a dosage form to a medicated tampon assembly: A method for manufacturing a medicated tampon assembly having a tampon body includes positioning a dosage form in a holder, heating the dosage form, contacting the dosage form with the tampon body, and allowing the dosage form to cool. The method may further include positioning a tampon first member in... Agent: Kimberly-clark Worldwide, Inc.

20070128256 - Soluble cosmetic article with a thermal effect: An article having a support in the form of at least one sheet containing fibers that are water-soluble at a temperature of 0-30° C., the support having a density less than or equal to 0.1 g/cm3, and a composition carried by the support, containing at least one compound with a... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070128259 - Al-2 neurotrophic factor: The present invention provides nucleic acids encoding AL-2 protein, as well as AL-2 protein produced by recombinant DNA methods. Such AL-2 protein and nucleic acid are useful in preparing antibodies and antagonists and in diagnosing and treating various neuronal disorders and disorders or conditions associated with angiogenesis.... Agent: Heller Ehrman LLP

20070128258 - Emulsion-containing medical articles: Oil-in-water emulsion gels and medical articles containing an omega-3 oil are disclosed. Also disclosed are methods of preparing and using such emulsion gels and medical articles.... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP

20070128260 - Aqueous polymer dispersions for stabilizing actives: An aqueous dispersion comprising: a) from 5 to 99.9% by weight, based on the weight of solids in the aqueous dispersion, of one or more polymers having a number average molecular weight less than 10,000; b) from 0.1 to 94.9% by weight, based on the weight of solids in the... Agent: Rohm And Haas Company Patent Department

20070128261 - Method of cancer screening and method of cancer treatment: A method of cancer screening comprising the steps of administering the Blood CA 27,29 testing procedure; if the result is positive administering a mammogram; if the result is positive administering an needle biopsy; if the result is positive administering a PET scan; if the result is positive administering a blood... Agent: Michael A. O'neil Michael A. O'neil, P.C.

20070128264 - Method of cancer screening and method of cancer treatment: A method of cancer screening comprising the steps of administering the Blood CA 27,29 testing procedure; if the result is positive administering a mammogram; if the result is positive administering an needle biopsy; if the result is positive administering a PET scan; if the result is positive administering a blood... Agent: Michael A. O'neil Michael A. O'neil, P.C.

20070128262 - Package containing adhesive patch and method of inhibiting drug migration: m

20070128263 - Transdermal therapeutic system: The present invention relates to Transdermal Therapeutic Systems having a silicone adhesive layer, to Transdermal Therapeutic Systems providing specific plasma concentrations, to their manufacture and use.... Agent: Novartis Corporate Intellectual Property

20070128265 - Regulation of cell proliferation and differentiation using topically applied peptides: Methods are disclosed for the regulation of cell differentiation and proliferation, e.g., for treating hyperproliferative skin disorders, such as psoriasis, for enhancing wound healing, for stimulating hair growth and inhibiting hair growth, by topical administration of parathyroid hormone (PTH), parathyroid related peptide (PTHrP), or fragment, analog or derivative thereof, and... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070128267 - Blends of gelling and non-gelling starches with gellan gums and plasticizer: The present invention relates to a blend of gelling and non-gelling starches with gellan gums and a plasticizer having similar textural and functional properties compared to gelatin. Films prepared using such blends have excellent strength and elongation. The blend can also be used to prepare capsules without heat. The present... Agent: National Starch And Chemical Company

20070128271 - Formulation and manufacturing process for calcium acetate capsules: The present invention relates to a pharmaceutical calcium acetate formulation and a process for making the same. In particular, the present invention relates to a calcium acetate capsule formulation comprising granules comprising calcium acetate along with other formulation adjuvants contained within a pharmaceutically acceptable capsule.... Agent: Pearne & Gordon LLP

20070128272 - Multi-vitamin and mineral supplement: A nutritional solid oral dosage form for administering a calcium nutrient with an iron nutrient includes enterically coated particles, granules or pellets containing a calcium nutrient. An iron nutrient is incorporated into an immediate release matrix. The coated calcium nutrient may be located in a core surrounded by the immediate... Agent: Price Heneveld Cooper Dewitt & Litton, LLP

20070128268 - Pharmaceutical compositions comprising an antibiotic: The present invention relates to cefdinir. More particularly to pharmaceutical formulations comprising cefdinir in a defined polymorphic form and processes for the preparation thereof. Furthermore, the present invention relates to processes to keep cefdinir in a defined polymorphic form.... Agent: Novartis Corporate Intellectual Property

20070128270 - Pharmaceutical formulations containing 5-cyclopropyl-2-(4-fluorophenyl)-6-[(2-hydroxyethyl)(methylsulfonyl)amino]-n-methyl-1-benzofuran-3-carboxamide and method of making the same: Pharmaceutical formulations containing 5-cyclopropyl-2-(4-fluorophenyl)-6-[(2-hydroxyethyl)(methylsulfonyl)amino]-N-methyl-1-benzofuran-3-carboxamide and pharmaceutically acceptable additives including at least one surfactant are made.... Agent: Fitzpatrick Cella (wyeth)

20070128266 - Pharmaceutical or dietary compositions based on short-chain fatty acids and complex sugars, for intestinal disorders: Pharmaceutical and/or dietary compositions for supplying energy and eutrophication factors to the large intestine to improve its functionality and prevent the appearance of pathological conditions are described. The pharmaceutical and/or dietary compositions described are composed of one or more short-chain monocarboxylic acids or their salts, esters and/or amides, mixed with... Agent: Nixon & Vanderhye, PC

20070128269 - Sustained drug release compositions: The invention relates to a sustained release formulation for delivering one or more pharmaceutically active agents. The formulation comprises cross-linked high amylose starch and at least one pharmaceutically active agent, and optionally can be subdivided into smaller dosage forms where the smaller dosage forms have substantially the same sustained release... Agent: Goodwin Procter LLP Patent Administrator

20070128273 - Composition containing medicine extremely slightly soluble in water and method for preparation thereof: A composition containing a very low water-soluble drug, which composition is produced by treating, with a supercritical or subcritical carbon dioxide fluid, a mixture containing a very low water-soluble drug and a porous material (exclusive of a porous silica material characterized in that the material has an average pore diameter... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070128274 - Direct coating solid dosage forms using powdered materials: The present invention provides a method and apparatus for dry coating solid dosage forms. The method includes the steps of placing solid dosage forms in a rotatable, electrically grounded housing, and spraying a film forming polymer powder composition into the housing during rotation thereof to form a polymer coating on... Agent: Ralph A. Dowell Of Dowell & Dowell P.C.

20070128276 - Controlled release compositions comprising nimesulide: A controlled release composition comprising nimesulide as an active agent formulated as a gastroretentive system, preferably as a solid oral dosage form is provided, wherein the residence time of the active agent is increased in the stomach, duodenum, jejunum or ileum. The present invention also provides process of preparing such... Agent: Ladas & Parry

20070128275 - Trazodone composition for once a day administration: The invention relates to a once a day formulation of trazodone or a trazodone derivative. The formulation contains trazodone or a trazodone derivative and a controlled release excipient so that, once administered orally, the trazodone or the trazodone derivative is maintained at a therapeutic plasma concentration from at least 1... Agent: Goodwin Procter LLP Patent Administrator

20070128277 - Coated tablets: The invention relates to coated tablets comprising the pharmaceutically active substance diclofenac. Said tablets are characterized by a special, very beneficial coating based on hydroxypropyl methylcellulose.... Agent: Novartis Corporate Intellectual Property

20070128279 - Extended release dosage form: A membrane system comprising an interior wall, a fluid-permeable exterior wall surrounding the interior wall and an internal compartment defined by the membrane system, wherein fluid permeability of the interior wall is responsive to osmolarity of an osmotic core within the internal compartment are disclosed. A controlled release dosage form... Agent: Dewipat Incorporated

20070128278 - Pharmaceutical formulations: The present invention relates to oral formulations comprising an active agent comprising at least one of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, salts of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid or buffered 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid.... Agent: Robert Deberardine Abbott Laboratories

20070128280 - Oral osmotic drug delivery system: An oral osmotic delivery system and methods of using the oral osmotic delivery system that provide controlled and sustained delivery of a drug. The osmotic drug delivery system includes a drug layer comprising a drug and a first hydrophilic polymer wherein the drug layer comprises about 14.8% to about 100%... Agent: Arent Fox PLLC

20070128281 - Oral osmotic drug delivery system: The present invention relates, generally, to oral osmotic drug delivery systems, methods of preparing same, and methods of using oral osmotic drug delivery systems to provide controlled delivery of a drug that is provided in an amount of from about 8 mg to about 20 mg. The oral osmotic drug... Agent: Arent Fox PLLC

20070128282 - Oral osmotic drug delivery system: The present invention relates, generally, to oral osmotic drug delivery systems, methods of preparing same, and methods of using oral osmotic drug delivery systems to provide controlled delivery of a drug. The oral osmotic drug delivery systems include a drug layer, an osmotic layer, and an outer coating surrounding the... Agent: Arent Fox PLLC

20070128283 - Oral osmotic drug delivery system: The present invention relates, generally, to oral osmotic drug delivery systems, methods of preparing same, and methods of using oral osmotic drug delivery systems to provide controlled delivery of a drug that is provided in an amount of from about 2.5 mg to less than 8 mg. The oral osmotic... Agent: Arent Fox PLLC

20070128284 - Treatment of xerostomia: Xerostomia is treated with a sulfur-containing antioxidant, such as N-acetylcysteine. Delivery compositions including polyoxyalkylene block copolymers may be used, which may be formulated to exhibit reverse-thermal viscosity behavior.... Agent: Guy Donatiello Endo Pharmaceuticals

20070128287 - Dermal composition for external use: The object of the present invention is to provide a dermal composition for external use which keeps skin healthy and demonstrates a sufficient effect in treating skin diseases. The present invention relates to a dermal composition for external use, which comprises sodium cromoglycate and a monoester of polyvalent alcohol and... Agent: Sughrue Mion, PLLC

20070128288 - Ophthalmic compositions containing a synergistic combination of three polymers: Ophthalmic compositions suitable for use as artificial tears or as vehicles for ophthalmic drugs are disclosed. The compositions contain a combination of three polymers that have a synergistic effect on viscosity.... Agent: Alcon

20070128285 - Pharmaceutical composition for oral administration: Provided is a pharmaceutical composition for oral administration containing a 5-HT.3 receptor antagonist, which is suitable for self-medication because of good preservation stability, low synthesis, good uniformity and good external appearance, and good smoothness in throat, and easiness to be taken. Concretely, it is a jellied pharmaceutical composition for oral... Agent: Knobbe Martens Olson & Bear LLP

20070128286 - Production of polymer matrix for delivery (pmd): This invention is a means of production of polymer matrix for delivery. This invention employs amino acid chelated minerals as an ionic cross-linking agent, which forms colloidal solution containing delivery molecules after fully mingling with chitosan-acid solution that contains delivery molecules. This invention uses amino acid chelated minerals and chitosan... Agent: Wpat, PC Intellectual Property Attorneys

20070128289 - Nano-and/or micro-particulate formulations for local injection-based treatment of vascular diseases: The present invention relates to nano- and/or micro-particulate formulations that can be locally injected into arterial walls at or near target sites to achieve a prolonged and sufficiently high local concentration of at least one pharmacologically active agent for treatment of vascular diseases, such as, for example, restenosis, vulnerable plaque,... Agent: Philip S. Johnson Johnson & Johnson

20070128290 - Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof: In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of substantially water insoluble pharmacologically active agents (such as the anticancer drug paclitaxel) in which the pharmacologically active agent is delivered in the form of suspended particles coated with protein (which acts... Agent: Morrison & Foerster LLP

20070128291 - Method and apparatus for forming chromonic nanoparticles: A method and apparatus for forming guest molecules encapsulated with chromonic material are described. The method includes atomizing a solution to form a pre-atomized particle stream. The solution includes chromonic material, a guest molecule and a carrier fluid. Then, atomizing the pre-atomized particle stream to form an atomized particle stream;... Agent: 3m Innovative Properties Company

20070128292 - Novel nutraceutical and pharmaceutical compositions and their uses: The invention relates to organic chemistry area and more particularly to the polyunsaturated fatty acids area. The invention specifically relates to nutraceutical or pharmaceutical compositions rich in unsaturated fatty acids, characterized in that they contain free or combined α-linolenic acid, associated with fatty acids having five and six double-bonds, admixed... Agent: Hedman & Costigan P.C.

20070128293 - Extrapallial fluid of molluscs, methods of obtaining same, formulation and use thereof: The invention relates to a fluid preparation method comprising the recovery of the fluid that is located between the shell and the body of a mollusc. The invention also relates to the liquid obtained using said method, and to the use thereof in the pharmaceutical field, in particular in order... Agent: Nixon & Vanderhye, PC

20070128294 - Treatment and prevention of liver adverse conditions using gallium: The invention provides methods and compositions for treating adverse conditions of the liver in an individual. A pharmaceutical composition including gallium, in the form of a coordination complex of gallium (III), a salt of gallium (III), an inorganic gallium (III) compound other than a gallium salt, or protein-bound gallium (III),... Agent: Morrison & Foerster LLP

20070128295 - Composition for disinfection of plants animals humans byproducts of plants and animals and articles infected with pathogens and method of producing and application of same: The present invention discloses a composition and method of providing ionic forms or compounds of any combination of three metals to produce a product that can be used as a antimicrobial as defined by the U.S. Environmental Protection Agency (EPA) such as a hard surface disinfectant and as a foliar... Agent: Jackie Jay Schwartz

20070128296 - Reduction of reactive oxygen species in chronic wound management: Reactive oxygen species associated with a wound are modulated through treatment of the wound with a solution of metal ions selected from the group consisting of potassium ions, zinc ions, calcium ions and rubidium ions, at a pH of between about 5 and about 7. Preferably, citric acid is employed... Agent: O'melveny & Myers LLP

20070128297 - Apparatus and method for treatment of nasal congestion: An apparatus for treatment of sinus problems includes a single-use container with hypertonic saline solution. The concentration of Sodium chloride within the saline solution may fall within the range of 0.9% to 3.0%. The single-use container may be an ampule, or resilient, flexible bottle, for example. A package containing a... Agent: James W. Wiegand Suite 700

20070128298 - Compositions and methods for increasing insulin sensitivity: Methods and compositions for treating a blood glucose condition involve identifying a suitable subject and administering an effective amount of a composition that contains one or more of an opioid antagonist, an anticonvulsant, and a psychotherapeutic agent. The compositions can include insulin. In some embodiments, such methods and compositions can... Agent: Knobbe Martens Olson & Bear LLP

20070128299 - Functional beverage and composition: t

20070128300 - Natural tea having effects of hangover relief and liver function recovery and method for preparing the same: A natural tea has effects of relieving hangovers and revitalizing liver functions, contains an extract from natural plant Robinia pseudo-acacia as a main active ingredient, and is obtained under optimal extraction conditions. The natural tea comprises an extract from the leaf, stem, flower and root of Robinia pseudo-acacia as a... Agent: St. Onge Steward Johnston & Reens, LLC

20070128301 - Immune enhancement by seed oil and/or seed flour: A composition useful as an immunostimulant and as an adjuvant to support various cancer treatment modalities is disclosed. Additionally, the use of a composition comprising seed oils and/or flours derived from the seeds and/or mixtures thereof as immunostimulants and as a daily supplements to enhance the immune system activity of... Agent: Hunton & Williams/new York Intellectual Property Dept.

20070128302 - Composition containing an extract of the fruit of schisandra chinensis and process for producing same: A composition including (a) an extract from the fruit of Schisandra chinensis; and (b) at least one auxiliary and/or additive is provided. A composition also provided includes (a) a component selected from the group of an extract of the fruit of Schisandra chinensis, schizandrin, deoxyschizandrin, schisandrin C, gomisin A, gomisin... Agent: Cognis Corporation Patent Department

20070128303 - Anti-inflammatory, cytoprotective factor derivable from a probiotic organism: The invention provides an isolated, anti-inflammatory, cytoprotective compound that is soluble in aqueous fluid, is derivable from the conditioned medium of a probiotic culture, such as VSL#3, induces heat shock protein expression, and has shown the capacity to inhibit NF-κB activation. The compound is amenable to formulation in a pharmaceutical... Agent: Marshall, Gerstein & Borun LLP